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The immune response to maedi-visna virus has been investigated, both in persistently
infected sheep and in the acute phase of the primary immune response to infection with
maedi-visna.
Maedi-visna infected sheep develop detectable levels of anti-viral antibody by 4-6 weeks
after experimental infection. These antibodies are directed against the envelope and core
structural proteins of the virus and initially are of the IgM isotype, but later switch to IgG.
These IgG anti-visna antibodies are restricted to the IgGj subclass.
The functional significance of this isotypic restriction of the anti-visna antibody response
was studied using in vitro assays of antibody activity against virus infected cells. It was
found that visna specific antibodies were able to direct antibody-mediated complement-
dependent cytotoxicity, but not antibody dependent cell mediated cytotoxicity against
virus infected cells. These observations are consistent with the known properties of
ruminant immunoglobulin G subclasses. These persistently infected sheep were also
shown to have developed a CD4+ T cell response to maedi-visna virus.
The acute phase of the immune response to maedi-visna infection was studied in a
lymphatic cannulation model. Infection with maedi-visna induced both virus neutralising
antibodies and vims specific T cells, but these failed to prevent the establishment of a
persistent viral infection.
The generation of the data on immune responses to maedi-visna virus describe^ above
was facilitated by the production of recombinant p25 gag protein and p25 specific
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Maedi-visna virus was originally described in Iceland as an aetiologic agent of chronic
interstitial pneumonia (maedi) and demyelinating leukoencephalomyelitis (visna) in sheep
(Sigurdsson, 1954., Sigurdsson & Palsson, 1958., Sigurdsson et al, 1952., 1957). Maedi-
visna is a relatively common infection of sheep in most parts of the world (Adams et al,
1984), but the incidence of clinical disease is relatively low. However in the last decade
lentiviral infections of both man, the human immunodeficiency virus (HIV), and other animals
have been described (reviewed in Narayan & Clements, 1990) and these viruses have been
recognised as important pathogens. The advent of HIV has resulted in the development of
intense interest in all aspects of lentiviral biology, and maedi-visna virus is now studied, not
only as a pathogen in its own right, but also as a model for some aspects of the pathogenesis
of HIV infection and disease (Haase, 1986., Narayan & Clements, 1990).
1.2 Classification of Retroviruses
Retroviruses are a family of viruses with positive-sense, single-stranded RNA genomes,
but which replicate via a double-stranded DNA intermediate (Teich, 1984). Traditionally the
Retroviridae have been divided into three subfamilies; the Oncovirinae, the Spumavirinae and
the Lentivirinae (Teich, 1984). This classification is based primarily on pathogenicity and
morphologic criteria, rather than genome relationships. When nucleotide sequence data and
genome structure are used as criteria for classification seven groups of retroviruses,
composed of all well analysed isolates, can be defined (Coffin, 1990).
In either classification, the Lentivirinae form a discrete subfamily of exogenous
retroviruses which cause slow, progressive inflammatory disease in vivo, a highly lytic
infection in vitro, but are not directly implicated in any malignancies (Teich, 1984., Haase,
1986., Coffin, 1990). Maedi-visna virus is the prototype of the Lentivirinae, although the
Human Immunodeficiency Virus, type 1 (HIV-1) is now the best characterised member of this
subfamily.
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1.3 Genome of the virus
The genomic RNA of visna is a positive sense, linear, single stranded RNA (60S-70S)
composed of two identical sub-units (30S-35S) (Beemon et al, 1976., Vigne et al, 1977).
Each retroviral genomic RNA molecule is associated with a single tRNA molecule: the primer
on which reverse transcriptase initiates DNA synthesis (Coffin, 1990). The specific tRNA
molecule appropriated for this purpose by visna vims is tRNA|ys_1|2 (Sonigo etal, 1985).
The genomic RNA of retroviruses resembles messenger RNA's of eukaryotic cells in that
its 5' end has a methylated cap structure and its 3' end is polyadenylated (Varmus, 1982.,
Coffin, 1990). Sequences at the 3' end of the viral RNA, in the U3 region contain the
enhancer-promoter elements for initiation of RNA transcription (Sonigo et al, 1985., Hess et
al, 1986). In addition, the 5' and 3' ends of the RNA also contain short repeated sequences
('R' sequences) that are important for viral replication (Varmus, 1982). During the synthesis of
proviral DNA (reviewed in Varmus & Swanstrom, 1985) the 5' and 3' ends of genomic RNA
molecules are duplicated and a copy of each transposed so that the DNA provirus has
identical terminal regions; the long terminal repeats (Fig 1.1).
The visna genome encodes the three structural genes, organised 5' to 3' (gag, pol,
env), typical of all retroviruses. However, visna also displays a genetic feature unique to the
lentiviruses: the presence of a collection of short open reading frames (ORF's) located
between the pol and env genes and at the 3' end of the env gene (Sonigo etal, 1985).
The functions of proteins encoded by these open reading frames are best characterised for
HIV-1, the genome of which codes for at least six accessory genes (reviewed in Cullen &
Greene, 1990). Visna virus displays a less complex genetic organisation; it appears to
express only three auxiliary gene products (Fig. 1.1) (Davis etal, 1987., Vigne et al, 1987.,
Sargan & Bennet, 1989).
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Figure 1.1
A comparison between the DNA genome of the ruminant lentivirus, Maedi-visna and HIV-1,
the best characterised member of the Lentivirinae.
ORF Q, has been suggested, on the basis of its central position in the genome, to encode
the visna equivalent of the vif protein of HIV-1 (Sonigo et al, 1985). However there is no
significant amino-acid sequence homology between the protein product of ORF Q and HIV-1
vif (Sonigo et al, 1985).
The question marks indicate short ORF's in the visna genome whose codon usage is
compatible with eventual translation (Sonigo et al, 1985). To date, neither RNA transcripts nor
protein products of these ORF's have been reported.
The expanded view is a schematic diagram showing the organisation of the visna LTR.
Important enhancer-promoter elements are found in the U3 region. The cap site, the 5'
terminus of all the viral RNA's, is situated at the 5' end of the R region. The TATA box, located
5' of the cap site, is the recognition signal (promoter) for pol II RNA transcription (reviewed in



















Virions of Maedi-visna virus (MVV) are enveloped particles 70-1 OOnm in diameter
(Thormar, 1961Coward et al, 1970). Their surface is decorated with clusters of spikes
which are believed to represent the envelope glycoprotein of visna virus (Dubois-Dalcq et al,
1976). The internal nucleocapsid, or core, has a distinctive bar-shape typical of lentiviruses
(Gonda et al, 1985), and is 30-40nm in diameter (Thormar, 1961).
1.4.2 Viral Antigens
1.4.2.1 Virion peptides
About twenty polypeptides are incorporated into the visna virus particle (Haase &
Baringer, 1974., Lin & Thormar, 1979). The major constituents of the virion are the envelope
glycoprotein gp135, and the gag proteins p16, p25 and p14 (Haase & Baringer, 1974., Vigne
et al, 1982), which form the nucleocapsid of visna virus.
The virion core also contains several proteins that have important roles during viral
replication. These include the enzyme reverse transcriptase, p68 (Lin & Papini, 1979., Filippi
et al, 1982). By analogy with other retroviruses (Varmus, 1982., Coffin, 1990), the core
probably also contains a protease and integrase.
Other polypeptides present in the virion (Haase & Baringer, 1974., Lin & Thormar, 1979)
are believed to be either the polypeptide precursors or intermediates of viral structural
proteins, or cellular proteins incorporated in virus particles as they bud from the infected cell
(Vigne et al, 1982).
1.4.2.1.1 Gag gene products
The three gag proteins of visna are produced by proteolytic cleavage of a major
polyprotein precursor, pr55 (Vigne et al, 1982). The order of gag proteins within the
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precursor is NH2-p16-p25-p14-COOH (Sonigo et al, 1985). The gag polypeptides of
lentiviruses form the capsid structure within the enveloped virion and are important in
maintaining critical protein-nucleic acid contacts during viral assembly and reverse
transcription (reviewed in Arnold & Arnold, 1991., Coffin, 1990). Assembly of virions is a
relatively poorly understood aspect of retroviral replication (see section 1.5.8), but it is
interesting to note that the gag precursor protein of HIV-1, p55, when expressed in
eukaryotic cells is able to assemble into a virus-like particle and bud from the cell in a manner
reminiscent of the morphogenesis of HIV (Gheysen et al, 1989., Hu et al, 1990).
In most retroviruses the matrix protein, p16 in visna, is the gag protein in closest
association with the virus membrane (Coffin, 1990). Consistent with this observation, the NH2
terminus of most retroviral matrix proteins are myristylated (Dickson et al, 1985., Mervis et
al, 1988., Veronese et al, 1988), a modification characteristic of many proteins that lie on
the internal face of the cell membrane. It has been suggested that some mammalian
retroviruses may exploit this modification of the gag polyprotein as a targeting mechanism to
localise viral budding (Rein et al, 1986., Rhee & Hunter, 1987). It is not known whether the
visna p16 is myristylated, but myristylation of the matrix protein is not a feature of all
retroviruses; the matrix proteins of neither Avian leukaemia-sarcoma vims (ALSV) nor Equine
infectious anaemia virus (EIAV) are myristylated (Pepinsky & Vogt, 1984., Henderson et al,
1984).
The capsid protein, p25, is hydrophobic and forms the major internal structural feature of
the virion - the core shell (Vigne et al, 1982., Sonigo et al, 1985). Little is known about
capsid protein structure or mechanism of action in any retrovirus, but in Moloney murine
leukaemia (MuLV) virus mutations in the capsid protein eliminate vims assembly altogether
(Hsu etai, 1985).
The nucleocapsid protein, p14, of maedi-visna is a small basic protein containing the
'zinc-finger' motif, Cys-X2-Cys-X9-Cys, characteristic of retroviral nucleic acid binding proteins
(Sonigo et al, 1985). Although the function of this protein in visna virus is not definitely
known, this protein is found in association with the genomic RNA in the virion (Lin & Thormar,
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1974., Filippi etal, 1982). It has been suggested that in Rous sarcoma virus the
nucleocapsid protein may be involved in the process of retroviral virion RNA dimerisation
(Bieth et al, 1990). For HIV-1, transfection of cells with viral genomes containing mutations in
the cysteine motif of the nucleocapsid protein led to the production of virus particles normal in
protein content, but lacking detectable viral RNA (Aldovini & Young, 1990), implying a role for
the nucleocapsid protein in packaging of genomic RNA within virions.
The gag genes are highly conserved among lentiviruses of each host species. p25, the
major core protein of visna, is the most highly conserved of any of the visna virus genes
(Sargan et al, 1991). Moreover the gag proteins, especially p25, are immunogenic, eliciting
a strong antibody response during visna infection (Houwers & Nauta, 1989). The antibodies
are group specific, recognising a wide spectrum of visna isolates, but the significance of anti-
gag antibodies in the immune response to visna is unclear (see section 1.6.3). The gag
proteins of lentiviruses are also major targets forT-cell responses (Miller et al, 1990., Nixon
etal, 1988).
1.4.2.1.2 Pol gene products
The pol gene of visna encodes the RNA dependent DNA polymerase (reverse
transcriptase) and putative endonuclease/integrase and protease of visna (Sonigo et al,
1985., Sargan et al, 1991). The pol gene products are believed to be produced as a
gag/pol precursor, pr150, (Sonigo etal, 1985., Vigne et al, 1982) which the viral protease
cleaves to liberate the pol gene products. By analogy with other retroviruses, it is thought
that this precursor polyprotein is generated by ribosomal slippage in the gag-pol overlap
leading to a frameshift during translation (Jacks et al, 1988., reviewed in Hatfield & Oroszlan,
1990). Of the three putative pol gene products only the reverse transcriptase of visna virus
has been characterised (Lin et al, 1973., Lin & Papini, 1979). The virion DNA polymerase is
associated with the viral core (Lin & Thormar, 1974) and, like all reverse transcriptases, the
visna enzyme has been shown to have an absolute requirement for divalent cations for
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polymerase activity in vitro (Haase et al, 1974., Coffin, 1990). In visna the preferred ion is
Mg2+ at 1-4mM (Lin & Papini, 1979).
1.4.2.1.3 Env gene products
The env gene of MVV encodes a single large, 115kd, precursor polypeptide (Sonigo et
al, 1985., Sargan et al, 1991) with approximately thirty potential glycosylation sites, many of
which are utilised (Vigne et al, 1982). These carbohydrate moieties protect the virions from
proteases and reduce the affinity of neutralising antibodies for the virus, in some cases
sequestering neutralising epitopes from the immune system (Huso et al, 1988).
The env gene is translated to produce a single, glycosylated precursor polypeptide,
gpr150, which is then thought to be proteolytically cleaved to produce the two major
glycopeptide species associated with the virion, the outer membrane envelope glycoprotein
gp135, and the transmembrane glycoprotein gp46 (Haase & Baringer, 1974., Vigne et al,
1982). It has been shown for HIV-1 that endoproteolytic cleavage of the env precursor gp160
is essential for virion infectivity and syncytium formation (McCune et al, 1988).
In lentiviruses the external envelope glycoprotein then associates with the
transmembrane glycoprotein via noncovalent interactions (Kowalski et al, 1987). However
the surface envelope glycoprotein spikes are easily lost from the virion surface (Gelderblom
et al, 1985., Schneider et al, 1986). In HIV-1, loss of virion gp120 has been shown to result
in reduced virus infectivity (McKeating et al, 1991), but the relevance of these in vitro
observations to disease states in vivo in HIV infection is unclear as is whether a similar
situation obtains during infection with maedi-visna.
The nature of the higher order structures of lentivirus envelope glycoproteins is unclear.
The structure of MVV glycoproteins is not known: the envelope glycoproteins of HIV have
been variously reported to exist in the virion as dimers, (Earl et al, 1990., Thomas et al,
1991), trimers (Einfield & Hunter, 1988., Weiss et al, 1990) and tetramers (Pinter et al,
1989., Schawaller et al, 1989) stabilised by interactions between their gp41 domains.
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The envelope glycoproteins contain many biologically important determinants: the
determinants of virus-cell receptor interaction and virus induced cell fusion (Crane et al,
1988., Lifson et al, 1986a., 1986b), and the major epitopes for virus neutralising antibody
(Scott et al, 1979).
1.4.2.2 Regulatory proteins
The genome of visna virus includes several short ORFs, at least two of which have been
shown to encode positive acting regulatory proteins(Davis & Clements, 1989., Gourdou et al,
1989., Tiley et al, 1990) ( see sectionl .5.6.2). The protein products of these two genes have
been named Tat and Rev, after their functional equivalents in HIV-1, and both of these
proteins have been reported to be recognised by sera from visna infected sheep (Davis &
Clements, 1989), suggesting that these proteins are expressed in vivo.
The tat gene (ORF-S) of visna, present as a single coding exon, encodes a 10-11 kd
protein. This protein includes a basic domain and a cysteine cluster, both of which features
are important for protein function (Davis & Clements, 1989., Gourdou et al, 1989). The visna
tat protein has been shown to act as a post-transcriptional transactivator of visna virus LTR-
dependent gene expression.
The other short ORF of visna virus, whose protein product has an identified function is
the rev gene. This protein, which has an Mr of around 18kd, contains a basic domain and a
leucine rich motif, both features which have been identified as being critical for rev function in
vitro (Malim et al, 1989., Flope et al, 1990., Tiley et al, 1990). During in vitro infection rev
protein is expressed both early, when it is a major viral product, and late in the course of
visna replication (Mazarin et al, 1990). The rev protein of maedi-visna virus localises to the
nuclei and particularly to the nucleoli of transfected cells (Tiley et al, 1990), like the rev
proteins of primate lentiviruses (Felber et al, 1989., Malim et al, 1989). Visna rev protein
has been shown to act as a post-transcriptional activator of viral structural gene expression
(Tiley et al, 1990).
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The gene product of the third ORF, Q, is a hydrophilic and basic protein of 29kDa. The
function of the protein is unknown, but it is expressed late in the virus life cycle and is located
in the cytosol, although it does not accumulate at the cell membrane and is not found in
virions (Audoly et al, 1991).
1.5 Infection and virus replication
1.5.1 Infectious inocula
Infectious inocula of visna virus are likely to comprise a population of related viral
quasispecies. This situation is a reflection of the remarkable plasticity of the retroviral genome
and its capacity for rapid evolution, a feature of retroviral/lentiviral biology thought to be of
great importance in the pathogenesis of lentivirus-induced disease.
Replication of retroviral genomes proceeds by a series of enzymatic reactions initiated by
the virus-encoded reverse transcriptase (RT), but also involving host cell-encoded enzymes
such as DNA polymerases which are involved in DNA replication, and RNA polymerase II,
which transcribes proviral DNA into both genomic RNA and viral mRNA's (Coffin, 1990.,
Varmus & Swanstrom, 1985) and a variety of mutational mechanisms act, during replication,
to maintain the heterogeneity of retroviral populations.
Due to the lack of an exonucleolytic (proofreading) activity (Battula & Loeb, 1976),
reverse transcriptase is prone to error. The error rate of the visna RT enzyme has not been
characterised, but in vitro other retroviral RT's have been shown to have rates of base
misincorporation ranging from 10~4/base for the reverse transcriptases of avian retroviruses
(Dougherty & Temin, 1988., Leiderefa/, 1988) to four to five-fold that rate for the RT of
HIV-1 (Preston et al, 1988., Roberts et al, 1988). It is important to note that the rate of
misincorporation is not likely to be uniform across the genome, but seems to be dependent
on the specific sequence context (Roberts et al, 1988., 1989), some types of error being
more common than others. Deletions, insertions, duplications and recombinational events
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with viral and/or cellular sequences may also occur during reverse transcription (Dorner et al,
1985., O'Rear & Temin, 1982), although it should be noted that nucleic acid sequences
related to visna virus are absent from uninfected sheep cells (Haase & Varmus, 1973., Weiss
etal, 1975., Brahic et al, 1977).
Host cell DNA polymerases show an extremely low rate of misincorporation and are
unlikely to contribute to retroviral mutation. However, if the error rate of RNA polymerase II
approximates to that of other RNA-synthesising enzymes then errors in genomic RNA
synthesis may also be important in generating sequence diversity within the viral population
(reviewed in Coffin, 1990).
The above describes the mechanisms by which the heterogeneity of retroviral populations
is generated and maintained, but it should be remembered that mutations in the viral genome
gain significance only insofar as they confer a selective advantage to the variant virus, so
favouring continued replication.
Evidence for visna virus variation in vivo is drawn mainly from studies documenting the
co-existence of antigenic variants within individual sheep. This has been defined by biological
assays such as neutralisation phenotype (Narayan et al, 1978., Lutley et al, 1983., Thormar
et al, 1983), and epitope-mapping experiments (Stanley et al, 1987). Genetic change in the
visna genome in vivo has also been demonstrated. Clements et al, (1980., 1982), using
RNase T, fingerprint analysis of viral RNA's of serial visna isolates, demonstrated that visna
variants emerge primarily through the accumulation of point mutations, mainly within two
kilobases of the 3' terminus of the genome, ie. in the envelope glycoproteins. The limited
amount of sequence information available on visna isolates confirms that regions of env,
especially those overlapping rev sequence, are the most variable between visna isolates
(Querat et al, 1990., Sargan et al, 1991). It has been suggested that the extensive variation
in env may be a result of env variant viruses being fixed in the population by immune
selection (Sargan et al, 1991., see section 1.6.5).
The population of lentiviral species that exist within an individual may differ in biological
properties other than antigenicity. In HIV-1 infection, variant genomes from a single patient
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may show differential tropism for T-cell and myelomonocytic cell lines (Cheng-Mayer et al,
1990., Fisher et al, 1988., Sakai et al, 1989). In addition to host cell range, HIV isolates have
been shown to be distinct with respect to other biological parameters such as replication rate
& syncytium-inducing capacity (Tersmette etal, 1988., 1989a). The prevalence of particular
types of HIV variants is different in early and late stages of infection and this may be related
to disease progression (reviewed in Miedema et al, 1990).
A similarly detailed analysis of the biological phenotypes of visna isolates has not been
reported. However, in preliminary studies, Querat et al (1984) classified ovine lentivirus
isolates into two groups, on the basis of their replication in fibroblast cultures in vitro: Group I
isolates replicate rapidly and cause complete lysis of the infected cultures, whereas group II
isolates fail to induce complete lysis of the cells, but instead establish a persistent infection of
the cell line. Querat et al could isolate only one type of virus, either lytic or persistent, from
naturally infected sheep, however it is possible that highly lytic isolates may have been
isolated preferentially in their culture system since virus infectivity was assessed by the
development of cytopathic effects in a cell line co-cultivated with the material from which virus
isolation was being attempted. Analysis of the protein and nucleic acid content of each of
these types of isolate demonstrated that lytic and persistent isolates, although related, were
genetically distinct (Querat etal, 1984).
Lairmore et al (1987) compared the replication phenotypes of ovine lentivirus isolates in
vitro in synovial membrane cells and alveolar macrophages. These workers demonstrated
that isolates which are highly lytic in cell culture in vitro (group I isolates) could be subdivided
into two groups: isolates which are lytic in synovial cells, but grow only poorly in
macrophages, and isolates which cause rapid fusion and lysis of both synovial cells and
macrophages. Further it was demonstrated that this in vitro replication phenotype correlated
with in vivo pathogenicity; isolates causing highly lytic infections of macrophages in vitro
being the most pathogenic in vivo (Lairmore et al, 1987., 1988). Thus disease pathogenesis
may be markedly influenced by biologic differences between visna isolates, which may co¬
exist within an infected individual.
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1.5.2 Transmission of virus
Horizontal transmission is the primary means of viral dissemination between sheep, and
virus infected colostrum and milk are probably the major vectors for transmission, although
infection via the respiratory route by inhalation of infected droplets has also been implicated
(De Boer et al, 1979., Gudnadottir, 1974., Narayan & Cork, 1985). Visna infection is probably
transmitted by virus inside monocyte/macrophages in these secretions (Haase, 1986). This is
likely since in vivo visna infection is characterised by minimal levels of cell-free infectious
virus. Viraemia is almost exclusively cell-associated (Petursson et al, 1976), and
monocyte/macrophages are the major cell types infected in vivo (Narayan et al, 1982.,
Gendelman et al, 1985).
Most of the published evidence suggests that germline and intrauterine transmission of
visna do not occur (De Boer et al, 1979., Gudnadottir, 1974., Haase, 1986., Houwers et al,
1983), although some reports have suggested that there may be a small chance of
intrauterine infection occurring (Cross et al, 1975., Cutlip et al, 1981).
1.5.3 Cellular tropism of visna
Both in vitro and in vivo the ruminant Antiviruses have a marked tropism for cells of the
monocyte-macrophage lineage; in vitro visna replicates productively in macrophages
cultivated from either the peripheral blood or the lungs of uninfected sheep (Narayan et al,
1982., Gendelman et al, 1986). In vivo the virus maintains this tropism for cells of the
monocyte/macrophage lineage, although in vivo viral replication is restricted (Geballe et al,
1985., Gendelman et al, 1985).
The basis of the restricted cellular tropism exhibited by visna virus is not understood.
Retroviruses have a specific requirement for interaction with a cell-surface receptor molecule
for infection (reviewed in Weiss, 1985., Coffin, 1990) and this interaction is likely to be of
crucial importance in determining the cellular tropism of the virus. However this only refers to
infection of a cell by a free virus particle. In visna, as in other Antiviruses, infection may also
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occur by direct fusion of an infected cell with uninfected cell(s) (Harter & Choppin, 1967.,
Thormar, 1963),thus bypassing any need for a specific receptor.
To date, a cell-surface molecule which acts as a specific receptor for visna virus has not
been identified, thus the contribution of a putative receptor moiety to determining tropism
cannot be defined. However, it has recently been shown that visna virus binds specifically to
cell membrane proteins of 15, 30 and 50 kDA, and that antibodies to the 50kDA protein block
the binding of visna virus to permissive cells (Crane et at, 1991 a). It has been claimed that
molecules of the ovine MHC class II complex may be components of a cellular receptor for
maedi-visna virus (Dalziel et at, 1991), however monoclonal antibodies to sheep MHC class
II molecules do not infection of permissive cells by visna virus. Moreover, cell susceptibility to
visna infection does not correlate with expression of MHC class II molecules.
It has been reported that cell lines from a variety of species possess receptors which
allow the attachment of visna/vesicular stomatitis virus pseudotypes, but not productive
infection by visna virus itself (Gilden et at, 1981), suggesting that events after receptor-
binding are important in the infective process. Moreover, it has also been suggested that
group I and group II visna isolates (see section 1.4.1) form distinct interference groups which
may differ in receptor specificity (Jolly & Narayan, 1989).
Apart from the CD4-gp120 interaction (reviewed in Capon & Ward, 1991), very little is
known about how retroviruses interact with their receptors, and it is difficult to generalise from
what is known. However, it is generally assumed that the retroviral protein involved in binding
to the cellular receptor is the virion surface envelope glycoprotein (Weiss 1985., Coffin, 1990)
and therefore that important determinants of cellular tropism reside in this protein.
It has also been reported that antibodies to visna enhance virion binding to macrophages
in vitro; this process being mediated by antibody-Fc receptor interactions (Jolly et at, 1989)
and this is another potential route of viral infection.
The cellular tropism of retroviruses may also be affected by later, biochemical, aspects of
viral replication machinery. For example, it has been shown that the cellular tropism of some
murine retroviruses is affected by specific alterations in their long terminal repeats (LTR's)
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(Celander& Haseltine, 1984., Holland et al, 1985., Rosen etal, 1985). In contrast the
cellular tropism of HIV-1 is believed to be determined by events early in viral replication, prior
to provirus formation (Cann et al, 1990., Kim et al, 1990) and that the viral LTR is not a
major determinant of cellular tropism (Pomerantz et al, 1991).
The role of the visna virus LTR in determining cellular tropism has been investigated in a
transgenic mouse model (Small et al, 1989). In these experiments transgenic mice were
constructed which expressed the bacterial gene chloramphenicol acetyl transferase (CAT)
under the control of the visna LTR. Expression of CAT activity in these mice was mainly
restricted to macrophages, or tissues expected to contain macrophage populations such as
brain, lung and spleen. Activation of peritoneal macrophages resulted in enhanced induction
of the visna LTR. Small et al interpreted these results as evidence of a central role for the
visna LTR in determining macrophage tropism, possibly indicating that cellular factors
required for visna virus LTR-dependent gene expression in this system are mainly restricted
to macrophages. An interpretation supported by the finding that in vivo visna replication
appears to be confined mainly to sheep monocytes/macrophages (Gendelman et al, 1986).
1.5.4 Entry of the virion into the cell
1.5.4.1 Entry
In vitro experiments indicate that visna attaches to cells quickly, within 5-15 minutes
(August et al, 1977., Kennedy-Stoskopf & Narayan, 1986) and with high affinity: the rate of
virus binding to cells is faster than the rate of virus neutralisation by immune serum
(Kennedy-Stoskopf & Narayan, 1986).
Following binding of the virus to its receptor, entry of the virion into the cell occurs by
fusion of the virion envelope and the cell membrane as a result of which process the virion
core is released into the cytoplasm (reviewed in Marsh & Helenius, 1989). Membrane fusion
by lentiviruses occurs at a pH typical of the cell surface (Stein et al, 1987., McClure et al,
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1988) and neither viral endocytosis nor intracellular compartmentalisation of intact virions
appear to be a feature of the infective process (Maddon et al, 1988., Stein et al, 1987).
The mechanisms by which fusion and viral entry occur are poorly understood. The visna
transmembrane envelope glycoprotein, gp46, contains a conserved sequence of hydrophobic
amino-acids at its NH2 terminus (Sargan et al, 1991), which shows some homology to the
fusion domains of other fusogenic viruses (Gallaher, 1987., Freed et al, 1990., White et al,
1983) and it may be that membrane fusion is mediated by this region of the visna
transmembrane protein. Consistent with this, it has been reported that in the primate
lentiviruses gp41 is likely to be the viral protein which mediates fusion (Bosch et al, 1989.,
Kowalski et al, 1987). Antisera against visna gp135 have been reported to block visna-
induced cell fusion (Crane et al, 1988), but this report did not distinguish between a direct
effect of gp135 in fusion and steric hindrance of the gp46/cell membrane interaction by
antibodies bound to gp135. Subsequent studies by these workers (Crane et al, 1991 b)
demonstrated both, that a peptide derived from the hydrophobic domain of gp46 could induce
cell-cell fusion and that antisera to this peptide could inhibit visna virus induced cell fusion.
It has also been reported that penetration, at least in HIV-1, is also dependent on an as
yet unidentified cellular component (Maddon et al, 1986., Tersmette et al, 1989b), which
may be a cell-surface protease capable of cleaving specific sites within the envelope
glycoprotein leading to activation/exposure of the fusion domain (Hattori et al, 1989.,
Stephens et al, 1990).
1.5.4.2 Interference
In general, cells infected by retroviruses display a very strong resistance to superinfection
by viruses that utilise the same receptor as the preinfecting virus, while remaining susceptible
to infection by viruses that use a different receptor. This phenomenon, called interference, is
believed to arise by. interaction between the env protein of the preinfecting virus and its
receptor. The level at which this interaction occurs is not known, but virion formation is not
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necessary for interference. In vitro interference is virtually absolute (reviewed in Weiss,
1985).
A related phenomenon, known as 'early interference' occurs without viral infection of the
cell and is believed to be due to interaction between the viral env protein and the cellular
receptor at the cell surface, thus blocking access of other viruses to the receptor (Weiss,
1985). Early interference has been demonstrated to occur in visna infection in vitro (Jolly &
Narayan, 1989), preincubation of cells with group I isolates causing reduced binding of other
group I isolates, but not group II isolates and vice versa.
1.5.5 Reverse Transcription & Proviral DNA
After entry of the virion into the cytoplasm the retroviral RNA genome is reverse
transcribed into double-stranded proviral DNA (reviewed in Varmus & Swanstrom, 1985.,
Coffin, 1990). This process is carried out in a structure derived from the virion core, using
enzymatic activities that enter the cell in the virion, although it has been shown that cellular
factors may be required for complete reverse transcription: infection of resting, quiescent
CD4+ cells by HIV-1 results in incomplete reverse transcription yielding a labile replicative
intermediate and abortive infection (Zack et at, 1990). If the resting cell harbouring this
structure is mitogenically stimulated then virus production can result, suggesting that cellular
activation may allow completion of reverse transcription. Similarly, in a murine retrovirus
system, defects affecting cellular DNA synthesis appear to alter reverse transcription (Richter
et al, 1984). That said, visna replication during in vitro infection has been shown to be
independent of cellular DNA synthesis and mitosis (Haase, 1975., Trowbridge et al, 1980).
Visna DNA replication occurs predominantly in the nucleus of the infected cell (Haase et
al, 1982), rather than in the cytoplasm as occurs in oncovirus infections (Varmus &
Swanstrom, 1985). In vitro visna proviral DNA is detectable within the first hour post infection
(Clements et al, 1979., Haase et al, 1982), and the time course of virus production can be
altered by manipulation of the extent of early proviral DNA synthesis (Haase et al, 1982).
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In tissue culture visna virus DNA is predominantly present as extrachromosomal DNA
molecules that are linear duplexes with a gap close to the centre of the plus strand (Harris et
al, 1981). A minor population of viral DNA is composed of two circular forms differing by the
length of one long terminal repeat (Clements & Narayan, 1981., Harris et al, 1981). In
contrast to the oncoviruses whose expression is dependent on integrated provirus (Varmus,
1982), integration of visna proviral DNA appears to play a relatively insignificant role in viral
gene expression (Harris et al, 1984), suggesting that, at least In vitro, unintegrated visna
virus DNA can serve as a template for transcription. The significance of the apparently
insignificant role of integration in the life cycle of visna is difficult to assess. Several studies
attempting to correlate lentivirus DNA forms and growth in vitro have been described
(Cheevers et al, 1982., Harris et al, 1984., Muesing et al, 1985). In general these studies
suggest that persistent, non-cytopathic infections are associated with a predominance of
integrated viral DNA, whereas cytopathic infections display a predominance of unintegrated
proviral DNA.
Analyses of the state and structure of the DNA provirus in vivo have not been reported
for visna, but this topic has been investigated in other lentiviral diseases. In SIV infected
macaques the vast majority (85%-100%) of proviral DNA, in a variety of tissues, was found to
be unintegrated (Hirsch et al, 1991). Similarly, analysis of lymph node tissue from an AIDS
patient revealed that high levels of unintegrated proviral DNA were present (Shaw et al,
1984). To date, information on the significance of the relatively large amounts of linear, non-
integrated provirus found in in v/Vo-derived material in the pathogenesis of lentiviral disease
has not been reported.
1.5.6 Viral gene expression
Lentiviruses, like other retroviruses, utilise cellular transcription machinery for the efficient
expression of the DNA provirus. Transcription of viral DNA into genomic RNA and mRNA is
accomplished by cellular RNA polymerase II (reviewed in Coffin, 1990., Varmus &
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Swanstrom, 1985). The U3 region of the viral DNA genome contains sequences homologous
with regions of cellular genes known, or suspected, to be important for transcription (Chen &
Barker, 1984) and transcription begins downstream of these elements. It is thought that pol II
binds to the viral DNA at or near the TATA box. Transcription is then initiated at the U3-R
junction (or cap site) and proceeds through the viral genome to the poly (A) sequence in the
R region of the 3' LTR (Narayan & Clements, 1990). Efficient recognition of the 3' poly (A)
site, rather than the 5' poly (A) tract, may be due to the close proximity of the latter to the cap
site (Sanfacon & Hohn, 1990), alternatively, efficient recognition of the 3' poly (A) site may be
mediated by transcribed sequences located 5' of the downstream, but not the upstream poly
(A) signal (Brown et al, 1991).
The viral LTR thus acts as a promoter for transcription of proviral DNA and gene
expression of visna virus is regulated through transcriptional control elements in the viral LTR
(reviewed in Clements et al, 1990).
The basal activity of the visna virus LTR in the resting ceil is poorly defined. It is known
that viral gene expression is highly restricted in monocytes in vivo, and that differentiation
and/or activation of these cells results in activation of viral gene expression (Gendelman et al,
1985., 1986), indicating that cellular transcriptional factors that activate macrophage specific
genes may be necessary for activation of viral transcriptional control elements. In HIV,
external signals which may induce cellular activation and viral replication include mitogens
and cytokines such as TNFa and IL-6 (Rosenberg & Fauci, 1989). Many of these signals
exert their effect via transcriptional activators such as NF-kB (reviewed in Steffy & Wong-
Staal, 1991) and it is likely that a similar situation exists in visna infection.
A number of sequences within the visna virus LTR have been identified as being
important both for basal transcriptional activity and for activation of the viral LTR (Hess et al,
1989., Gabudza et al, 1989).These include the TATA box and recognition sequences for the
transcriptional factors AP-1 and AP-4. The AP-4 site is present as a single copy, whereas
multiple degenerate copies of the AP-1 element are found in the visna LTR, although the AP-
1 site most proximal to the TATA box is the most important for transcriptional activity.
20
After activation, ientiviral gene expression, at least in vitro, is characterised by a more
complex pattern of transcription than other retroviruses: visna virus infected cells contain at
least six species of mRNA (Davis et al, 1987., Vigne et al, 1987., Sargan & Bennet, 1989).
Early virus gene expression is marked by the accumulation of doubly spliced mRNA's
which encode viral regulatory gene products including tat and rev (Davis & Clements, 1989.,
Gourdou et al, 1989). The visna tat gene product increases gene expression from the viral
promoter by increasing the steady-state level of viral RNA (Hess et al, 1989). Whether tat
acts at a transcriptional or post-transcriptional level is not fully understood, but unlike HIV-1
tat the primary targets for the visna transactivating protein are believed to lie upstream of the
TATA box in the U3 region (Hess et al, 1989). These tat responsive sequences in the U3
are the same sequences as are required for basal transcriptional activity.
The other regulatory gene product of visna virus, rev, localises to the nucleoli of infected
cells (Tiley et al, 1990., Audoly et al, 1991) and is required for the expression, late in the
virus life cycle, of the unspliced and singly spliced mRNA's encoding gag, pol, env & Q
ORF gene products. The mechanism of action of rev protein is uncertain but appears to
involve activating nuclear export of incompletely spliced viral mRNA species which would
otherwise be sequestered within the nucleus of infected cells. This effect is dependent on
cis -acting rev-response elements (RRE) located within the env mRNA (Tiley et al, 1990). It
has been proposed, in HIV, that rev acts to regulate viral RNA expression by selectively
packaging viral transcripts, carrying the RRE, into rod-like nucleoprotein completes blocking
the access of cellular splicing machinery to the viral mRNA (Heaphy et al, 1991).
Thus early in infection doubly spliced 1.4kb and 1.7kb mRNA transcripts are the
predominant species of viral RNA present in infected cells. Later however, around 72 hours
post-infection, larger unspliced and singly-spliced mRNA transcripts which encode the viral
structural proteins are predominant (Davis et al, 1987., Vigne et al, 1987).
The pattern of transcription described above is that observed during lytic replication in
vitro. However in vivo, viral gene expression is highly restricted. Relatively few cells are
infected: 1 in 106/1 in 107 leukocytes in peripheral blood, (Petursson et al, 1976.,
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Gendelman et al, 1985., 1986). Moreover, expression of proviral DNA is blocked at the level
of transcription (Haase et al, 1977., Brahic et al, 1981). The viral RNA content of infected
cells in vivo is about two orders of magnitude less than during lytic replication in vitro and
only a very few of the infected cells contain viral structural proteins (Haase et al, 1977.,
Brahic et al, 1981., Gendelman et al, 1985., 1986).
The basis of this restricted replication in vivo is not well understood, but a variety of
factors could influence viral replication.
It is not known whether true latency, ie. persistence of viral DNA in the absence of
transcription, occurs during lentiviral infection in vivo. The peripheral blood of HIV-infected
individuals contains 1 in 10" to 1 in 105 cells expressing viral mRNA (Harper et al, 1986),
whereas the frequency of cells containing proviral DNA, as assayed by PCR and limiting
dilution, is around 100 times greater (Schnittman et al, 1989). This has been interpreted as
suggesting that the majority of infected cells are transcriptionally inactive (McCune, 1991), an
interpretation supported by experiments quantitating infectious virus in PBMC's and plasma
(Ho et al, 1989). However, quantitative in-situ hybridisation studies on the choroid plexus of
visna infected sheep have revealed that the proportions of cells expressing viral DNA or RNA
in vivo are similar and that this number agrees well with the total number of infected cells in
the tissue as determined in endpoint dilution assays (Haase et al, 1977., Brahic et al, 1981),
If latency does not occur during visna infection in vivo it could be hypothesised that the
low (basal ?) level of transcription detected in vivo may produce regulatory mRNA's that act
to suppress viral replication. To date, however, the nature of the RNA transcripts detected in
in vivo remains completely uncharacterised for both visna and HIV. A candidate negative
regulatory protein, in HIV, is that encoded by the net (negative factor) gene. Some studies
have suggested that net acts to inhibit LTR-dependent gene expression, however others
have observed no effect of net on either viral replication or gene expression (reviewed in
Cullen & Greene, 1990). The existence of neither a discrete nef ORF nor a net-like protein
have been reported in visna or any of the other non-primate lentiviruses.
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Another potential constraint on visna replication is the seeming requirement for
macrophage activation for efficient viral replication (Narayan et al, 1983., Gendelman et al,
1986). In vivo cellular activation is likely to be transient, thus viral replication will not be
favoured. Moreover, at least for HIV-1, it has been reported that a protein, rpt-1, selectively
expressed in resting cells can down-regulate viral gene expression (Patarca et al, 1988).
1.5.7 Translation
Translation of retroviral mRNA's is believed to follow the standard 'scanning' model, in
which ribosomal subunits initially bind to the 5' capping group and then move down the RNA
until an AUG initiation codon is recognised (Petersen & Hackett, 1985).
In all retroviruses analysed to date the gag and pol genes can be thought of as a single
translalional unit which is expressed to yield either gag or gag/pol polyproteins, in a ratio of
around 20:1, gag:gag/pol (reviewed Coffin, 1990). In Antiviruses it is thought that the
gag/pol precursor is generated by ribosomal slippage in the overlap between the gag and
pol ORF's (Jacks et al, 1988., Hatfield & Oroszlan, 1990). A potential ribosomal slippage
sequence (AGGGAAA) has been identified in this location in the visna genome (Querat et al,
1990., Sargan et al, 1991).
Unlike the translation of gag and pol, which are synthesised from full length RNA
species by free polyribosomes in the cytosol, env protein is synthesised, from a singly-
spliced subgenomic mRNA transcript, by polyribosomes in the rough endoplasmic reticulum.
Env proteins are first glycosylated shortly after translation and later, after removal of a signal
peptide, env proteins undergo further post-transiational modifications, including further
glycosylation and cleavage into outer and trans-membrane subunits, in the Golgi as they
move to the cell surface (reviewed in Dickson et al, 1982., 1985).
Analysis of the translation of tat and rev proteins has not been reported.
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1.5.8 Virion assembly & egress
Virion assembly is a poorly understood aspect of retroviral replication, but electron
microscopic studies have revealed that in most retrovirus groups capsid assembly and
budding of virions occur almost simultaneously.
A generally accepted model of retrovirus virion assembly (Bolognesi et al, 1978),
hypothesises that virus assembly is modulated by interactions between the plasma
membrane, virion RNA and the three domains of the gag precursor protein: the C-terminal
(nucleocapsid) protein interacts with the genomic RNA to cause RNA dimerisation and ensure
its incorporation into the assembling virion (Aldovini & Young, 1990., Bieth et al, 1990).
Interactions between the central capsid domains determine the shape of the virion, while the
myristylated NH2-terminal matrix domain targets this complex to the cell membrane (Rein et
al, 1986., Rhee & Hunter, 1987) and may also interact with env proteins to ensure
envelopment of the virus (Gebhardt et al, 1984., Satake & Luftig, 1983).
Extensive mutational studies (reviewed in Coffin, 1990), have shown that only the matrix
and capsid gag proteins are absolutely required for formation of a retroviral virus-like
particle.
Assembling visna virions are first seen as a crescent-shaped patch on the cell membrane
which gradually bulges from the membrane until the the ends of the crescent meet to form a
complete envelope and the virus buds from the cell (Thormar, 1961., Dubois-Dalcq et al,
1976). This protrusion of the cell membrane, characteristic of the budding process, appears
to be initiated by attachment of a capsid to a region of the cell membrane slightly modified in
the appearance by the formation of clusters of globular units, suggested to be viral env
proteins (Dubois-Dalcq et al, 1976). Interestingly, visna virus differs in its pattern of budding
between infected macrophages and fibroblasts. During infection of monocyte/macrophages
virus particles accumulate intracellularly in intra-cytoplasmic vacuoles (Narayan et al, 1982),
whereas infection of fibroblastic cells is marked by extensive virus budding from the plasma
membrane (Thormar, 1961., Dubois-Dalcq et al, 1976). The basis of this different behaviour
is unclear, but a similar situation pertains in HIV, infected macrophages accumulate virus
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particles intracellular^, while infected T cells release large numbers of virions into the
extracellular environment (reviewed in Meltzer et al, 1990). The HIV particles which
accumulate inside macrophages are infectious when mechanically released from the cell, but
do appear to differ from 'T-cell grown' HIV in being relatively lacking in gp120, the outer
membrane envelope glycoprotein. Whether this is true for 'macrophage-grown' visna virus is
at present unknown.
Following assembly and budding the retroviral protease, incorporated into the virion as a
gag-pol fusion protein is somehow activated, possibly the protease domain of the gag/pol
precursor is only slightly active and requires a high local concentration of precursor such as
occurs in the virion before it can cleave the gag/pol precursor to liberate the protease
moiety. Alternatively protease activity may be dependent on dimer formation and this may not
occur until encapsidation is complete. Whatever the mechanism, once cleavage occurs the
free protease may exert its full activity to cleave the gag precursor into the individual gag
proteins (Coffin, 1990) and this structural rearrangement of the capsid results in a visible
condensation of the virion core shortly after release of the virus from the infected cell
(Thormar, 1961). HIV mutants lacking protease activity synthesise non-infectious virions
which have an 'immature' appearance, but are still capable of budding from the infected cell
(Peng et al, 1989).
1.5.9 Effect of infection on the host cell
Typical retrovirus infections in vitro produce relatively low copy numbers of viral mRNA's
and use only 1-2% of host cell protein synthesis (reviewed in Varmus & Swanstrom, 1982.,
Dickson et al, 1982), although high levels of HIV-1 RNA (300,000 to 2,500,000 copies) and
correspondingly high levels of protein synthesis have been reported in cytocidal infections in
vitro (Somasundaran & Robinson, 1988). Choroid plexus cells infected in vitro with visna
virus contain/on average, only 5,000 copies of viral RNA per infected cell (Haase et al,
1982).
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In both monocyte/macrophages and fibroblasts in vitro infection with visna virus leads to
the development of a cytopathic effect characterised by the appearance of stellate cells,
extensive syncytium formation and degeneration of infected cells (Sigurdsson, 1960.,
Narayan et at, 1982), although the rate of development of these changes is slower in
macrophage cultures. In HIV, cell fusion and syncytium formation are mediated by the viral
envelope glycoproteins (Lifson et at, 1986a., 1986b), although molecules important in
cellular adhesion may also play a role in this process (Pantaleo et al, 1991). It is known that
visna virus proteins, including gp135 & gp46, are involved in cell fusion (Crane et al, 1988.,
1991 b., Harter & Choppin, 1967) but the role of host cell proteins in visna virus-induced fusion
is unknown.
1.6 Virus - Host Relationship
1.6.1 Introduction
It is thought that the major routes for transmission of maedi-visna infection are via
colostrum and respiratory secretions (Narayan & Cork, 1985., Narayan & Clements, 1990),
and since viraemia is almost exclusively cell-associated (Petursson et al, 1976), it is believed
that infected cells, in these fluids, are the major vehicle for dissemination of visna infection.
As the major cell type infected in vivo is the monocyte/macrophage (Gendelman et al,
1985., 1986), it is likely that the cell spreading visna virus infection is a macrophage.
In vivo the majority of infected cells are expressing viral RNA, but not viral structural
proteins (Haase et al, 1977., Brahic et al, 1981., Gendeiman et al, 1985). It is unknown
whether these cells contain viral regulatory proteins such as rev and tat. Thus the
dissemination of visna both between and within individuals while sequestered within an
infected macrophage, not expressing viral antigens, may effectively be invisible to the
immune system. This has been termed the 'Trojan-Horse' hypothesis for spread of lentiviral
infection (Peluso et al, 1985., Haase, 1986).
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From the preceeding it can be seen that there are two major stages in the virus life cycle
at which lentiviruses and the host defence mechanisms may interact: the virus infected cell
which is induced/activated to synthesise viral antigens, and cell-free virus released perhaps
by lysis of infected cells. The former is primarily a target for cell-mediated immune responses,
whereas the latter is mainly a target for humoral immune mechanisms, although this division
is not absolute.
1.6.2 Natural resistance mechanisms
Natural resistance mechanisms of the host require no previous exposure to foreign
antigen for induction and so are immediately available against infection. Effector mechanisms
of this type include macrophages, natural killer (NK) cells and interferon. These are all
relatively non-specific in their action.
To date no information on antiviral effects mediated by monocyte/macrophages in visna
infected sheep has been reported. In HIV infection purified monocytes were unable to lyse
HIV infected target cells, even after activation with gamma interferon (IFN-y) (Ruscetti et al,
1986). Moreover monokines such as IL-6 and TNF-a have been implicated both in
upregulating HIV replication and in the pathogenesis of disease symptoms during HIV
infection (Rosenberg & Fauci, 1990., Poli et al, 1990). In contrast Wong et al (1988)
reported that the combination of IFN-y and TNF-a could not only protect cells from HIV
infection, but also kill HIV infected cells.
Monocytes and macrophages are the major cell types infected with visna in vivo
(Gendelman et al, 1985., 1986), but the effect of lentiviral infection on monocyte/macrophage
function is uncertain. The effect of visna virus infection on accessory cell antigen-presenting
function has not been studied directly, but alveolar macrophages from visna infected sheep
have been reported to be activated in vivo, as assessed by spontaneous release of
chemotactic factors and fibronectin (Cordier et al, 1990). In contrast, others have reported
that alveolar macrophages infected with visna in vitro, show reduced responses to
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chemotactic factors (Myer et al, 1988). It has been reported that HIV infection of
mononuclear phagocytes results in a reduced ability to mediate extra- and intra-cellular killing
(Baldwin et al, 1990). Some workers have reported that antigen-presenting functions of
monocytes infected with HIV in vitro is decreased (Petit et al, 1988., Macatonia et al, 1989.,
Ennen et al, 1990), whereas others have reported no effect (Mann et al, 1990). Defects
were not observed in accessory cell function of PBMC's from HIV infected individuals (Clerici
et al, 1990b). This is probably a reflection of the very low frequency of circulating infected
monocyte/macrophages in vivo in HIV infected individuals (Massari et al, 1990., Schnittman
et al, 1989), an observation similar to that reported for visna infected sheep (Petursson et al,
1976., Gendelman et al, 1986). The function of tissue monocyte/macrophages in lentivirus
infection has received very little study, but it has been reported that SIV infection of bone-
marrow macrophages in macaques correlated with disease progression in vivo (Kitagawa et
al, 1991).
To date there are no reports investigating a role for NK cells in the immune response to
visna infection. However several studies have examined the role of this ceil type in the
immune response to HIV infection. Non-MHC (Major histocompatability complex) restricted
cytotoxicity against HIV infected target cells has been reported in HIV infected patients
(Ruscetti et al, 1986), the highest levels occurring in asymptomatic seropositive individuals
(Weinhold et al, 1988). it has been suggested that much of this activity may be mediated by
circulating non-T, CD16+ large granular lymphocytes (LGL's) armed in vivo with cytophilic
antibody (Tyler et al, 1990). However NK cell mediated cytotoxicity against HIV infected
targets has also been observed in unfractionated cells from both HIV-infected and uninfected
individuals in the presence of IL-2 (Rook et al, 1985).
The major target antigen for non-MHC restricted cytotoxicity, in HIV infection, is thought
to be gp120 since uninfected target cells coated with purified gp120 become susceptible to
lysis by NK cells (Weinhold et al, 1988). Moreover, in both HIV and SIV systems, it has been
shown that target cells infected with recombinant vaccinia-env, but not vaccinia-gag,
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viruses are recognised and lysed by CD16+, MHC class I unrestricted cells (Riviere et al,
1989., Yamamoto ef a/, 1990).
Much of the literature published on the role of interferons in the immune response to
visna is contradictory, consequently interpretation of the data is difficult.
In vitro co-cultivation of peripheral blood mononuclear cells (PBMC's) with visna infected
macrophages results in the production of a unique interferon (Narayan et al, 1985), termed
lentivirus-induced interferon, LV-IFN (Zink et al, 1987). LV-IFN is a non-glycosylated protein
which is heat and acid stable (Lairmore et al, 1988., Narayan et al, 1985), and is reported to
have an Mr of either 54-64 kDa (Narayan et al, 1985), or 25-34 kDa (Lairmore et al, 1988).
Induction of LV-IFN production appears to require the interaction of T-cells with infected
macrophages and this process can be blocked by antibodies to MHC class II (Narayan et al,
1985., cited in Zink & Narayan, 1989). LV-IFN thus appears to have properties of both IFN-a
and IFN-y.
In vitro LV-IFN has been reported to inhibit the replication of visna virus in macrophages
(Kennedy et al, 1985). Lentiviral replication in infected monocyte/macrophages is closely tied
to cellular activation and differentiation (Narayan et al, 1983., Gendelman et al, 1986) and it
has been proposed that LV-IFN indirectly restricts the replication of visna virus in vitro by
inhibiting proliferation and differentiation of monocytes (Zink & Narayan, 1989). These
workers also reported that LV-IFN had a direct inhibitory effect on virus gene expression in
infected macrophages, blocking the viral life cycle at the level of transcription. In contrast,
other workers reported that in vivo levels of spontaneous IFN production, by pulmonary
leukocytes from visna infected sheep, are positively correlated with lentiviral infection of
alveolar macrophages (Lairmore et al, 1988). Moreover Lairmore et al also reported that
ovine lentivirus replication in fibroblastic cells was inhibited only slightly by IFN produced by
cultured pulmonary lymph node leukocytes from visna/maedi infected sheep, either with or
without lentivirus-infected macrophages in the cultures. Carroll et al (1978) also reported that
the replication of visna virus in sheep choroid plexus cells was not affected by natural, in vivo
prepared, ovine IFN.
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LV-IFN has also been reported to induce the expression of MHC class II antigens on
macrophages in vitro (Kennedy et at, 1985), a finding which may be reflected in vivo: a
persistent and high level of MHC II antigen expression is seen in macrophage like cells in
inflammatory lesions in the lung. Moreover alveolar macrophages isolated from visna infected
sheep show increased levels of MHC II expression (Cordier et al, 1990), as do
macrophage/dendritic cells isolated from the carpal joints of visna infected sheep with
inflammatory synovitis (Harkiss et al, 1991). It has been suggested that both in vitro and in
vivo LV-IFN may cause other changes in macrophages associated with macrophage
activation eg. the induction of prostaglandin E2 (PGE2) (Zink & Narayan, 1989) and increased
levels of spontaneous release of neutrophil chemotactic activity and fibronectin. However
Lairmore et al, (1988), reported that there were no significant differences in the levels of
either IL-2 and PGE2 production or mitogen responsiveness between pulmonary lymph node
leukocytes from visna-infected sheep and uninfected controls.
Thus local IFN production, associated with visna infection, may have either beneficial
and/or detrimental effects on the infected host. Inhibition of monocyte/macrophage
maturation, and possibly viral gene expression, may slow viral replication and postpone the
onset of disease. Alternatively local IFN production in infected tissues, by induction of MHC
class II antigen expression and possibly activation of macrophage populations, may serve to
accelerate the entry of leukocytes into virus-induced lesions thus promoting inflammatory
changes and cell-mediated tissue damage.
In summary, at the moment the role of interferons in visna infection in vivo is unclear.
The discrepancies in results described above may be due to differences between groups in
the preparation of the IFN containing material and in the cell types in which the influence of
IFN on viral replication was assessed. HIV replication has been shown to be susceptible to
IFN control, but again the mechanisms by which these effects are achieved are unclear
(reviewed in Kornbluth et al, 1990).
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1.6.3 Humoral immune responses
Sheep infected with maedi-visna virus develop a virus specific serum antibody response
in the first few months post infection (Petursson et al, 1976). Visna virus-specific antibodies
are first detected 1-2 months after infection using complement fixation and indirect
immunofluorescence assays (Gudnadottir & Kristinsdottir, 1967., De Boer, 1970., Petursson
etal, 1976). A longer period, 3-6 months, is required before the development of virus
neutralising antibodies (Gudnadottir & Palsson, 1966., De Boer, 1970., Petursson et al,
1976), although these then remain at high levels throughout the course of the disease
(Gudnadottir & Palsson, 1966).
Visna virus infected sheep have been shown to make antibodies reactive with virtually all
the viral proteins (Lin & Thormar, 1979), but the pattern of development of these antibodies
after infection and their persistence through the course of disease are unclear. Using agar gel
precipitation techniques Dawson, (1985), and Klein et al, (1985), suggested that antibodies
to gp135 were the first to appear after infection and that not all infected sheep made
antibodies to the gag proteins. In contrast, other workers have reported that antibodies to
p25 appear early in the course of infection and that they persist and predominate (Houwers &
Schaake, 1987., Houwers & Nauta, 1989). In HIV infection, antibody responses are directed
to both structural and non-structural viral proteins, but the major antibody responses are
against the env and gag gene products (Pan et al, 1987).
It is believed, for both visna virus and HIV, that virus neutralising antibodies are reactive
predominantly with the outer membrane envelope glycoprotein, gp135 (Scott etal, 1979.,
Matthews et al, 1986). Fine mapping of the epitopes in visna gp135 which elicit neutralising
antibodies has not been carried out, but in HIV-1 infection the majority of virus neutralising
antibodies are directed against a single epitope in the third variable domain of gp120 (the so-
called V3 loop) (Matsushita et al, 1988., Palker et al, 1988., Rusche et al, 1988). However
this region is not generally accepted to be a potent neutralisation epitope for either HIV-2 or
SIV (Moore & Weiss, 1991).
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Although the external envelope glycoproteins of lentiviruses are the major antigens which
elicit neutralising antibodies other viral proteins such as the transmembrane envelope
glycoprotein, gp41, and the matrix protein, p17, may also be targets for virus neutralising
antibodies, at least in HIV infection (Schrier et al, 1988., Sarin et al, 1986., Papsidero et al,
1989).
The gag proteins of maedi-visna, especially p25, elicit a strong antibody response during
infection. These antibodies are group specific, probably reflecting the highly conserved nature
of the gag genes between visna isolates (Sargan et al, 1991), and are often used as an
index for infection (Houwers & Nauta, 1987). In general the functional significance of anti-gag
antibodies in lentivirus disease pathogenesis is unclear, but decline or loss of antibody titre to
the viral core proteins in HIV infection is strongly associated with progression to AIDS
(Kalyanaraman et al, 1984., Weber et al, 1987). Although it has been suggested, in HIV,
that a decline in anti-p24 antibody titres may simply reflect an increase in p24 antigenaemia
with consequent immune complex formation and clearance (Lange & Goudsmit, 1987., Von
Sydow et al, 1988)^ Loss of antibody responses to viral core proteins may correlate with the
development and extent of pathological lesions in visna infection also (Houwers & Nauta,
1989), but the basis of this association between anti-core protein antibody reactivity and
disease progression is unknown. The major core proteins of neither visna nor HIV are targets
for virus neutralising antibody (Scott et al, 1979., Weber et al, 1987). However HIV p24 is
expressed on the surface of virus-infected cells, at least in vitro, (Laurent et al, 1989) and
thus may be a target for antibody mediated cytotoxicity.
The role of virus neutralising antibody in the protection from lentiviral disease in vivo is
unclear. In Equine Infectious Anaemia Virus (EIAV) infection, virus infection and replication
results in acute disease which ceases after induction of type-specific neutralising antibodies
(reviewed in Clements et al, 1988). However, in both visna and HIV, it is unclear whether
there is any correlation between neutralising antibody titres and disease progression
(Narayan & Clements, 1990., Rosenberg & Fauci, 1989). In kinetic experiments it has been
shown that the rate at which neutralising antibody binds to free visna virus is significantly
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slower than that of virus binding to cells (Kennedy-Stoskopf & Narayan, 1986), suggesting a
possible mechanism for virus spread in vivo in the presence of high levels of serum
neutralising antibodies. Moreover antigenic variation in the envelope proteins of visna virus
(see section 1.6.5) may also allow the virus to evade immune surveillance: the presence of
neutralising antibody has been shown to select for neutralisation-resistant visna variants both
in vitro (Narayan et ai, 1977), and in vivo (Narayan et al, 1981).
As well as virus neutralisation, virus-specific antibody may also direct the destruction of
virus-infected cells (reviewed in Sissons & Oldstone, 1980). This may occur by either, or
both, of two processes: antibody dependent cell-mediated cytotoxicity (ADCC) and/or
antibody-mediated complement-dependent cytotoxicity (ACC).
ADCC has been suggested to play an important role in the control of several viral
infections: herpesvirus (IBR) and paramyxovirus (PI3) infection of cattle (Rouse ef al, 1976.,
Stott et al, 1975), cytomegalovirus infections of man (Quinnan et al, 1982) and retroviral
diseases of cats (de Noronha et al, 1978). To date, no studies on this aspect of immunity in
relation to MVV infection have been reported, but several groups have reported that sera
from HIV-infected individuals can mediate ADCC activity in vitro (Rook et al, 1987.,
Ojo-Amaize et al, 1987).
Antibodies mediating ADCC in HIV infection are believed to react predominantly with the
outer membrane envelope glycoprotein (Lyerly et al, 1987., Shepp et al, 1988), although the
transmembrane glycoprotein may also be a target for ADCC (Blumberg et al, 1987).
However there is no correlation between titres of virus-neutralising antibody and ADCC
antibody titres (Bottiger et al, 1988), and ADCC reactivity is mainly group specific (Lyerly et
al, 1987). Interestingly, several investigators have reported that there may be a correlation
between ADCC antibody titre and clinical stage of disease, in that AIDS patients tend to have
lower titres of ADCC activity than healthy seropositive individuals (Rook et al, 1987.,
Ljunggren ef a/, 1987).
Antibody-mediated complement-dependent cytotoxicity (ACC) has been shown to be an
important component of the immune response to feline and murine retroviruses (Grant et al,
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1978., Fischinger et al, 1982). It has also been demonstrated that ACC is involved in the
immune response of ruminants to herpesvirus infection (Babiuk etal, 1975), moreover
antibody-mediated fixation of complement has also been shown to enhance ADCC in a
ruminant system (Rouse etal, 1977a., 1977b).
Visna-specific complement fixing antibodies are first detected 1-2 months post infection
and persist thereafter (Gudnadottir & Kristinsdottir, 1967., De Boer, 1970., Petursson et al,
1976), but results of direct tests of the ability of these antibodies to lyse visna virus or visna
infected cells have not been reported. Group-specific ACC has been observed in
chimpanzees experimentally infected with HIV (Nara et al, 1987a), but even high titre anti-
gp120 human sera have been reported not to mediate HIV-specific ACC (Lyerly et al, 1987.,
Nara etal, 1987b). It has been suggested that the occurrence of anti-HIV ACC in infected
chimpanzees may be related to the ability of these animals to remain relatively healthy
despite infection with HIV (Rosenberg & Fauci, 1989).
It has been reported that non-neutralising antibodies to Antiviruses may enhance viral
infection of macrophages by allowing the uptake of virus, as immune complexes, via Fc
receptors (Takeda et al, 1988) and/or complement receptors (Robinson et al, 1989). This
mechanism of virus infection has been suggested to occur in visna infection (Jolly et al,
1989). However these studies were all carried out in established cell lines and/or cultured
blood mononuclear cells. Cell types which may not be representative of the situation in vivo.
Antibody to HIV, in either the presence or absence of complement, has been reported to
have no enhancing effect on vims replication in freshly isolated normal, primary blood
monocytes and peritoneal macrophages (Shadduck et al, 1991).
The antibody isotypes that are produced in the humoral immune response to visna virus
infection have not been well characterised. Mehta & Thormar (1974), reported that vims
neutralising activity was associated with both IgM and IgG isotypes, whereas Petursson etal
(1983), suggested that no anti-visna reactivity was associated with antibodies of the IgM
isotype. Both groups reported that anti-visna antibody activity was readily demonstrated in the
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IgG-, subclass, while the occurrence and significance of lgG2 antibodies to visna virus were
unclear (Petursson et al, 1983).
The significance of virus-specific antibodies in protection from lentivirus infection in vivo
is not well understood. Recently it has been reported that passive transfer of plasma,
containing high titres of anti-HIV antibodies, from healthy HIV-infected individuals to AIDS or
ARC patients resulted in a sustained decrease in p24 antigenaemia and an increase in anti¬
viral antibody titre to levels higher than those expected from the passive immunisation alone,
however this did not appear to alter disease progression as assessed by CD4+ lymphocyte
depletion (Jackson et al, 1988., Karpas et al, 1988). More persuasive evidence of a
protective role for antibody has been obtained in an SIV system in which passive
immunisation of macaques with high titre anti-SIV serum from vaccinated, immune macaques
protected the recipients from subsequent viral challenge (Putkonen et al, 1991). However
this study did not define the mechanism of antibody protection: whether the challenge virus
was neutralised by antibody or subsequently eliminated by antibody-mediated cytotoxicity. A
recent report (Stott et al, 1991) has suggested that protection of monkeys from HIV-2/SIV
challenge may be correlated with antibody reactivity to components of the human cell lines in
which these virusesare routinely grown, rather than with antiviral antibody titres. Thus at the
moment data obtained from monkey-protection experiments should be interpreted only
cautiously.
1.6.4 T cell mediated immunity
Cell-mediated immune responses in visna infection have not been well characterised, but
in the majority of viral infections studied T cell mediated immune responses are believed to be
of prime importance both for clearance of virus infected cells and in regulating aspects of the
humoral immune response (Mims & White, 1984., Vitetta et al, 1991).
Griffin et al (1978), reported that sheep experimentally infected with maedi-visna made
only a transient cell-mediated immune response to visna virus: lymphocyte proliferation
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against MVV being undetectable after 6 weeks post-infection. This study however was
terminated only three months after infection. Larsen et al (1982b), and Sihvonen (1984)
reported that intermittent and irregular cellular responses to visna could be detected in a three
year period following experimental visna infection. These studies however, were poorly
controlled and consequently the data presented is difficult to interpret. Moreover none of
these studies made any attempt to characterise either the viral antigens eliciting a response,
or the lymphocyte populations responding in these assays.
That visna virus does elicit T-cell mediated immune responses is suggested by the
observation that the basic lesion of visna-induced pathology is infiltration and proliferation of
mononuclear cells in an active-chronic inflammatory process (Oliver et al, 1981., Narayan &
Cork, 1985), both CD4+ and CD8+ lymphocytes comprise a proportion of these infiltrating
cells (Lairmore et al, 1986., Harkiss et al, 1991). Moreover inflammatory foci in the brain
correspond to areas containing cells that are actively expressing viral RNA and antigen
(Stowring et al, 1985). It has also been shown that the development of these lesions is due,
at least in part, to an immunopathological response to viral antigens; vigorous
immunosuppression, commenced shortly prior to infection, markedly reduced the level of
inflammatory lesions seen in experimentally infected sheep (Nathanson et al, 1976).
Cellular immune responses to lentivirus infection have, however, been well studied in HIV
and SIV infected individuals. These studies have shown that there is a complex and vigorous
T-lymphocyte response during lentivirus infection in vivo. Virus-specific, MHC restricted
cytotoxic T-lymphocytes (CTL) can be detected in peripheral blood (Walker et al, 1987.,
Riviere et al, 1989), cerebrospinal fluid (Sethi et al, 1988) and in inflammatory lung lesions
(Plata et al, 1987). Viral antigens recognised by circulating CTL's of HIV seropositive
individuals include the structural proteins gag, env and pol as well as the viral regulatory
proteins nef and vif (Walker et al, 1987., 1988., Riviere et al, 1989., Nixon et al, 1988.,
Langlade-Demoyen et al, 1988., Chenciner et al, 1989). The effector cells mediating these
effects are mainly CD8+, MHC class I restricted T cells although some anti-env cytotoxicity
has been found to be non-MHC restricted (see section 1.6.2).
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It has been reported that CD4+, MHC class II restricted T-cells reactive with gp120 can
be derived from the peripheral blood of HIV seronegative individuals after primary
immunisation either in vitro (Lanzavecchia etal, 1988., Siliciano et al, 1988) or in vivo
(Orentas et al, 1990). These CD4+ T cells can exert cytotoxic activity in vitro, but CTL's with
this phenotype have not been detected in vivo, in HIV infected patients.
HIV specific CTL's appear to be present in unusually high frequencies in infected
individuals (Hoffenbach et al, 1989., Gotch et al, 1990). HIV specific CTL activity can be
demonstrated in freshly isolated PBMC's without in vitro restimulation (Walker etal, 1987.,
Koup et al, 1989). With the possible exception of acute infectious mononucleosis, where
there is a high level of 'HLA-unrestricted' cell mediated lysis (Strang & Rickinson, 1987), such
a response has not been observed in other viral infections.
It has been demonstrated that virus-specific CD8+ lymphocytes can suppress both initial
and ongoing HIV replication in autologous PBMC's in vitro (Walker et al, 1986., Tsubota et
al, 1989). These depletion and reconstitution experiments showed that CD8+ T ceils could
reduce reverse transcriptase activity in infected cultures in an antigen specific,
MHC-restricted manner. Similar results have been obtained in an SIV system (Kannagi etal,
1988). The mechanisms by which CD8+ T cells mediate these effects have not been well
defined. Cytotoxic activity may be of importance for control of virus growth (Tsubota et al,
1989), although other workers have suggested that HIV replication is inhibited via non-
cytotoxic mechanisms (Brinchmann et al, 1990., Walker et al, 1991).
The significance of CTL in the pathogenesis of HIV disease is unclear. In various model
systems virus-specific T-cell mediated lysis of infected cells has been shown to be necessary
and sufficient for clearance of viral infection (Larsen et al, 1983., Moskophidis et al, 1987.,
Taylor & Askonas, 1986). That HIV infection invariably proceeds to AIDS and death indicates
that the occurrence of a strong CTL response in the initial phase of infection is somehow
insufficient for protection. In longitudinal studies of HIV infected individuals it has been
observed that there is a decline in frequency of virus-specific CTL and CTLp as the patient
progresses to ARC and AIDS (Hoffenbach et al, 1989). This may be due to a reduction in the
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growth potential of CD8+ cells in infected persons (Pantaleo et al, 1990), a defect which may
specifically affect memory/precursor T cells (Gotch et al, 1990). Alternatively this may reflect
the development of suppressor T cells in later stages of HIV disease (Joly etal, 1989).
In this connexion it is interesting to note that protective retroviral cellular immunity has
been shown to require both CD4+ and CD8+ immune T-cells (Horn et al, 1991). In natural
HIV infection virus-specific CD4+ 'T-helper' cell responses appear to be specifically deficient
in both prevalence and strength: lymphocyte proliferation in response to inactivated HIV
antigen is weak or absent in HIV seropositive persons (Reddy et al, 1987., Wahren et al,
1987), whereas the proliferative responses of the same individuals to cytomegalovirus and
herpes simplex virus are similar to normal controls (Wahren et al, 1987). This has been
interpreted as evidence for HIV antigen specific anergy (McChesney & Oldstone, 1989),
however PBMC's from HIV seropositive individuals respond to culture with synthetic peptides
corresponding to regions of HIV gag, pol and env genes, by proliferation and/or production
of IL-2 (Schrier et al, 1989., Glerici et al, 1990a). The significance of these observations is
unclear, but chimpanzees and gibbon apes chronically infected with HIV have strong
group-specific lymphoproliferative responses to HIV antigens (Eichberg et al, 1987., Lusso et
al, 1988) and it has been suggested that the occurrence of these responses may contribute
to the prevention of the development of AIDS in these species.
1.6.5 Antigenic variation
As described previously (section 1.5.1) Antiviruses mutate at a high rate, ensuring
genetic heterogeneity in the viral population. Visna virus undergoes antigenic variation, as
assessed serologically, during infection in individual hosts (reviewed in Narayan et al, 1987.,
Clements etal, 1988). Narayan et al (1977), demonstrated that antigenically distinct strains
of visna could be isolated from sheep persistently infected with visna virus. The presence of
neutralising antibody selecting for neutralisation-resistant variants both in vitro (Narayan et
al, 1977) and in vivo (Narayan et al, 1981). These variants arise mainly by point mutations
within the env gene (Scott et al, 1979., Clements et al, 1980., 1982), which result in
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conformational alterations of the outer membrane envelope protein (Stanley eta/, 1987). In
visna infection in vivo, however, these variants do not replace the infecting serotype and, in
most long-term infections, the inoculum virus strain persists and spreads without the
emergence of antigenic variants (Lutley et at, 1983., Thormar et al, 1983). Antigenic
variation has also been described during HIV infection (Nara et al, 1990), but again the
functional significance, if any, of these observations is unclear.
Antigenic variation in T cell epitopes is theoretically possible also. This mechanism has
been formally demonstrated as operative during LCMV infection of mice transgenic for an
LCMV-specific T cell receptor molecule (Pircher et al, 1990). Evidence for mutation in CTL
epitopes of HIV has recently been obtained (Phillips et al, 1991), however these mutations
did not result in escape from CTL surveillance, but rather a change in the CTL epitope
recognised. In contrast, the persistence of a CTL epitope in vivo over a 14 month period,
despite the presence of specific CTL activity has recently been reported in an HIV-infected
individual (Meyerhans et al, 1991). Given these contrasting observations, the significance of
such mutantions in an outbred population is unclear. In HIV infection heterogeneity of CTL
activity, both with respect to HLA restriction and recognition of specific epitopes, has been
observed for both gag-specific and reverse transcriptase-specific CTL clones (Johnson et al,
1991., Walker et al, 1989).
1.6.6 Maedi-visna disease
The major clinical presentation of the disease complex caused by maedi-visna virus
infection of sheep is dyspnoea and wasting (maedi) (Sigurdsson, 1954). Visna, a neurological
manifestation of MVV infection, is characterised by afebrile posterior ataxia which progresses
over a course of weeks to months leading to recumbent hind limb paralysis (Sigurdsson et al,
1957). Other diseases associated with MVV infection include arthritis and mastitis (Oliver et
al, 1981., Narayan & Cork, 1985).
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Clinical maedi-visna disease is due to chronic inflammation in particular organs or
tissues. Histologically, the lesions are characterised by the infiltration and proliferation of
mononuclear cells in an active-chronic inflammatory process in organ systems such as the
brain, lung, joints and mammary gland (Narayan & Cork, 1985). As disease progresses this
inflammatory infiltrate destroys normal tissue architecture and compromises function. The
basis of these inflammatory changes is unknown, but could include virus antigen-specific
responses and chemotactic responses to abnormal cytokine release.
Unlike HIV infection, secondary disease resulting from the gross immune deficiency
associated with CD4+ lymphocyte dysfunction and destruction in HIV infection (reviewed in
Rosenberg & Fauci, 1989), is not a major feature of MVV disease (Narayan & Clements,
1990). Some workers have suggested that infection with MVV may cause a mild
immunosuppression (Myer et al, 1988), however most studies have found no convincing
evidence for immunosuppression associated with MVV infection (Griffin et al, 1978., Larsen
et al, 1982a., Dr. P. Bird, personal communication ). It has been reported that there is a
reduction in the CD4/CD8 ratio in the peripheral blood of sheep in late stages of MVV disease
(Kennedy-Stoskopf et al, 1989). However this has not been observed by other groups,
studying both experimentally infected sheep and field cases of maedi, (P. Bird, personal
communication, G. Petursson, personal communication )
9-
The progression of madi-visna-induced disease may be enhanced by the presence of
other viruses. This has not been demonstrated formally, but strong circumstantial evidence,
from Iceland and Holland, indicates that visna virus is disseminated more readily, and that
disease is more severe, in flocks where sheep affected with sheep pulmonary adenomatosis
(SPA) coexist (Palsson, 1976., Houwers & Terpstra, 1984). Moreover it has been shown that
experimental co-infection of sheep with SPA and visna leads to an extremely rapid
progression of disease, which has been suggested to result from a 'pathogenetic synergism'
between the two agents (DeMartini et al, 1987), but the basis of this phenomenon is
unknown.
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For HIV-1 it has been shown that gene products from a number of viruses can trans-
activate the HIV LTR in vitro (reviewed in Nelson et al, 1990., Tevethia & Spector, 1989),
and it has also been shown that prior infection of cells with another virus may induce
susceptibility to HIV infection in previously non-permissive cells (Lusso et al, 1991
McKeating et al, 1990). It is possible that similar phenomena may play a role in the
pathogenesis of visna-induced disease.
1.7 Conclusion
Lentiviral disease, with its long incubation period, gradual onset and protracted
progressive course requires continuous virus replication. Viral persistence, in the face of a
vigorous host immune response, is thus the central feature of lentiviral pathogenesis (Haase,
1986).
It is likely that sequestration of visna virus within infected macrophages is a major
mechanism of viral persistence and yet mechanisms of immunity against virus infected cells
have received very little study in maedi-visna infection. The other major mechanism of
lentiviral persistence in vivo is the ability of the virus to maintain itself in a state of restricted
replication within infected cells. However, neither the molecular basis of this replication state
nor the reasons why it occurs are understood. A plausible hypothesis as to why viral
replication in vivo is restricted, rather than lytic, is that this is, at least in part, a response by
the virus to the development of an active immune response in the initial period post-infection.
Yet despite the vast amount of work which has been done on the immunology of HIV infection
in persistently infected individuals, our understanding of the immediate, acute immune
response to lentiviral infection of lymphoid tissue is poor and thus our knowledge of factors
affecting viral replication in vivo incomplete.
Thus the aims of this project were two-fold. Firstly, to investigate more closely the
immune responses of sheep persistently infected with maedi-visna virus, in particular
mechanisms of immunity to virus infected cells. Secondly to attempt to analyse the acute
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immune responses of sheep to visna infection. This work was to be based on experiments
involving lymphatic cannulation (Hall & Morris, 1962), a technique which allows direct access





All chemicals were supplied by SIGMA Chemical Co., Poole, Dorset, England or BDH
Chemicals Ltd., Poole, England unless otherwise stated. Radiolabeled compounds were
supplied by Amersham International pic., Amersham, Bucks, England. Unless otherwise
stated all enzymes used in molecular biological techniques were supplied by Boehringer
Mannheim, BCL, Lewes, England.
2.2 Bacterial culture
2.2.1 Media
The basic bacterial growth medium was LB (Luria-Bertani) medium (1% tryptone, 0.5%
yeast extract, 1% NaCI made to pH 7 with NaOH). Ampicillin was added to 150pg/ml. All the
plasmids used in this project conferred ampicillin resistance. LB agar plates were made with
LB medium and 1% Bacto-agar (Difco, Molesley, Surrey). For "blue-white" selection
(Sambrook et al, 1989) of bacteria transformed with pTZ derived plasmids, 40pl of 5-bromo-
4-chloro-3-indolyi-f3-D-galactoside (X-gal) (20mg/ml in dimethylformamide) and 20pl of
isopropylthio-B-D-galactoside (IPTG) (40mg/ml in SDW) were spread on the surface of
premade LB agar plates and allowed to dry before plating out bacteria.
2.2.2 Bacterial strains and culture
E. coli strain JM101 ( supE, thi, A(lac-proAB), [F, traD 36, proAB, laclQ Z AM 15]
(Yanisch-Perron et al, 1985) was used for bacterial transformations involving pTZ based
plasmids, while the E. coli strain JM83 (ara, A( lac-proAB), rpsL(=strA), ^80, lac Z AM15)
(Yanisch-Perron et al, 1985) was used for transformations with non-pTZ-based plasmids
(see section 2.3.1). Single colonies of untransformed E. coli were grown by streaking an
inoculum from a frozen stock on 1% agar plates made with minimal medium (42mM
Na2HP04, 22mM KH2P04, 19mM NH4CI, 9mM NaCI, 100pM CaCI2, 0.2% glucose).
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Transformed bacteria were grown on LB agar supplemented with 150pg/ml ampicillin.
Bacterial stocks were frozen in 15% glycerol and stored at -70°C (Maniatis et al, 1982).
2.2.3 Transformation of E.coli
E. coli cells competent for transformation by plasmid DNA were prepared by a
modification of the method of Hanahan (1983). 0.2mi of a fresh overnight culture of E. coli in
LB medium was diluted 1:100 in psi broth (2% tryptone, 0.5% yeast extract, 20mM MgS04,
10mM NaCI, 5mM KCI) and grown, with shaking at 37°C, until the OD550=0.3 . 5ml of this
culture were diluted 1:20 in psi broth and grown until the OD550=0.48. This culture was
chilled briefly on ice, and then centrifuged (2000x g, 4°C, 5min). The cell pellet was
resuspended in 33ml ice-cold TfBI (35mM sodium acetate, 100mM CaCI2, 100mM RbCI,
50mM MnCI2, 15% glycerol, made to pH 5.9 with acetic acid), held on ice for a further 10-15
min. and then centrifuged (2000x g, 4°C, 5min). This cell pellet was resuspended in 4mi of
TfBII ( 10mM morpholinopropane sulfonic acid, 10mM RbCI, 75mM CaCI2, 15% glycerol,
made to pH 6.8 with KOH) and kept on ice for 20min. Aliquots (0.2mi) were then snap-frozen
in liquid N2 and stored at -70°C. Competent £. coli prepared in this manner routinely yielded
5 x 106-107transformants per pg of intact pTZ 19R.
For bacterial transformation, aliquots of competent £. coli were thawed on ice and DNA
(2-5pl) added. The suspension was then chilled on ice for 30min prior to heat-shocking (42°C,
60-90s), to increase the uptake of DNA. Cells were cooled briefly and then each aliquot was
made to 1 ml with LB (no antibiotics) and incubated, with vigorous shaking (230rpm), at 37°C
for 1 hr. 200(jl of these bacteria were plated out onto LB agar plates supplemented with
150pg/ml ampicillin.
Ampicillin resistant colonies were picked and checked for the required plasmid by
restriction enzyme analysis.
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2.3 Preparation of DNA and molecular cloning techniques
Many of the methods used in handling and cloning DNA were based on methods given in
'Molecular Cloning. A laboratory manual.' (Sambrook et al, 1989). Routine techniques, such
as phenol-chloroform extraction, butanol extraction and ethanol precipitation were performed
as described in this manual.
2.3.1 Vectors used in cloning, sequencing and expression
Some of the characteristics of the plasmids used in this project are summarised in Table
2.1. pTZ 18R, pTZ 19R and M13K07 were purchased from Pharmacia. Plasmids pMA5620,
pOGS 40 and pUG 41S were gifts from Dr. S.E. Adams, British Bio-technology Ltd., Oxford.
The LEU2 gene in pMA5620 and pOGS 40 lacks a promoter and is referred to as
LEU2-d. It is thought that the poor expression of this gene creates a selective advantage for
cells that have a higher copy number of the plasmid (Kingsman et at, 1990).
2.3.2 Polymerase Chain Reaction (PCR)
Low molecular weight DNA, prepared from EV1 (Sargan et al, 1991) infected fibroblasts
by the method of Clements et al, (1979), (a gift from Dr. D.J. Roy, Dept. Vet Pathology,
University of Edinburgh) was used as the template in a PCR. This material contains less than
0.1% proviral DNA (Dr. D.J. Roy, personal communication). 1 pig of low molecular weight
DNA was mixed with O.lnmol of each primer (Oswel DNA, Edinburgh) and this was made to
10pl with sterile distilled water (SDW). Remaining PCR reagents were then added.
Amplifications were done,under liquid paraffin, in 90pl of 50mM KCI, 25mM Tris-HCI pH 8.8,
6mM MgCI2, 3mM dithiothreitol, 170pg/ml bovine serum albumin (BSA), 300pM (each)
dNTP's and 5 units of Taq polymerase.
Thirty cycles of PCR were carried out: denaturation at 95°C, 0.6min; annealing at 45°C,














pTZ18R pMB1 N/A Ampr, AlacZ N/A Pouwels et al,
1985
pTZ 19R pMB1 N/A Ampr, AlacZ N/A Pouweis et al,
1985
M13K07 p15A N/A Kanr N/A Vieira &
Messing, 1987
pMA5620 pAT153 2pm Ampr Leu+ Adams et al,
1987a
pOGS 40 pAT153 2pm Ampr Leu+ Gilmour et al,
1989
pUG 41S pMB1 ARS1 Ampr Ura+ Lue et al,
1987
N/A - none available
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from under paraffin, extracted once with phenol-chloroform, once with chloroform and ethanol
precipitated. The PCR product was then gel purified for use in subsequent cloning steps.
2.3.3 DNA agarose gel electrophoresis
Agarose gels, 0.8-1% agarose, were made using TAE buffer (40mM Tris-HCI, 8mM
sodium acetate, 0.4mM EDTA, pH 7.85), Ethidium bromide was added to the agarose, when
cool, to a final concentration of 0.1pg/ml. DNA was loaded into wells in 5% glycerol, 12.5mM
EDTA pH 7.9, 0.01% SDS, with bromophenol blue. Preparative gels were run in the dark, and
minimally exposed to ultraviolet light. Gels were examined on an ultra-violet (UV)
transilluminator (UV emission ?i=304nm).
DNA was recovered from agarose gels using a Geneclean II kit (BIO 101 Inc., La Jolla,
California, USA.) as described by the manufacturerer.
2.3.4 Preparation of DNA fragments for blunt-ended cloning
Conversion of protruding ends to blunt ends was done, using the Klenow fragment of E.
coli DNA polymerase 1 (Jacobsen et at, 1974), according to Sambrook et at, (1989).
Fragment ends were phosphorylated by treatment with T4 polynucleotide kinase (Sambrook
et at, 1989).
2.3.5 Restriction endonuclease digestion of DNA
Digestions were carried out, in the incubation buffer supplied with the enzyme, in 20-50pl
total volumes with 1-25U enzyme/pg purified DNA. DNA was digested for 2-3hrs at 37°C
unless otherwise stated. Miniprep DNA (2pl) was digested with 5-10U of enzyme for 2-3hrs at
37°C.
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2.3.6 Preparation of cut vector
Purified plasmid DNA was digested with the required restriction endonuclease (10U/pg
DNA) for 3hrs at 37°C. To remove the 5' phosphate of the linearised plasmid, and so reduce
the chances of plasmid religating to itself (Sambrook etal, 1989), calf intestinal phosphatase,
in excess, was added for the last 30min of the digestion. Digested plasmid DNA was then
separated on a preparative agarose gel and linearised plasmid recovered from the agarose
using a Geneclean II kit. This DNA , in SDW, was stored at -20°C.
2.3.7 Ligation of DNA
For ligation of DNA fragments with cohesive termini, 5U of T4 DNA ligase were used,
10U of enzyme were used for ligation of fragments with blunt, phosphatased ends. Ligation
reactions were carried out, in the incubation buffer supplied with the ligase, in a final volume
of 10pil. 50-1 OOng of vector DNA were used in each ligation, at a molar ratio of insert: vector
of 5: 1.
In ligation reactions where the DNA fragments had cohesive termini, insert and vector
DNA were mixed and heated to 65°C. The mix was allowed to cool to room temperature and
then ligase and ligase buffer were added. Ligation reactions were incubated, at room
temperature, for 16-20hrs.
For blunt-ended ligations, insert and vector DNA were treated as described above except
that the reaction was incubated for 16-20hrs at 15°C.
Ligation mixtures were used to transform E. coli without purification.
2.3.8 Miniprep of plasmid DNA
Transformed E. coli were grown overnight in LB broth supplemented with ampicillin
(150(jg/ml) and 1.5ml of this culture were used for preparation of plasmid DNA. Plasmid DNA
was isolated by a modification of the 'alkaline lysis' method of Ish-Horowicz & Burke (1981).
Briefly, the bacteria were pelleted, digested with lysozyme and then lysed in alkaline SDS.
Chromosomal DNA was precipitated by addition of high salt (3M Na acetate, pH 4.8), spun
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out and plasmid DNA recovered from the supernatant by ethanol precipitation. The
phenol/chlorotorm extraction and RNase treatments described in the original protocol were
omitted. The final DNA pellet was resuspended in 20pl of SDW & 2pl of miniprep DNA were
used for each restriction enzyme digestion.
2.3.9 Purified plasmid preparations
Large scale preparations of plasmid DNA were based on the alkaline lysis methods of
Birnboim & Doly, (1979) and Ish-Horowicz & Burke (1981). E coli were grown, with shaking
(230rpm) at 37°C, for 24hrs in 500ml of LB broth with ampicillin (150pg/ml). Bacteria were
pelleted by centrifugation (7500x g, 4°C, 5min) and the supernatant removed. Cells were
resuspended in 36mls of GTE (50mM glucose, 25mM Tris-HCI pH 8, 10mM EDTA) and 4ml
of freshly made lysozyme (40mg/ml in GTE) were added, mixed in thoroughly and incubated
at room temperature for 10min. 80ml of freshly prepared alkaline SDS (0.2M NaOH, 1%
SDS) were then added, swirled gently to mix fully, and the suspension incubated on ice for a
further 10min. To this, 40ml of ice-cold 5M potassium acetate, pH 4.8 was added, mixed well
and incubated on ice for 1 hr with occasional gentle stirring to break up lumps of precipitate.
10ml of SDW were then added and the suspension centrifuged (15000x g, 4°C, 5min) to
pellet chromosomal DNA and bacterial debris. Avoiding any floating precipitate, the
supernatant was transferred to a fresh centrifuge bottle and 0.6 volumes of cold (-20°C)
isopropanol added. This was mixed well and allowed to stand at room temperature for 15min.
Nucleic acid was recovered by centrifugation (9500x g, 4°C, 5min) and the pellet
resuspended in 30ml TE, pH 8 (10mM Tris-HCI pH 8, 1mM EDTA). 30g of solid caesium
chloride were dissolved in this suspension, ethidium bromide (10mg/ml in SDW) was added
to a final concentration of 800pg/ml and allowed to intercalate to the DNA. The caesium
chloride gradient was formed by centrifugation at 40000rpm for 18hrs at 20°C in a Beckman
VTi 50 rotor (Beckman L8-60M ultracentrifuge). After centrifugation the lower, closed circular,
plasmid DNA band was collected and butanol extracted 3-5x to remove the ethidium bromide.
Plasmid DNA was then precipitated with 2.Vz volumes of 70% ethanol and washed with 70%
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ethanol. This was repeated twice. The purified preparation of DNA was then taken up in SDW
and the concentration measured by spectrophotometry. Plasmid DNA, in SDW, was stored at
-70°C.
2.3.10 Quantitation of DNA
The absorbance of purified DNA solutions was measured spectrophotometically at 260nm
and 280nm. Pure DNA gives an approximate OD260/OD28o absorption ratio of 1.8. An OD260
of 1 corresponds to approximately 50pg/ml of double stranded DNA. The concentration of
DNA in less highly purified solutions, such as miniprep DNA, was estimated by running an
aliquot on ethidium bromide containing agarose gels and comparing the fluorescence of the
sample with that of a series of standards of known DNA concentration (Maniatis et al, 1982).
2.4 Blot hybridisations
2.4.1 Southern blotting
Restriction endonuclease digested DNA was electrophoresed through 0.8% horizontal
agarose gels for 16-20hrs at 20mA. The gel was examined under UV, photographed, and the
DNA was then transferred to a nitrocellulose filter (Hybond-C, Amersham) according to
Southern (1975). After electrophoresis, the DNA in the gel was denatured by soaking the gel
in two changes (500ml) of 1,5M NaCI, 0.5M NaOH over 1 hr, with gentle shaking. The gel was
then neutralised by soaking in three changes (500ml) of 1M Tris HCI, pH 8, 1.5M NaCI over
1 hr. Transfer of DNA was carried out by blotting 20x SSC (0.3M tri-sodium citrate, 3M NaCI,
pH 7) through the gel, through the nitrocellulose membrane and into Whatman 3MM paper,
overlaid with a stack of paper towels, overnight. After blotting the agarose gel was examined
under UV to check the efficiency of transfer of DNA from the gel to the filter. The
nitrocellulose was washed in 6x SSC, drained and allowed to dry for 30min at room
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temperature. The DNA was baked onto the filter for 2hrs at 80°C in a vacuum oven. Filters
were used immediately in hybridisation experiments.
2.4.2 Preparation of [32P]-labelled DNA probes
DNA fragments to be used as probes were prepared by restriction enzyme digestion from
plasmids and purification from agarose gels. Probe fragments were labelled in vitro with
[a-32P]-dCTP using the Klenow fragment of E. coli DNA polymerase 1 and random
oligonucleotide primers (Feinberg & Vogelstein, 1983, 1984). The reaction mix was incubated
for 3-4hrs at 37°C, and the reaction stopped by the addition of oligo-stop buffer (50mM Tris
HCI pH 7.5, 50mM NaCI, 5mM EDTA pH 8, 0.5% SDS). Incorporation of radioactive
precursors was monitored by acid precipitation (12% trichloracetic acid) (Sambrook eta/,
1989). Probes with a specific activity of 108-109cpm/pg DNA were used in hybridisations.
Immediately before use, probe DNA was denatured by boiling for 5min and then
quenching on ice.
2.4.3 Hybridisation of nitrocellulose filters
Nitrocellulose filters were floated on the surface of 6x SSC until wet and were then
prehybridised for 16-18hrs at 68°C in 6x SSC, 0.5% SDS, 5x Denhardt's solution (Denhardt's
solution is 1% Ficoll, 1% polyvinylpyrrolidone, 1% BSA; Denhardt, 1966) & 100pg/ml sheared,
denatured salmon sperm DNA (approximately 200pl prehybridisation fluid/cm2 of filter).
Hybridisation reactions were performed at 68°C for 16-18hrs in 6xSSC, 0.01 M EDTA, 5x
Denhardt's solution, 0.5% SDS & 100pg/ml sheared, denatured salmon sperm DNA with
32P-labelled, denatured probe (approximately 50pl hybridisation mix/cm2 filter). After
hybridisation, filters were submerged in 2x SSC, 0.5% SDS for 5 min and then transferred to
a fresh tray containing 2x SSC, 0.1% SDS and incubated at room temperature for 15min. The
blots were then washed in 0.1 x SSC, 0.5% SDS at 68°C with gentle agitation, after 2hrs the
buffer was changed and the incubation continued for a further 30min. The filter was air-dried
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at room temperature and then exposed to Kodak XS-1 film, with phospho-tungstate
intensifying screens, at -70°C.
2.5 DNA Sequencing
2.5.1 Preparation of single stranded DNA
Single stranded DNA, for use as template in sequencing reactions, was prepared by a
modification of the method of the protocol obtained from the supplier of the 'phagemid
(Pharmacia literature). JM101 cells transformed with the recombinant pTZ were grown in 2x
YT (1.6% tryptone, 1% yeast extract, 86mM NaCI, made to pH 7.4 with K2HP04)
supplemented with ampicillin (150pg/ml) till OD660= 0.5. 400pl of this culture (approximately
1.6 x 108 cells) were infected with helper phage M13K07, at a multiplicity of infection of 10,
and shaken vigorously for 1 hr at 37°C. The culture was then made to 10ml with 2x YT
supplemented with ampicillin (150pg/ml). Kanamycin was added to 70pg/ml and the culture
was grown at 37°C for 16-18hrs with vigorous shaking. The supernatant was then centrifuged
(4000x g, 4°C, 15min) to remove bacterial cells and 'phage was precipitated from the
supernatant by the addition of of polyethylene glycol/ NaCI (to final concentrations of 4%
PEG, 700mM NaCI). After 30min on ice the precipitated phage was recovered by
centrifugation (11000x g, 4°C, 40min), resuspended in 400pl of TEN buffer (20mM Tris HCI
pH 7.5, 20mM NaCI, 1mM EDTA) and extracted four times with phenol/chloroform pH 8,
three times with chloroform and ethanol precipitated. The DNA pellet was resuspended in
22pl of SDW and 2pl of this suspension were electrophoresed through 1% agarose and
examined under UV to determine the yield of DNA.
2.5.2 Sequencing reactions
DNA was sequenced using the dideoxynucleotide chain termination method (Sanger et
at, 1977) and [a-^SJ-dATP (Biggin et at, 1983) with a Sequenase kit (USB corporation) and
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M13 reverse sequencing primer (Pharmacia). Sequencing reactions were done according to
the protocol supplied with the Sequenase kit.
2.5.3 Double strand sequencing
Double-strand sequencing of supercoiled plasmid DNA was performed as follows;
plasmid DNA, purified on caesium chloride/ethidium bromide gradients, was used as template
for the sequencing reaction. 3-5pg of purified plasmid DNA were boiled for 3min with primer
(20:1 molar excess, primer:template) in Sequenase reaction buffer and snap cooled on ice.
This procedure denatured the DNA and allowed the primer to anneal. Sequencing reactions
were performed as for single-strand sequencing except that the labelling reaction was done in
the presence of 8% dimethyl sulphoxide (DMSO).
2.5.4 Sequencing gel electrophoresis
DNA sequencing samples were electrophoresed through 6% acrylamide (19:1
acrylamide/bisacrylamide, 7.67M urea in 45mM Tris HCI, 45mM Boric acid, 5mM Na2EDTA,
pH 8.3) slab gels cast in a Bio-Rad Sequi-Gen nucleic acid sequencing cell (38 x 50cm). Prior
to casting the gel, acryiamide solutions were de-gassed under vacuum and filtered through a
0.45pm filter. 5mm wide loading wells were formed using a 'sharksteeth' comb. The buffer in
the electrode tanks was TBE (45mM Tris HCI, 45mM H3B04, 5mM EDTA, pH 8.3). Prior to
loading samples gels were pre-run at 50W until the gel temperature reached 50°C.
Gels were loaded with 3pl volume of sequencing samples, in adjacent tracks, in the order
ATGC. Immediately before loading onto the gel sequencing samples were denatured by
heating to 80°C for 3min and then quenching on ice. Sequencing gels were run for 2-6hrs at
50°C (40-50W).




Sequence analysis was done using version 6.2 of the University of Wisconsin Genetics
Computing Group package (Devereux et al, 1984).
2.6 Yeast culture
2.6.1 Media
Non-transformed yeast were grown in YEPD medium (2% peptone, 1%yeast extract, 2%
glucose). Yeast transformants were grown in selective medium; either Sc-glc medium (0.67%
yeast nitrogen base (YNB) without amino-acids (Difco Ltd.), 1% glucose) or Sc-gal medium
(0.67% YNB, 0.3% glucose, 1% galactose). Agar plates were made with either YEPD or SC-
glc medium and 2% bacto-agar. Where indicated, tryptophan and uracil were added to a final
concentration of 20pg/ml.
2.6.2 Yeast culture and strains
Yeast culture conditions and induction for protein expression were based on the protocols
described oy Kingsman et al, (1990).
The protease deficient Saccharomyces cerevisiae strain BJ 2168 (a, leu2-3, Ieu2-112,
trpl, ura3-52, prbl-1122, pep4-3, pcr1-407, gal2) (Jones, 1991) (a gift from Dr. S.E. Adams,
British Bio-technology Ltd., Oxford) was used for all yeast expression work.
Single colonies of BJ 2168 were grown by streaking an innoculum from a frozen stock on
YEPD plates. Transformed yeast were grown on Sc-glc media, with appropriate supplements
for the auxotrophic requirements of the yeast transformant.
Yeast stocks, for long term storage, were prepared from cultures in late-log/ early
stationary phase (OD600=1). Equal volumes of yeast culture and sterile 40% glycerol were
thoroughly mixed, placed at -20°C for 3-4hrs and then transferred to -70°C for long term
storage.
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For large scale culture yeast were grown, from glycerol stocks, in sterile conical flasks
(culture fluid no more than a quarter of the flask volume), on an orbital shaker (New
Brunswick Scientific) operating at 260rpm. Typically, 100ml of Sc-glc media (plus
supplements) were innoculated with a single glycerol stock of yeast transformant and
incubated, with vigorous shaking, till the cell density was 2-4 x 107 cells/ml. Each of 2 x 500ml
of Sc-glc media was then innoculated with 50ml of the pre-culture and grown to 4-6 x 107
cells/ml. This litre of culture fluid was used to innoculate 8 x 500ml of either Sc-glc media (for
constitutively expressing transformants) or Sc-gal media (to induce protein expression in
pOGS transformants) and cultured for a further 24-48hrs.
2.6.3 Yeast transformation
For yeast transformation, DNA was purified by centrifugation on caesium-chloride/
ethidium bromide gradients. Transformants were selected by their ability to grow on minimal
media without leucine and/or uracil supplementation. Yeast were transformed using the
method of Hinnen et al, (1978). 100ml of BJ 2168 were grown in YEPD, with shaking, to a
cell density of 1-2 x 107cells/ml. Yeast were harvested by centrifugation (200x g, 5min, room
temperature), washed in 1M sorbitol pH 5.6 and treated with glusulase (NEN Research
Products, Stevenage, Herts.), to digest the yeast cell wall, till approximately 90% of the yeast
cells had been spheroplasted, as monitored by phase contrast microscopy. Spheroplasts
were washed twice in 1M sorbitol, once with STC (1M sorbitol, 10mM CaCI2, 10mM Tris HCI
pH 7.5) and resuspended in 1ml STC. DNA (2-3pg, in less than 10pl final volume) was added
to 10Opil of competent cells, the suspension was mixed gently and incubated at room
temperature for 15min. The yeast cells were then osmotically shocked, to increase the uptake
of DNA, by addition of 1ml 44% PEG for 10min. Spheroplasts were spun down gently (200x
g, 5min), the supernatant decanted and the pellet resuspended in 1ml 1M sorbitol. Aliquots of
this suspension were added to 20ml of warm regeneration agar (1M sorbitol, 0.67% YNB, 1%
glucose, 3% Bacto-agar), mixed gently and poured into a petri dish. Agar plates were allowed
to set, inverted and incubated at 30°C.
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2.6.4 Preparation of protein extracts
5 x 108 cells were harvested, after galactose induction where necessary, and washed
once in ice-cold SDW. All subsequent procedures were carried out at 4°C. Cells were
resuspended in 1ml of TEN buffer ( 100mM Tris pH 7.4, 140mM NaCI, 2mM EDTA) and
vortexed, for three periods of 1min, with 1min on ice between vortexing, with 1g of acid-
washed and baked glass beads (BDH, 40 mesh). The whole mixture was collected after
allowing the glass beads to settle. This is a total cell extract (Kingsman et al, 1990).
2.7 Mammalian tissue culture
2.7.1 Cell lines and cell culture
Sheep epidermal fibroblast cultures were grown in Dulbecco's modified Eagle's medium
(DME) (Cat No. 074-02100, Gibco Biocult, Uxbridge) supplemented with 2mM L-glutamine,
25mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethane sulfonic acid) and 10% foetal calf
serum (FCS) (Azo-Tek, Ltd., Herts.).
Cell lines were passed using 0.05% (w/v) trypsin and 0.02% (w/v) EDTA in phosphate
buffered saline (PBS) (0.8% NaCI, 0.02% KCI, 27mM Na2HP04, 1,5mM KH2P04, pH 7.2)
and were grown at 37°C with 5% C02 in either 75, 175 or 225cm2 tissue culture flasks.
Stocks of cells were cryopreserved, at 2 x 106 cells/ml, in an ice-cold mixtureof 90%
FCS, 10% DMSO. 2 x 106 cells, in freezing mix, were cooled to -70°C using a programmed
cell freezer (Planar Products, London) and stored under liquid nitrogen. To resuscitate frozen
cell lines, an aliquot was thawed quickly at 37°C, diluted 1:1 with warm DME/10% FCS and
then spun through 20ml of DME/ 10% FCS (200x g, 5min) before being layered on the
bottom of a 25cm2 tissue culture flask in DME/ 10%FCS. Cells were incubated overnight and
the medium replaced with fresh DME/10% FCS.
57
2.7.2 Viruses
Visna isolates EV1 (Sargan et al, 1991) and K1514 (Petursson et al, 1976) were grown
in sheep fibroblast cultures maintained in DME/ 2% FCS. Cultures were infected with visna at
a low multiplicity of infection (approximately 0.05 tissue culture infectious doses(TCID50/cell)
and virus containing supernatant was harvested when the cultures displayed extensive
cytopathic effect. Visna virus was titred on epidermal fibroblasts in a quantal assay. Virus
titres were calculated by the method of Reed and Muench (1938).
2.7.3 Monoclonal antibody production
2.7.3.1 Myeloma cell culture
Myeloma cells, NSO/1 (Galfre & Milstein, 1981) were grown in RPMI 1640 (Cat. No. 074-
1800, Gibco Biocult, Uxbridge) supplemented with 2mM L-glutamine and 10% foetal calf
serum. Cells were maintained at 37°C in a humid atmosphere of 5% C02. Prior to a fusion
NSO/1 were revived from frozen stocks into RPMI/10% FCS and maintained in logarithmic
growth for 6-7 days by passing the culture daily at 105celis/ml.
2.7.3.2 Procedure of cell fusion
Cell fusion was done according to Eshhar (1985). Spleen lymphocytes (no more than
108cells) and myeloma cells were mixed at a ratio of 5:1 and spun down gently (200x g,
5min). The pellet was gently resuspended in 2ml of 40% PEG 1500 (Boehringer Mannheim),
which had been prewarmed to 37°C, and incubated at 37°C for 2min. The PEG was then
diluted by slow addition of prewarmed RPMI (supplemented with 2mM glutamine and 1mM
sodium pyruvate, without serum). The cells were washed once and then plated out at (1-5) x
105 cells/ml in RPMI/ HAT ( RPMI 1640, 15% FCS, 2mM glutamine, 1mM pyruvate, 100pM
hypoxanthine, 0.4pM aminopterin, 16pM thymidine). Cultures were incubated at 37°C in 5%
C02 in a humid incubator.
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2.7.3.3 Cloning of hybridoma cells
Hybridoma cell lines were cloned by either of two methods:
a) Soft agar cloning: RPMI (with glutamine and pyruvate)/ 20% FCS containing 0.5% Bacto-
agar (Difco Ltd.) was prepared and held at 46°C. 15ml of this mixture were put into 90mm
petri dishes and left at room temperature to set. Cell dilutions, 105-102cells/ml, were prepared
in RPMI/20%FCS, mixed 1:1 with agar-RPMI and spread out on the solidified agar plates.
Plates were left 10min to allow the agar to set and were then incubated at 37°C, 5% C02 for
10-12 days. Single colonies were picked using a pasteur pipette and transferred to 24 well
plates, for expansion and testing.
b) Limiting Dilution cloning: Irradiated (2000 Rads), syngeneic spleen cells were prepared as
feeder cells (for preparation of spleen cell suspension see section 2.14.1.3), plated out in 96
well flat-bottomed tissue culture plates and incubated overnight at 37°C/5% C02. Hybridoma
cells to be cloned were prepared at cell dilutions of 50, 10 and 1 ce!l(s)/ml and plated out at
10Opil/well. Cultures were incubated for 5 days at 37°C, 5% C02. Wells containing single
colonies were identified by visual inspection, expanded, tested and then recloned.
2.7.3.4 Hybridoma culture
Hybridoma cell lines were maintained in RPMI 1640 supplemented with
2mM L-glutamine, 1mM sodium pyruvate and 10% FCS. Cells were cryopreserved and
resuscitated as described previously (section 2.7.1) except that cell lines were revived into
RPMI/10% FCS.
2.8 Antigen preparation
2.8.1 Preparation of visna antigen for Western blotting
Fibroblast cultures were infected with visna at 0.05 TCID^/ cell and maintained in DME/
2% FCS until extensive cytopathic effect was observed. Culture supernatant and infected
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cells were collected and pelleted by centrifugation (10000x g, 4°C, 16hrs). The pelleted
material was resuspended in PBS and then centrifuged (120000x g, 4°C, 3hrs) to
concentrate and disrupt the virus/ cell mix. The pellet was resuspended in PBS and this
material was stored, in aliquots, at -70°C for use in immunoblotting experiments.
2.8.2 Purification of visna
Visna virus was purified from the supernatant of infected cell cultures by centrifugation on
sucrose gradients. Briefly, the supernatant of cultures showing extensive cytopathic effect
was harvested and clarified by centrifugation (10000x g, 4°C, 30min). Virus was pelleted from
this material by centrifugation (10000x g, 4°C, 16-18hrs) and resuspended in a minimal
volume of PBS. 25%-60% sucrose gradients were prepared by layering 3mi of each of 25%,
35%, 45%, and 60% sucrose solutions in a Beckman centrifuge tube (14mm x 95mm,
ultraclear). These were held at 4°C overnight to diffuse and form the sucrose gradient. The
clarified, pelleted visna was layered onto the sucrose gradients and centrifuged (100000x g,
4°C, 16hrs). Gradients were fractionated into 0.5ml aliquots and the virus containing fractions
identified by analysis on SDS-PAGE and reverse transcriptase assay. Peak fractions were
pooled, diluted in PBS and visna recovered by centrifugation (100000x g, 4°C, 16hrs).
Purified virus was stored in aliquots at -70°C. This material contained all the major structural
proteins of visna, as judged by immunoblot analysis with sera from infected sheep (data not
shown).
2.8.3 Purification of Ty-virus-like particles (Ty-VLP's) from yeast
Ty-VLP's were purified from yeast by a modification of the method of Adams et at,
(1987a ) All steps in the purification protocol were performed at 4°C using pre-chilled buffers.
Yeast cells were harvested by centrifugation (2500x g, 4°C, 10min) and, washed'four times in
ice-cold SDW. Approximately 5ml of packed cells were obtained per litre of culture fluid. Cell
pellets were resuspended in 4ml of TEN buffer (100mM Tris HCI pH 7.4, 2mM EDTA, 140mM
NaCI) plus a cocktail of protease inhibitors (chymostatin, antipain, leupeptin and pepstatin A
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in DMSO, aprotonin in SDW (all at 625ng/ml) and 5pM phenyl methylsulfonyl fluoride in
ethanol). 5ml of acid-washed and baked glass beads were added and the yeast cells broken
open by three rounds of vortexing with glass beads. After each round of vortexing the
suspension was centrifuged (2000x g, 4°C, 5min), the supernatant removed and kept on ice,
and the cells resuspended in fresh TEN plus protease inhibitors. 90-95% breakage of yeast
cells was achieved, as judged by phase contrast microscopy. The VLP-containing
supernatants (approx. 12ml) obtained after breaking open the yeast were pooled, clarified by
centrifugation (13000x g, 4°C, 20min) and then concentrated by centrifugation onto a 2ml
60% sucrose cushion (100000x g, 4°C, 1hr). Material at the interface and in the cushion was
collected and dialysed overnight against TEN, with protease inhibitors. Ty-VLP's were purified
from the dialysate by centrifugation through 15%-60% sucrose gradients (53000x g, 4°C,
3hrs). After centrifugation the gradient was fractionated into 2ml aliquots and VLP containing
fractions identified by analysis on SDS-PAGE. Fractions containing VLP's were pooled and
dialysed against TEN.
Protein concentrations were determined using a dye-binding assay (Bradford, 1976)
obtained from Bio-Rad laboratories, using purified IgG as a standard. Purity of the antigen
preparation was assessed by densitometric examination of Coomassie stained gels using a
Shimadzu densitometer.
2.8.4 Purification of p25 from the Ty-p25 VLP's
Hybrid Ty-p25 VLP's were dialysed against several changes of 100mM Tris HCI pH 7.4,
10mM CaCI2. The dialysate was then made to 0.05% CHAPS (3-[(3-cholamidopropyl)
dimethylammonio]-1 -propane sulphonate) and incubated with Factor Xa protease (BCL) at a
ratio of 100:1 (w/w) for 25hrs at 25°C. An aliquot of this digest was analysed by SDS-PAGE
to check that digestion was complete. The suspension was then centrifuged (100000x g, 4°C,
1 hr) to pellet the Ty-VLP's from the released, soluble p25. The p25 containing supernatant
was dialysed against several changes of PBS, to remove detergent, and the protein
concentration measured using the dye-binding assay. p25 protein was stored in aliquots at
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-70°C. Purity of the antigen preparation was assessed by silver-staining of the p25
preparation separated on SDS-PAGE.
2.9 Detection of antigen
2.9.1 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis of proteins
Protein separation was by discontinuous polyacrylamide gel electrophoresis with a Tris-
glycine buffer containing SDS (384mM glycine, 0.1% SDS, 50mM Tris HCI), (Laemmli, 1970).
Resolving gels were either 10% acrylamide slab gels or 5%-20% linear gradient acrylamide
gels (37.5: 1 acrylamide: bisacrylamide) made with 375mM Tris HCI pH 8.7 and 0.1% SDS.
Stacking gels were 3% acrylamide, 0.15% N,N'-methylenebisacrylamide made with 125mM
Tris HCI pH 6.8 and 0.1% SDS. Samples, mixed with an equal volume of sample buffer (10%
(v/v) 8-Me, 10% (w/v) SDS, 125mM Tris HCI pH 6.8, 20% (v/v) glycerol, 0.1% (w/v)
bromophenol blue), were boiled for 3min before electrophoresis through vertical slab gels
(Bio-Rad Mini-protean II Slab cells). Gels were run at 150V for 1-2hrs.
2.9.2 Staining of SDS-PAGE
Gels were stained by either of two methods:
a) Coomassie Blue staining: Coomassie Brilliant Blue G-250 was dissolved in methanol and
then made to 20% methanol, 5% acetic acid and filtered through Whatman No. 1 filter paper.
Gels were stained in Coomassie blue for 15min at room temperature and then destained in
several changes of 20% methanol, 5% acetic acid.
ia) Silver staining: Gels were fixed in 50% methanol, 10% acetic acid for 15min, 5% methanol,
7% acetic acid for 30min and then 10% glutaraldehyde for 30min. Gels were then washed
thoroughly in several changes of distilled water over several hours. After washing, gels were
stained in 0.1% silver nitrate solution for 15min, rinsed briefly in water and then developed
with Na2C03/formaldehyde solution (3% Na2C03, 0.02% formaldehyde). Development was
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halted by addition of solid citric acid and the gels were washed in several changes of distilled
water. Gels were then fixed in 10% 'llfofix' for 1min and washed in three changes of water.
Gels were dried at 80°C under vacuum.
2.9.3 Immunofluorescent staining of cell monolayers
Cells were grown to confluence on glass coverslips (10mm diameter, Chance Propper
Ltd., Smethwick, Warley, England) and infected with visna, at various multiplicities of
infection, mock-infected controls were prepared also. At various times after infection cells
were washed once in Hanks buffered salt solution (HBSS) (1mM CaCI2i 5.4mM KCI, 0.4mM
KH2P04, 0.4mM MgCI2, 0.4mM MgS04, 140mM NaCI, 0.7mM Na2HP04, 0.1% glucose,
0.001% phenol red, 25mM HEPES) and fixed in 80% acetone/ 0.15M NaCI for 5min at room
temperature. Coverslips were air dried and stored, dessicated, at -20°C till required.
Cells were first blocked in blocking buffer (PBS, 0.01 % Tween 80, 2% normal sheep
serum) for 30min at room temperature. Blocking buffer was removed and primary antibody,
diluted in blocking buffer, was added to the coverslip for 1 hr at room temperature with gentle
shaking. Cells were washed 5 times in PBS/ 0.01% Tween 80 (PBST) and incubated for 1 hr,
with shaking at room temperature, in a biotinylated anti-immunoglobulin antibody diluted in
blocking buffer. Cells were again washed 5 times in PBST and then incubated for 1 hr, with
shaking, in avidin-FITC (Serotec) diluted 1:5000 in blocking buffer. Cells were washed 5 times
in PBST and the coverslips were then mounted in Citifluor (Citifluor Ltd., London UK.) without
allowing them to dry. Cells were viewed with a Leitz Ortholux II microscope using a water
immersion lens at x625 magnification, and photographed under ultraviolet light with a Wild
MPS 51 photographic attachment (Heerbrugg, Switzerland) and either Fujichrome ISO 1600
colour slide film or Kodak T-Max ISO 3200 monochrome print film.
2.9.4 Reverse transcriptase assay
This assay was based on an unpublished protocol of Dr. D.R. Sargan (Dept. Vet. Path.
University of Edinburgh). Samples for assay (15pl), in triplicate, were placed in the wells of 96
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well round-bottomed microtitre plates on ice. 10pl of 2.5x reaction mix (375mM KCI, 25mM
MgCI2, 25mM Tris HCI pH 8, 5mM DTT, 1,25mM EDTA, 0.25% Triton X-100, 62.5pg/ml BSA,
75pg/mi poly (rA). oligo(dT(12. 18))' ^0/° deionised ethane diol, 100pCi/ml 3H-TTP (tritiated
thymidine tri-phosphate) (sp. act. 20Ci/mMol)) were added and the reaction incubated for 1 hr
at 37°C. The assay was stopped by the addition of 10Opil of 10% (w/v) trichloroacetic acid
(TCA) containing 50pg/ml yeast RNA to each well and the plate left on ice for 15min.
Samples were harvested onto glass filter paper using a semi-automated harvester (Titertek)
and the filters washed three times with 5% (w/v) TCA, twice with 70% ethanol and dried. 3H-
thymidine incorporation was assessed by liquid scintillation counting.
2.10 Transmission electron microscopy
2.10.1 Yeast sections
Yeast strains were prepared for transmission electron microscopy by a modification of the
method of Byers & Goetsch (1975). Late log phase cultures (OD600nm: 1-1.5) of yeast were
fixed (0.1 M cacodylate pH 6.8, 3% glutaraldehyde (EM grade), 5mM CaCI2) for 30min at
room temperature and then overnight, in fresh fixative, at 4°C with gentle mixing. Samples
were then washed twice in pretreatment buffer (0.02M EDTA, 0.2M Tris HCI pH 8.1, 0.1 M 8-
mercaptoethanol)and resuspended in 0.2M citrate phosphate buffer, pH 5.8 before treatment
with 200pl of glusulase for 1 hr at 30°C (to remove the cell wall). After spheroplasting, yeast
cells were washed twice in citrate-phosphate buffer and post-fixed in 1% osmium tetroxide.
Samples were then dehydrated through graded alcohol solutions and embedded in araldite.
Ultrathin sections were cut, stained with 50% uranyl acetate (in ethanol) and Reynold's lead
citrate and examined in a Philips TEM 400 operating at 100kV.
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2.10.2 Negative staining of purified particles
One drop of purified particles, 1 mg/ml in TEN, was placed on a Formvar coated grid and
allowed to adhere for lbs. Excess fluid was drained off using filter paper and the grid washed
three times with drops of distilled water. One drop of negative stain, 2% uranyl acetate in
water, was then applied to the grid and the liquid drained off till only a thin film of stain was
left. Grids were air-dried and examined in a Philips TEM 400 operating at 100kV.
2.11 Detection of specific antibody
2.11.1 Enzyme linked immunosorbent assay (ELISA)
Antigen was coated onto wells of 96 well, flat-bottomed Elisa plates by overnight
incubation at 4°C. Plates were washed six times in borate buffered saline ( 100mM H3B03,
25mM Na2HB04, 75mM NaCI, pH 8.2) (BBS)/ 0.05% Tween 20 (BBST) and then blocked in
BBS/1% BSA (BBA) for 1 hr at 37°C. Sera, diluted in BBS/1% BSA/ 0.05% Tween 20
(BBTA), were added to the wells for 1 hr at 37°C and the plates were again washed in BBST.
Affinity purified anti-immunoglobulin, of appropriate specificity, conjugated to horse-radish
peroxidase (HRP) (Dako), diluted in BBTA, was added to each well for 1 hr at 37°C, the plates
were washed in BBST and then developed with OPD substrate (ortho-phenylenediamine
0.4mg/ml in 50mM citric acid, 100mM Na2HP04, pH 5 with 0.006% H202) for 30min at room
temperature. The reaction was stopped by addition of 12.5% H2S04 and the plates were
read, at 492nm, in a Titertek plate reader.
2.11.2 Immunoblotting
After electrophoretic separation on SDS-PAGE, proteins were transferred to nitrocellulose
membranes (Hybond C, Amersham) using a semi-dry electroblotter (Ancos, Denmark)
according to Kyhse-Andersen (1984). After blotting, the nitrocellulose membranes were
'blocked' using 5% non-fat dried milk (Sainsbury's) in PBS before overnight incubation in
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primary antibody, also diluted in PBS/5% non-fat dried milk. Blots were washed in several
changes of PBS, 0.05% Tween 20 (Sigma) and then incubated for 1 hr in alkaline
phosphatase conjugated secondary antibody of appropriate specificity. Blots were again
washed in PBS/0.05% Tween 20 and then developed with nitro-blue tetrazolium (Sigma) &
5-bromo-4-chloro-3-indolyl phosphate (Sigma) in 0.1 M Tris HCI pH 9.5 and MgCI2 (Pluzek &
Ramlau, 1988).
Development of blots was halted by washing in water.
2.11.3 Virus Neutralisation
Serial dilutions of heat inactivated antisera/lymph plasma (56°C, 30min) were incubated
overnight at 4°C with 500 TCID^ of EV1. The serum/virus mixture was then aliquoted into
the first row of wells of a 96 well flat bottomed microtiter plate, seeded with 104 fibroblast cells
(in DME/10% FCS) the previous day, and titrated, in doubling dilutions, across the plate. The
plates were incubated for 2 hours at 37°C, 5% C02, after which the cells were washed once
and refed with DME/2% FCS. After incubation for 7-10 days at 37°C/5% C02 the media was
thrown off the culture and the cell monolayers were fixed for 5-1 Omin in ice-cold
acetone/methanol (1:1 mix). Fixed monolayers were then stained for 30min with 1% K2Cr207
and destained for 5min with acetone/methanol. Counterstaining was for 5min with freshly
made 50% Giemsa stain. Plates were destained for 1 min with tapwater, dried and examined
microscopically for the presence of cytopathic effect. Neutralisation of virus by serum was
determined as a reduction in virus titre, as calculated by a quantal method (Reed & Muench,
1938). Antibody titres were defined as the greatest dilution of antisera which gave a 50%
reduction in virus titre compared to controls (virus incubated with non-immune sera, or virus
incubated without sera).
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2.11.4 Antibody dependent cell-mediated cytotoxicity (ADCC)
a) Anti-visna ADCC
Prior to use in this assay test sera were heat-inactivated. 2 x 104 sheep epidermal
fibroblasts were plated out in 96 well flat bottomed microtiter plates and incubated overnight
at 37°C/5%C02. Cells were either mock infected or infected with visna at a multiplicity of
infection of 1 -2 TCIDgg per cell and incubated for 48hrs. Each well was then labelled by
addition of 3pCi of Na251Cr04 (sp. act. 18-30mCi/mg 51 Cr) and overnight incubation.
Monolayers were washed four times with RPMI/ 2%FCS, incubated with 10Opil of dilutions of
antisera, in RPMI/10% FCS and effector cells, PBMC, prepared as described in section
2.13.1, were added, in 10Opil. Plates were incubated for varying times at 37°C in a humidified
atmosphere of 5% C02. After incubation, the cultures were centrifuged (200x g, 2min) and
10Opil of supernatant were taken and counted in a gamma counter (LKB-Wallac 1274
Riagamma) for one minute. Assays were performed in triplicate for each dilution of antisera
tested. Controls consisted of uninfected target cells, infected target cells incubated with
medium alone, antibody with no effector cells, and effector cells alone.
Minimum 51 Cr release was taken from wells which had been incubated with effector cells,
but no antibody. The cpm max. (total releasible 51 Cr) was determined by measuring the
amount of radioactivity released in wells to which 1% Triton X-100 had been added in place of
effector cells.
Results were expressed as the % specific lysis, calculated as below:
% specific lysis = mean cpm test - mean cpm minimum
mean cpm max. - mean cpm minimum
b) Anti-SRBC ADCC
Sheep red blood cells (SRBC) were prepared from freshly collected heparinised
peripheral blood by washing twice with PIBSS. For labelling, 5 x 106 or 107 SRBC in 0.2ml
RPMI/10% FCS were incubated with 10OpiCi of Na251Cr04 for 1 hr at 37°C. Target cells were
then washed four times in RPMI/2% FCS before being resuspended in RPMI/10% FCS
supplemented with 1 mM sodium pyruvate, to minimise spontaneous 51 Cr release (Colsky &
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Peacock, 1990). Assays were carried out in 96 well round-bottom microtiter plates. 50pl each
of target cell (104 cells) and effector cell (106 cells) suspensions were added to each well and
then 10Opil of antiserum, diluted in RPMI/10% FCS, were added. The antiserum used was a
polyclonal rabbit anti-SRBC antiserum (gift of Dr. J. Hopkins, Dept. Vet. Path., University of
Edinburgh). This antiserum has been shown to mediate rosetting between antibody-coated
SRBC and sheep macrophages (Gonzalez, 1989). Plates were incubated for 6-8hrs at 37°C
in a humidified atmosphere of 5% C02. After incubation, the cultures were centrifuged (200x
g, 2min) and 100pl of supernatant were taken and counted in a gamma counter (LKB-Wallac
1274 Riagamma) for one minute. Assays were performed in triplicate for each dilution of
antisera tested. Controls consisted of target cells incubated with medium alone, antibody with
no effector cells, and effector cells alone.
Results were calculated as described in (a).
2.11.5 Antibody-Complement-mediated lysis
Target cells, both infected and uninfected were prepared as described in section 2.11.4.
Cells were washed and incubated with dilutions of heat inactivated serum (1 OOpil) and baby
rabbit serum, 1:5 dilution (1 OOjjI), as a source of complement. After 1-3hrs incubation at
37°C/5%C02, 100pl of supernatant were taken and counted as above. Assays were
performed in triplicate for each serum dilution tested.
Controls included cells incubated with medium alone; antibody, but no complement, and
complement alone. Minimal release was taken from wells incubated with antibody, but no
complement. Maximal release was taken from wells to which 1% Triton X-100 had been
added. Results were calculated as described in 2.11.4.
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2.12 Immunochemistry
Many of the methods used in the purification and preparation of immunoglobulins were
based on protocols given in 'Immunochemistry in Practice' (Johnstone & Thorpe, 1987).
2.12.1 Coupling of protein to cyanogen bromide activated sepharose 4B
Ligands were coupled to CNBr activated Sepharose 4B (Pharmacia (Great Britain Ltd.),
Bucks, U.K.) according to the protocol described in the Pharmacia guide to affinity
chromatography (Pharmacia literature, 1983). Briefly, the required amount of CNBr-activated
Sepharose 4B was washed and swollen on a sintered glass filter with 1mM HCI. Protein, in
0.1 M NaHC03 pH 8.3 containing 0.5M NaCI, was added to the swollen Sepharose 4B and
mixed for 2hrs at room temperature. To block remaining active groups the gel was washed
into 1M ethanolamine pH 8 and mixed for 16hrs at 4°C. After blocking the gel was washed
into BBS and stored at 4°C.
Before use the column was pre-eluted with 0.1 M glycine pH 2.5 containing 0.5M NaCI
and re-equilibrated in BBS.
2.12.2 Affinity chromatography
Sample was applied to the column and allowed to flow through slowly (approximately
20ml/hr). This was repeated and the column was then washed extensively with BBS (till no
protein was detectable in the flow-through). The bound material was eluted by washing the
column with 0.1 M glycine-HCI pH 2.5, collected in 0.5ml fractions into 2M Tris HCI pH 9 (to
neutralise the acid). Protein containing fractions were identified by spectrophotometry at
280nm. Peak fractions were pooled, dialysed against BBS, and stored at -20°C. The column
was regenerated by extensive washing with BBS.
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2.12.3 Purification of IgG
Rabbit, mouse and sheep IgG were purified from heat inactivated whole serum or ascites
by affinity chromatography on either Protein-G Sepharose (Pilcher et al, 1991) or antigen-
Sepharose columns.
2.12.4 Determination of immunoglobulin class and subclass of monoclonal antibodies
Immunoglobulin class and IgG subclass of mouse monoclonal antibodies were
determined by double immunodiffusion analysis using class and subclass specific antisera
(Serotec).
2.12.5 Conjugation of biotin to immunoglobulin
Purified immunoglobulin was biotinylated according to Bujdoso et al, (1991). To purified
immunoglobulin, 1mg/ml in 0.1 M NaHC03 pH 8.3, biotin-o-succinimide ester, in DMSO, was
added in a ratio of 75pg biotin: 1mg immunoglobulin. This suspension was mixed immediately
and incubated, with mixing, for 4hrs at room temperature. The biotinylated Ig was then
dialysed extensively against BBS and stored, in aliquots, at -20°C.
2.12.6 Conjugation of Horse Radish Peroxidase (HRP) to IgG
Affinity purified IgG was conjugated to HRP by a modification of the method of Wilson &
Nakane (1978). 4mg of HRP was dissolved in 1 ml of distilled water, 0.2ml of freshly prepared
0.1M Nal04 was added and the solution stirred for 20min at room temperature. It was then
dialysed overnight at 4°C against several changes of 1 mM sodium acetate pH 4.4. The pH
was raised to pH 9.5 by addition of 20pl of 0.2M sodium carbonate pH 9.5 and 8mg of
immunoglobulin, in 1 ml 0.01 M sodium carbonate buffer pH 9.5. This was incubated for 2hrs
at room temperature. 0.1 ml of fresh NaBH4 (4mg/ml in water) was added, to reduce free
enzyme, and the mix left at 4°C for two hours. The peroxidase conjugated immunoglobulin
was dialysed against several changes of BBS and stored at 4°C.
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2.13 Cellular immunology
2.13.1 Preparation of sheep peripheral blood mononuclear cells (PBMC)
Sheep PBMC were prepared from peripheral venous blood taken into preservative free
heparin (1OU heparin/ ml blood). Buffy coat cells were obtained by centrifugation of
heparinised whole blood (800x g, 20min) at room temperature. PBMC were prepared by
centrifugation of the buffy coat, diluted in sterile PBS, over Lymphoprep (Nyegaard, Oslo,
Norway) (800 x g applied to the interface for 20min). In some experiments PBMC were
prepared by centrifugation of defibrinated blood over Lymphoprep. Sheep plasma, obtained
from the buffy-coating step, was aliquoted and stored at -20°C.
2.13.2 Antigen specific lymphocyte proliferation assay
Freshly isolated PBMC were cultured in RPMI 1640 supplemented with 2mM glutamine,
100U/ml benzyl penicillin, 100U/ml streptomycin, 5 x 10~5M 2-Mercaptoethanol and 10% FCS.
1 x 105 PBMC were cultured in 96 well flat-bottomed micro-culture plates, in a final volume of
200pl, with the indicated concentrations of antigen. After 3-5 days, cultures were pulsed with
1pCi of tritiated methyl thymidine (3H-TdR), specific activity 2pCi/mM, for five hours and then
collected onto glass filter paper using a semi-automated cell harvester. 3H-TdR incorporation
was assessed by liquid scintillation counting in an LKB-Wallac 1218 Rackbeta. Cultures were
set up in quadruplicate for each antigen concentration tested. Data is expressed as the
geometric mean for the quadruplicate cultures (± one standard deviation).
2.13.3 Flow cytometry
Cell surface phenotype was assessed using aliquots of 106 cells washed into ice-cold
PBS containing 1mg/ml BSA, 0.1% sodium azide (PBA). Cells were incubated with 25pl of
monoclonal antibody supernatant, or ascites (diluted in PBA) for 40min on ice. After three
washes, 25pl of FITC-conjugated rabbit anti-mouse IgG were added for 20min on ice. Cells
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were washed three times arid resuspended in PBA. Staining was analysed by flow cytometry
using a Becton-Dickinson FACScan.
2.13.4 Cell depletion
To deplete lymphocyte populations the method of magnetic cell sorting (MACS) was used
(Miltenyi et al, 1990). Briefly, sheep PBMC were stained with the biotinylated monoclonal
antibodies: SBU-T4 (anti CD4), SBU-T8 (anti-CD8) (Maddox et al, 1983) or an irrelevant,
isotype-matched, control antibody (Sigma). The cells were washed once in PBS/5mM EDTA,
incubated with streptavidin (Boehringer) for 15 min., washed again and then incubated with
superparamagnetic biotinylated microbeads (Becton-Dickinson). Antibody stained cells were
removed using a MACS cell sorter (Becton-Dickinson). Efficiency of cell depletion was
monitored by flow cytometry.
2.14 Procedures involving experimental animals
All procedures involving experimental animals were carried out so as to comply with the
regulations laid down in the Animals (Scientific Procedures) Act, 1986.
2.14.1 Mice
Balb/c mice were bred in the Department of Veterinary Pathology Animal House,
University of Edinburgh.
2.14.1.1 Immunisation of mice for monoclonal antibody production
Mice were primed by subcutaneous injection of antigen, emulsified in Freund's complete
adjuvant, in several sites. Subsequent immunisations were given by intraperitoneal injection
of 10 - 20pg antigen in PBS at 2 - 3 week intervals. Mice were test bled 7 -8 days after each
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booster immunisation. Three days prior to fusion mice were immunised by intravenous
injection of 10pg of antigen in PBS.
2.14.1.2 Collection of mouse serum
Live mice were warmed under a heat lamp and then bled by removing a portion of the tail
and collecting 100 - 200pl of blood. The blood was left at room temperature for 1 hr to clot.
The sample was then microfuged for 5min, the serum removed and stored, in aliquots,
at -70°C.
2.14.1.3 Preparation of single cell suspension of mouse splenocytes
Mice were killed by cervical dislocation. The spleen was removed aseptically and teased
apart in RPMI medium. Single cell suspensions were prepared by sedimentation of debris at
1x g for 5min. The cell suspension was then washed in RPMI and resuspended in medium.
2.14.1.4 Production of ascitic fluid
Six week old Balb/c mice were injected intraperitoneal^ with 0.5ml of pristane
(tetramethylpentadecane). Seven to ten days later 107 hybridoma cells, in PBS, were injected
intraperitoneally into each animal. Mice were inspected daily for signs of ascites formation.
Ascitic fluid was tapped from the abdomen, using a wide gauge needle, centrifuged to remove
cells and stored at -70°C. Mice were tapped twice only and then killed.
2.14.2 Rabbits
Rabbits ( New Zealand White x Dutch) were bred in the Department of Veterinary
Pathology Animal House, University of Edinburgh.
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2.14.2.1 Immunisation of Rabbits
Rabbits were primed by deep intramuscular injection of 100pg antigen, emulsified in
Freund's compleie adjuvant, in two sites. Secondary immunisation was 100pg of antigen, in
Freund's incomplete adjuvant, injected intramuscularly in two sites. Subsequent booster
injections were administered by intravenous injection of antigen in PBS.
2.14.2.2 Collection of rabbit sera
Rabbits were bled from the lateral ear veins. Briefly, the ear over the vein was shaved
and a spot of xylol applied to the ear tip. A single transverse incision was made through the
lateral ear vein and blood collected into a sterile glass universal. The sample was left at room
temperature to clot. After 1 hr the clot was wrung and then left overnight at 4°C to allow the
clot to contract. Clot free liquid was removed and the clot centrifuged (2500x g, 15min, 4°C).
The expressed liquid was collected and pooled with the clot free serum. The pooled liquid
was then centrifuged (1500x g, 15min, 4°C), the supernatant serum removed and stored, in
aliquots, at -20°C.
2.14.3 Sheep
Finnish Landrace sheep (1-3yrs of age) were purchased from the Moredun Research
Institute, Edinburgh. Infected and uninfected sheep were held, separately, in covered pens at
the Moredun Research Institute.
2.14.3.1 Experimental infection of sheep with maedi-visna
Sheep were infected by intradermal and subcutaneous injection of clarified tissue culture
medium containing 106 TCID^ maedi-visna virus. The virus stock used for infection of sheep
was minimally passaged in vitro.
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2.14.3.2 Field cases of visna infection
Field cases of visna infected sheep were purchased from a farm where visna infection
was endemic in the sheep flock.
2.14.3.3 Lymphatic cannuiation
Lymphatic cannulations were performed by either Professor Ian McConnell or by Dr. John
Hopkins (Dept. Veterinary Pathology, University of Edinburgh). Popliteal efferent lymphatics
were cannulated as described by Hall & Morris (1962), prefemoral efferent lymphatics were
cannulated according to Hall (1967). While cannulated, sheep were kept in standard pattern
metabolism cages and fed hay and water ad libitum. Lymph was collected into sterile 250ml




Immune responses to maedi-visna virus in persistently infected sheep
A. Humoral immune responses
3.1 Introduction
Serum antibody is the classical marker of exposure to a virus and is believed to play an
important role in the control of viral infections in vivo. Anti-viral antibody is thought to be of
major importance in preventing the spread of viral infection by virtue of its ability to neutralise
free virus in extracellular fluids (reviewed Daniels, 1975), however antibodies may also act
against virus infected cells (reviewed in Sisson & Oldstone, 1980). Specific antibody may
'coat' the target cell expressing viral antigens at the cell surface allowing the attachment of
cytotoxic cells, such as natural killer cells, monocyte/macrophages and neutrophils, via
antibody-Fc receptor (FcR) interactions. Alternatively virus infected cells coated with IgM
and/or IgG antibody may be rendered susceptible to complement-mediated lysis.
The ability of antibodies to mediate these effects; to interact with FcR-positive cells, or to
activate complement, is dependent on the class and subclass of immunoglobulin produced in
response to infection. The differing amino acid sequences of the constant region domains of
the heavy chains of each Ig class and subclass imparts each subclass with distinct
properties, most importantly in relation to the activation of biological effector mechanisms.
This has been best studied for human and murine immunoglobulin G molecules (Burton et al,
1986., Burton, 1990), and is of particular interest when it is realised that antibody activity is
not necessarily distributed evenly over the IgG subclasses: in humans, for example,
antibodies to polysaccharide antigens, in bacterial infections, are usually of the lgG2 isotype
(Flammarstrom & Smith, 1986), whereas anti-viral antibodies are predominantly of the lgG1
and lgG3 subclasses (Skvarii, 1986). In mice viral infections mainly elicit specific antiviral, and
polyclonal, antibodies of the IgG^ and to a lesser extent lgG2b subclasses (Coutelier et al,
1987., 1988., 1991).
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In ruminants three major classes of immunoglobulin (lg); IgM, IgA and IgG have been
isolated and characterised (reviewed in Butler, 1983., 1986). Information on the
physicochemical and biological properties of ruminant IgE is not available, although the gene
encoding the lgE heavy chain constant region has been cloned (Knight et al, 1988). A
ruminant IgD subclass has not yet been identified, but there is no reason to suppose that this
molecule does not occur in ruminants.
Ruminant IgG molecules are comprised of two major subclasses, lgG1 and lgG2 (Butler,
1983), although there may be additional heterogeneity within the lgG2 subclass (reviewed in
Butler et al, 1987). Cygenes encoding bovine lgG1 and lgG2 have been cloned (Knight et al,
1988) and two other Cy genes identified, although it is not known whether these are
expressed in vivo. Allotypic variants of both IgG^nd lgG2 have been described (reviewed
Butler, 1986) and Capparelli et at (1982) have described an age-dependent allotype, present
in both sheep and cattle, which they describe as associated with a third IgG subclass they
designated lgG3.
Some of the biological properties of ruminant immunoglobulins are summarised in Table
3.1. lgG1 is the predominant immunoglobulin in serum, lymph, colostrum (it is responsible for
the passive transfer of systemic immunity to the young ruminant) and at mucosal surfaces
(reviewed in Butler, 1983., 1986). In general lgG2 is found at lower concentrations, but, unlike
IgG^ considerable differences in lgG2 concentration may occur between animals.
Extensive studies on the roles of the different IgG subclasses in immune responses of
ruminants have not been carried out. it has been reported that immunisation of sheep with
dinitrophenol conjugated to human y-giobulin elicits specific antibodies in both the IgG! and
lgG2 subclasses (Margni et al, 1973). Similarly rotavirus and coronavirus infections of calves
elicit both IgG! and lgG2 antiviral antibodies (Saif, 1987). Immunisation of sheep with
pneumococcal polysaccharides or killed Staphylococcus aureus elicits predominantly IgM
and IgG! antibodies (Emery et al, 1990., Kennedy & Watson, 1982), whereas live S. aureus
vaccines induce mainly lgG2 anti-staphyioccal antibodies and these are associated with





Heterologous complement + + -
Homologous complement + + +
Heterologous PCA ND + -
Homologous PCA ND + +
FcR binding
neutrophils +a - +
fresh monocytes +a +/- +
cultured monocytes +a + +
alveolar macrophages ND +/- +/•
a, in presence of added complement
PCA - passive cutaneous anaphylaxis
The information in the above table has been summarised from the following sources:
Feinstein & Hobart (1969), Watson (1975), Micusan & Borduas (1977), Rossi & Kiesel (1977),
McGuire et al (1979), Howard et al (1980), Yasmeen (1981) and Fleit et al (1986).
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deficiency of lgG2 in cattle is associated with an increased frequency of pyogenic bacterial
infections (Nansen, 1972). The protective effects of lgG2 antibodies against staphylococcal
infections have been ascribed to their efficiency as opsonins promoting phagocytosis
(Watson, 1987). It has also been reported that lgG2 antibodies are 100 times more efficient
than IgG-i immunoglobulins at mediating antibody-dependent cytotoxicity (cited in Butler,
1983), but in general the functional significance of particular antibody classes and subclasses
in immune responses of ruminants is unclear.
The antibody response to visna has mainly been studied in terms of virus-neutralising and
complement-fixing antibodies (Gudnadottir & Palsson, 1966., Gudnadottir & Kristinsdottir,
1967., De Boer, 1970., Petursson et al, 1976). Sheep persistently infected with maedi-visna
virus have been reported to make antibodies reactive with virtually all visna proteins (Lin &
Thormar, 1979), but the pattern of development of these antibodies after infection and their
persistence through the course of disease are unclear. Moreover knowledge of the antibody
isotypes produced in response to infection with maedi-visna virus is confused. Petursson et al
(1983), reported that antibodies to visna were mainly associated with the IgG-, subclass and
that they could not detect IgM or lgG2 anti-MVV antibodies. In contrast, Mehta & Thormar
(1974) could detect IgM visna-specific virus neutralising antibodies. CAEV infection of goats
has been reported to elicit virus-neutralising antibodies in both lgG-| and lgG2 subclasses
(McGuire et al, 1988).
In this chapter an analysis of the serum humoral immune response to visna virus is
presented. In particular, the isotypes of the antiviral antibodies produced and the viral
antigens recognised were analysed in detail. Subsequently experiments to assess some of
the biological activities of anti-visna antibodies were carried out: in particular, the ability of
anti-visna antibodies to direct lysis of virus-infected cells was investigated.
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3.2 Results
3.2.1 Development of the antibody response to maedi-visna virus
A group of four sheep (1-2 years old) were infected with maedi-visna and bled at various
intervals after infection. The anti-visna antibody titre was determined in ELISA assays using
visna virus, purified on sucrose gradients, as antigen (Figure 3.1). By day 43 post-infection all
the infected sheep had detectable anti-visna antibody titres, which increased gradually over
the next 100 days.
Immunoblot analysis, against lysates of visna infected cells (Figure 3.2), showed that at
the earliest time points at which anti-visna antibodies were detectable, both gag (p17 & p25)
and env (gp135) specific antibodies appear to be present. At later time points antibodies to
p25, p17 and gp135 still predominated, but the antibody response had broadened to include
other viral proteins of approximate Mr 35, 38, 41 and 55kD. These reactivities probably
include gag precursor proteins and processing intermediates and/or pol gene products, but
the protein polypeptides of visna virus are insufficiently well characterised to allow definite
identification of these bands as particular viral antigens.
The isotype of the anti-visna antibodies in plasma at these time points was then
investigated in ELISA assays using mouse monoclonal antibodies specific for sheep IgG^
lgG2 and IgM (Beh, 1987., 1988) (Figure 3.3). From these results it can be seen that anti-
visna antibody activity can be detected in both IgM and lgG1 isotypes, but that lgG2 anti-
visna antibody is undetectable. A similar pattern of results was seen when the isotype of the
anti-visna antibody response was investigated in immunoblot assays (data not shown., see
Figure 3.4). It is not possible to compare the quantity of antibody between the different Ig
classes because of inherent differences in assay sensitivity using MAbs with unique affinities.
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Figure 3.1 Development of the antibody response to maedi-visna virus
Four Finnish-landrace sheep, 1-2yrs old, were infected with maedi-visna by intradermal
and subcutaneous injection of 106 TCID^ of virus. Sheep were bled, by jugular venipuncture,
at the times indicated and plasma was collected and stored at -20°C until assayed for anti-
visna antibody.
For assay of anti-visna antibody in plasma samples, purified visna virus (200ng/ml in
PBS) was coated onto flexible Falcon PVC plates by overnight incubation at 4°C. After
washing in BBS/0.05% Tween 20, the wells were blocked by incubation with BBS/1% BSA
(200pl/well) for 1 hr at 37°C. Plasma samples, diluted in BBS/BSA/ 0.05% Tween 20, were
titrated in doubling dilutions starting from a 1/10 dilution. After 1 hr incubation at 37°C, the
plates were washed in BBS/Tween and then incubated for a further 1 hr with a 1/4000 dilution
of rabbit anti-sheep Ig conjugated to HRP (Dako) in BBS/Tween/BSA before washing and
developing the plates with OPD as substrate.
Antibody titre is expressed as the reciprocal of the highest dilution of plasma which gave























Figure 3.2 Specificity of anti-visna antibody in developing immune response
See Figure 3.1 for experimental details. Visna antigen, prepared as described in section
2.8.1 was separated on 5-20% linear gradient SDS-PAGE, run under reducing conditions,
and electroblotted onto a nitrocellulose membrane. Strips, cut from these blots, were
incubated overnight with pre- and post-infection plasma (days post infection are shown below
strips), diluted 1:10 in PBS/5% non-fat dried milk. Blots were developed using affinity-purified
anti-sheep immunoglobulin conjugated to alkaline-phosphatase (Sigma). Positions of
molecular weight standards are indicated.
The results shown, obtained by probing blots with sera from sheep 1540H and 848A, are
representative of the results seen with all four sheep. The bands seen at 17kD and 28kD are
probably the gag proteins p17 and p25. The bands seen at around 135kD are probably the
outer membrane envelope glycoprotein gp135.
The smearing seen at around 70kd is not visna specific since it is seen when blots are
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Figure 3.3 Analysis of the isotypes of anti-visna antibody in the developing immune response
For assay of individual Ig class and subclass the plasma samples were incubated on
ELISA plates coated with sucrose-purified visna as in Figure 3.1. After incubation with sheep
plasma, the plates were washed and incubated with mouse monoclonal antibodies specific
for the various sheep Ig class and subclasses (gifts from Dr. K.J. Beh, CSIRO, Sydney).
These monoclonal antibodies were used as ascites fluids diluted 1/500 - 1/2000 in BBS/BSA:
McM1 (anti-y1 -1/2000), McM3 (anti-72 - 1/500), McM9 (anti-p - 1/1000). The negative
control was normal mouse serum diluted 1/500 in BBS/BSA. After washing, the plates were
incubated with a 1/4000 dilution of rabbit anti-mouse IgG conjugated to HRP, preabsorbed
against sheep Ig, in BBS/BSA for 1 hr at 37°C, and developed with OPD as substrate.
Antibody titres are expressed as the reciprocal of the highest dilution of plasma which
gave an OD492 reading twice that of plasma collected pre-infection.
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3.2.2 Antibody responses in persistently infected sheep
The failure to detect anti-visna antibody activity in the lgG2 subclass was an unexpected
result and so this aspect of the immune response was investigated further. It has been
reported that, in sheep, antigen-specific lgG2 antibodies develop later in immune responses
than antibodies of the lgG1 subclass (English et al, 1976). Thus the pattern of anti-visna
antibody isotypes was investigated in persistently infected sheep. These were either sheep
which had been experimentally infected with maedi-visna for periods of 1-3 years or naturally
infected animals. The results obtained from both these groups were similar and so the data
from both groups have been pooled.
The isotypic restriction of anti-visna antibodies was analysed in immunoblotting
experiments using virus-infected cells as antigen. Representative sets of immunoblots from
six sheep are shown (Figure 3.4). These blots confirm that antibodies to visna virus antigens,
including envelope glycoproteins, are not present in the lgG2 subclass. Interestingly, these
data also suggest that IgM antibodies to the viral envelope glycoproteins may not be present.
In HIV infection IgM anti-HIV has been reported to be restricted to anti-p24 and anti-p17
activity (Bedarida et at, 1986., Joiler-Jemelka et at, 1987), although others have suggested
that there may be a weak IgM anti-env response (Gaines et al, 1988). Analysis of a larger
number of sera in ELISA assay against purified visna confirms that antibodies to visna virus
are detectable only in the lgG1 subclass (Figure 3.5).
To show that these mAb's could detect lgG2 antibodies in immunoblotting assays, the
antibody isotypes produced in response to Orf virus, a parapox virus infection of sheep, were
investigated (Figure 3.6). It can be seen that sheep infected with this virus do make lgG2
antibodies to Orf antigens, although the lgG1 response is predominant. This experiment also
demonstrates that restriction of the IgG antibody response to the IgG-, subclass is not a
general feature of ovine antiviral immune responses.
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Figure 3.4 Immunoblot analysis of the isotypic restriction of the anti-visna antibody response
Immunoblots of visna antigen were prepared as described in Figure 3.2. Blots were
-f&
incubated with sheep serum (1/10) in quadrupicate, after washing each strip was then probed
with either McM1 (1/2000), McM3 (1/500), McM9 (1/1000) or normal mouse serum (1/500)
and developed using affinity purified anti-mouse immunoglobulin conjugated to alkaline
phosphatase.
Representative blots from six sera; GO30, G027, G094, YT44, YT41 and GO90, are
shown. These are all naturally infected animals. Serum samples from experimentally infected




Figure 3.5 Isotypic restriction of the anti-visna antibody response in sheep persistently infected with
maedi-visna virus
Sera from sheep infected with visna virus for periods of at least 1 yr, were assayed for
anti-visna antibody of either IgG^ lgG2 or IgM isotypes by ELISA assay as described in the
legend to Figure 3.3.
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Figure 3.6 Analysis of the antibody isotypes produced in response to Orf virus infection
Orf virus antigen, purified from scabs from infected sheep by density gradient
centrifugation, was separated on 5 - 20% SDS-PAGE and immunoblotted onto nitrocellulose
membranes. Strips, cut from these blots, were probed with sera collected from three Orf
infected sheep (diluted 1/50, from left to right: 1195P, 1196P & D573) and then the isotype
specific monoclonal antibodies. Blots were developed as described previously.
Purified virions of Orf virus have been shown to contain at least 30-40 polypeptides
(Thomas et al, 1980., Buddie et al, 1984) and at least sixteen viral antigens are recognised
by sera from experimentally infected animals (McKeever et at, 1987). The major Orf virus
protein recognised by sera from infected sheep is a polypeptide of 40-45kD (McKeever et at,
1987). This protein is believed to be a major component of the surface tubule-like structures
on the virion (Thomas et al, 1980., Buddie et al, 1984., McKeever et at, 1987). Other viral
proteins, of Mr 16.5, 22.5, 25.5, and 64kD are also believed to be components of the virion
surface (Thomas et al, 1980), but the functions and/or structural roles of these proteins are
unknown.
Both the Orf antigen and anti-Orf sera were gifts of Drs. Hugh Reid & D. Yirrell, Moredun


















3.2.3 Action of anti-visna antibody against virus infected cells
Plasma from visna-infected sheep was examined for the ability to mediate antibody-
dependent cell-mediated cytotoxicity (ADCC) (Figure 3.7). Plasma from visna infected sheep
(n=32) did not exhibit ADCC in this assay. A number of variables, including effector:target cell
ratio, amount of anti-visna antibody and assay incubation time were modified to try and
optimise the assay, but no ADCC activity could be demonstrated. Similar results were seen
whether the PBMC effector cells were obtained from either visna infected or uninfected
sheep. Culture of PBMC with IL-2 prior to use in assay, an attempt to promote NK/LAK cell
activity (reviewed in Trinchieri, 1989), resulted in increased levels of lysis, but this was not
virus specific (data not shown). The data shown in Figure 3.7A are representative of several
assays performed over a 6-8hr incubation period. In some experiments target cells, antibody
and effector cells were incubated together for 18-20 hrs, but again no visna-specific ADCC
activity was detected (Figure 3.7B). However, levels of spontaneous 51Cr release by target
cells were high (30%) in these 20hr assays and it is possible that this could have masked low
levels of activity.
There were a number of possible explanations for the failure to detect anti-visna ADCC
activity in these assays and so a series of control experiments were carried out.
The target cells were confirmed as infected and producing viral antigens by
immunofluorescence assays (Figure 3.8). Cell-surface expression of viral antigens and
specific binding of anti-visna antibody to the target cells was demonstrated in antibody-
dependent complement-mediated cytotoxicity (ACC) assays. In these experiments visna-
infected and control, uninfected target cells were prepared and incubated with antibody as in
the ADCC assays,however a source of complement, baby rabbit serum, was added instead
of sheep PBMC. Results from such an experiment are shown in Figure 3.9.
These experiments show that viral antigens are expressed at the surface of the
infected cell and that antibody in plasma from visna infected sheep is capable of
binding to these antigens. That the cells can then be lysed by addition of complement
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Figure 3.7 Plasma from visna-infected sheep do not mediate visna-specific ADCC
Plasma from visna infected sheep (YT41 and GO30) and uninfected sheep (321) were
tested for activity in ADCC assays at the indicated dilutions. Effector cells were PBMC freshly
isolated from uninfected sheep, used at an effector:target cell ratio of 100:1. Target cells
were a skin cell line, infected with visna 72hrs previously at a multiplicity of infection of 2
TCID^/cell, and radioactively labelled by overnight incubation with 51Cr. Assays were
incubated for 6hrs (A) or 18hrs (B) and the 51 Cr release determined. Minimum 51 Cr release
into the supernatant was 8% (uninfected cells) and 11.2% (visna infected cells) in A; 20%
(uninfected) and 30% (visna infected) in B. Incubation of target cells with PBMC, but without
antibody gave levels of lysis comparable with target cells incubated with medium alone. Error
bars show one standard deviation from the mean experimental values.
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Figure 3.8 Immunofluorescence analysis of visna-infected fibroblasts 72hr post-infection
Fibroblasts, mock-infected and infected with visna virus at a multiplicity of infection of
ZTCID^/cell (as in Figure 3.7), were fixed in 80% acetone/0.15M NaCI and stained as in the
methods. A shows the staining pattern observed when infected cells were stained with a
rabbit antiserum to p25, the major core protein of maedi-visna virus (for characterisation of
antiserum see chapter 5). B shows the pattern observed when infected cells were stained
with non-immune rabbit antiserum. Both prints were exposed for the same length of time
(30s). Mock-infected cells stained with the anti-p25 antiserum showed similar fluorescence to





Figure 3.9 Plasma from visna infected sheep mediate ACC
Target cells prepared as described in Figure 3.7 were incubated with serial dilutions of
plasma from visna infected sheep, YT41 & GO30, and uninfected sheep 321 in a final
volume of 10Opil. Rabbit complement, 100pl of a 1/5 dilution of rabbit serum, was then added.
Assays were incubated for 3hrs and the 51 Cr release determined. Spontaneous release of
51 Cr into the supernatant was 6.4% (uninfected cells) and 12.4% (visna infected cells).
Incubation of target cells with antibody alone or complement alone gave levels of lysis similar
to those seen when targets were incubated with medium alone. Error bars show one
standard deviation from mean experimental values.
A and B show results obtained when plasma from visna seropositive sheep were used in
these assays, C shows the levels of lysis observed when control, visna-seronegative plasma




suggests that capping of viral antigens subsequent to antibody binding (reviewed in Sissons
& Oldstone, 1980) is not occurring in these assays. This experiment also suggests that target
antigen density on visna infected cells is unlikely to be a major problem in these assays since
in measles virus systems complement-dependent lysis requires approximately 10-fold more
antibody to bind to the target cell than is needed to confer susceptibility to ADCC attack
(Sissons & Oldstone, 1980).
Another possible explanation for the failure to detect visna-specific ADCC in these
assays was that the PBMC preparation did not contain cells capable of mediating ADCC. To
test the killing ability of the PBMC population usd here, the efficiency of PBMC in ADCC
assays against antibody-coated erythrocytes was investigated (Figure 3.10). This experiment
demonstrates that ovine PBMC are capable of mediating ADCC, at least against RBC. Other
workers have reported that mononuclear cells isolated from bovine peripheral blood are
capable of lysing bovine herpesvirus infected cells (Rouse et al, 1976). Sheep PBMC have
been shown to be capable of mediating antibody-dependent lysis of murine mastocytoma
cells (Grant et al, 1975).
It has been shown that, in ruminants, neutrophils and monocyte-macrophages are the
major effector cell populations in ADCC assays against either erythrocytes or virus-infected
cells (Rouse et al, 1976., Grewal et al, 1977., Grewai & Rouse, 1979). Flow cytometric
analysis of the PBMC preparations used in these experiments was carried out in order to
obtain some evidence of the proportions of monocyte/macrophages and myeloid cells in
these populations (representative data is shown in Table 3.2). Monoclonal antibody D9F has
been suggested to recognise the ovine analogue of FcyRIII (Gonzalez, 1988). In humans
expression of this molecule in the periphery is restricted to macrophages, PMN's and natural
killer cells (reviewed Ravetch & Kinet, 1991). As yet, no biochemical characterisation of the
antigen recognised by MAb M175 has been reported, but its expression has been reported to
be restricted to myeloid and erythroid cells (Miyasaka et al, 1986), however recently this
antibody has been shown to stain a small proportion of CD4+ and CD8+ lymphocytes
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Figure 3.10 ADCC activity of sheep PBMC against antibody coated erythrocytes
104 sheep RBC, labelled with 51 Cr, were incubated with the indicated dilutions of either
rabbit anti-SRBC or rabbit anti-p25 antiserum and 106 autologous PBMC. Assays were





□ SRBC incubated with Rabbit anti-SRBC (1/50), but without effector cells
Table 3.2
MAb (Ref) Antigen % positive cells
SBU-T4 (1) CD4 27.6
SBU-T8 (1) CD8 27.7
VPM 13 (2) p heavy chain 17.7
VPM 8 (2) slg (light chain) 34.1
M 175 (3) myeioid/erythroid cells 39.7
D9F (4) FoyRIII 26.2
VPM 19 (5) MHC Class I 100
The above percentages are determined by reference to cells stained with normal mouse
serum. The percentage of positively stained cells using this control was less than 1%.
Cells were analysed by FACS using a Becton-Dickinson & Co. FACScan system. 20,000
cells were analysed per sample with dead cells excluded on the basis of forward light scatter.
1. Maddox et al, 1985
2. Bird et a/, in preparation
3. Miyasaka et al, 1986
4. Gonzalez, 1988
5. Hopkins & Dutia, 1990
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(Dr. P. Bird, personal communication). This small amount of lymphocyte staining probably
accounts for much of the difference between the percentages of D9F and M175 staining
cells. These data indicate that the PBMC's used in these assays contained around 20-25%
monocytes. No specific antibody reagents defining polymorphonuclear neutrophils (PMN's)
are available for the sheep, however it has been reported that PBMC's prepared by gradient
centrifugation commonly contain 2-4% PMN's (Grewal & Rouse, 1979).
B. T cell responses
3.3 Introduction
In the majority of viral infections studied T cell mediated immune responses are believed
to be of prime importance for the clearance of viral infection (Mims & White, 1984), however
the significance of T cell immunity in lentiviral infection is unclear. Individuals infected with
HIV develop strong antibody and CTL responses to the virus (Rosenberg & Fauci, 1989) and
yet invariably HIV infection progresses to AIDS and death, indicating that these responses
are in in some way insufficient for clearance. It has been demonstrated in a murine retrovirus
system that both CD4+ and CD8+ immune T cells are required to confer immunity to
retroviral infection (Horn et al, 1991), yet in natural HIV infection virus-specific CD4+ T-
helper cell responses appear to be specifically deficient in both prevalence and strength
(Wahren et al, 1987., McChesney & Oldstone, 1989).
Cell-mediated immune responses to visna virus in infected sheep have not been well
characterised. Griffin et al (1978) reported that sheep experimentally infected with visna
virus made only a transient cell-mediated immune response to visna virus. However this
study was terminated after only three months. Other workers reported that cellular responses
to visna virus antigen could be detected intermittently over a three year period following
experimental infection (Larsen et al, 1982b., Sihvonen , 1984). The data of Larsen et al
(1982) should be interpreted only cautiously since not all of the challenged animals
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seroconverted after exposure to virus and virus could be isolated from only a few of the
'infected' animals. None of the experimental sheep developed any clinical evidence of
disease during the experiment and post-mortem examination for evidence of development of
pathological lesions was not carried out. Interpretation of the study reported by Sihvonen
(1984) is also complicated by the fact that not all the sheep challenged with visna virus
subsequently seroconverted, however a visna-like virus could be reisolated from these
animals. None of these studies made any attempt to characterise either the viral antigens
eliciting proliferative responses or the lymphocyte populations responding in these assays.
The first experiment described here is an investigation of whether sheep persistently
infected with visna virus mount lymphoproliferative responses to purified virus. Following this,
recombinant viral core protein (see Chapter 5) was tested as antigen in lymphoproliferation
assays, and the phenotype of the the lymphocytes responding in these assays investigated.
3.4 Results
3.4.1 Lymphoproliferative responses in persistently infected sheep
The occurrence of T-cell immune responses in sheep persistently infected with maedi-
visna for periods of 1-3 years was investigated using in vitro lymphocyte proliferation assays.
PBMC from visna infected and control, uninfected sheep were cultured in either the presence
or absence of visna virus purified by centrifugation through sucrose gradients and
lymphoproliferative responses measured by tritiated thymidine (3H-Tdr) incorporation.
Representative results of such an experiment are shown in Table 3.3.
These data document the occurrence of virus-specific lymphocyte proliferative responses
in sheep persistently infected with visna virus. Material prepared from uninfected skin cell
cultures did not stimulate proliferation of lymphocytes from either visna infected or uninfected
sheep (data not shown). Levels of antigen-specific proliferation fluctuated slightly between
assays, but were always detectable. The observed variation in responsiveness between
individual sheep is to be expected in an outbred population.
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Table 3.3
Response (cpm [3H1-Tdr ± sd) to
Visna status Sheep No. Medium Visna (S.I.)
Infected 90 4660 ± 537 13679 ± 1854 (3.4)
91 3910 ±126 22472 ± 2967 (5.7)
92 1180 ±332 6676 ± 554 (5.6)
93 2317±134 38764 ±2760 (16.7)
Uninfected 738 1003 ±361 566 ± 363 (0.56)
739 873 ±219 843 ± 366 (0.97)
PBMC's from both visna infected and uninfected sheep, prepared by differential
centrifugation over 'Lymphoprep', were cultured with either medium alone or sucrose-gradient
purified EV1 antigen (5pg/ml) for 5 days.
Lymphocyte proliferation was assessed by measuring 3H-thymidine (3H-Tdr)
incorporation over the last five hours of culture. Data is expressed as cpm. 3H-Tdr
incorporated ± one standard deviation. S.I. = (mean cpm. antigen stimulated cultures/mean
cpm. unstimulated culture).
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To begin to define the antigens recognised by these proliferating lymphocytes the major
core protein of maedi-visna virus, p25, was expressed (see Chapter 5) and the antigenicity of
the recombinant protein tested in lymphoproliferation assays. p25 protein induced in vitro
lymphocyte proliferation of PBMC from visna infected sheep in a dose dependent fashion
(Figure 3.11). A control antigen preparation, the supernatant from ultracentrifuged, 'mock-
digested' Ty-p25 (see Chapter 5) did not stimulate proliferation (Figure 3.11), nor did an
irrelevant protein antigen such as ovalbumin (data not shown).
Proliferative responses to p25 (Stimulation Index > 2) could be detected in visna infected
sheep (n=12), but not in uninfected controls (Figure 3.12). Several individuals proliferated
only weakly to p25, but these responses were consistently detected in these sheep (at least
three separate experiments). Statistical analysis, Wilcoxon's Rank Sum test for unpaired
data, indicated that the level of proliferation of even the weakest responder is highly
significantly different from uninfected controls (P < 0.01). No simple correlation was observed
between the level of proliferation of an individual sheep to whole virus and to p25, probably
reflecting the fact that in an outbred population differences exist between individuals in the
number of T cells specific for individual viral antigens.
To define the lymphocyte subpopulations responding to viral antigens in these assays,
lymphocyte depletion experiments were carried out. Using mouse monoclonal antibodies to
the ovine homologues of the CD4 and CD8 molecules (Maddox et al, 1985), PBMC from
visna infected sheep were selectively depleted of either CD4+, CD8+, or CD4+ and CD8+ T
cells using a magnetic activated cell-sorter system (Miltenyi et al, 1990). Efficiency of
depletion was over 95%, as monitored by flow cytometry. The anti-CD4 and anti-CD8
monoclonal antibodies are of the y2a isotype and so as a control PBMC were mock-depleted
using an irrelevant y^ mouse monoclonal antibody (UPC 10). The various depleted and
mock-depleted populations were then assayed for responsiveness to viral antigen, either
purified virus or recombinant p25. A similar pattern of results was observed when either
purified visna virus or recombinant p25 protein was used as antigen and so only the p25
response data are shown (Table 3.4).
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Figure 3.11 Lymphocytes from visna infected sheep proliferate in response to p25 antigen in
a dose dependent fashion.
PBMC's from an infected sheep were cultured with the indicated concentrations of either
p25 or a control antigen preparation for five days. The control antigen preparation shown
here is the supernatant obtained after ultracentrifugation of 'mock Factor Xa-digested' Ty-p25
VLP's.
Lymphocyte proliferation was assessed by measuring 3H-thymidine (3H-Tdr)
incorporation over the last five hours of culture. Data is expressed as cpm. 3H-Tdr

















Figure 3.12 Proliferative responses of sheep PBMC's to recombinant p25
PBMC's from uninfected or maedi-visna infected sheep were cultured for 5 days with an
optimal dose of purified recombinant p25 (15pg/ml). Cultures were then pulsed with 3H-Tdr
for 5 hours and harvested. Data is expressed as stimulation indices: S.I. = (mean cpm.
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These data demonstrate that for most visna infected sheep CD4+ T cells are the major
lymphocyte subset responding to viral antigen in these assays. However in some infected
individuals proliferation to visna antigen could only be completely abrogated by depletion of
both CD4+ and CD8+ T cells, depletion of CD8+ T cells alone did not significantly affect the
level of proliferation detected.
3.5 Summary of Chapter 3 results
1. After experimental infection of sheep with maedi-visna virus, the first antiviral
antibodies detectable are specific for either gag p25 or env gp135. With time the
antibody response broadens, but these reactivities predominate still.
2. The IgG antibody response to visna is restricted to the lgG1 subclass.
3. Anti-visna antibodies can mediate antibody-mediated complement-dependent
cytotoxicity (ACC), but not antibody-dependent cell-mediated cytotoxicity (ADCC),
activity.
4. Visna infected sheep contain circulating virus-specific CD4+ T cells, some of which
are specific for p25.
3.6 Discussion
Previous studies on the development of the humoral immune response to maedi-visna
virus have reported that visna virus specific antibodies are first detected 1-2 months after
experimental infection, but that a longer period, 3-6 months is required before virus
neutralising antibodies can be detected (Gudnadottir & Palsson, 1966., Gudnadottir &
Kristinsdottir, 1967., De Boer, 1970., Petursson et at, 1976). The data presented here
(Figures 3.1 & 3.2) are in broad agreement with these earlier studies with regard to the
kinetics of the development of the antiviral antibody response and extend these earlier
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reports by examining both the pattern of viral antigens recognised, and the antibody isotypes
produced, in the developing immune response.
The experiments described here (Figures 3.2 & 3.4) suggest that antibodies to both gag
and env antigens are produced early in infection and that these antibody reactivities
predominate in the antibody response to maedi-visna virus. Houwers & Nauta (1989)
reported that antibodies to p25 appeared early after infection, but that antibody to gp135
could be detected only infrequently. There are several points to be made regarding this
study; firstly the data on the development of the anti-visna antibody response was based on
experimental infection of only two sheep, each animal was infected by a different inoculation
route and in neither case was the infectivity titre of the visna inoculum determined. Further,
the immunoblot technique described was based on the use of viral antigen purified by
differential centrifugation on sucrose gradients, a procedure which has been reported to
result in the loss of external envelope glycoproteins from the purified virions (Bruns &
Frenzel, 1979). Thus the failure to detect anti-gp135 antibodies in this paper is not entirely
unexpected. The immunoblotting experiments presented here (Figures. 3.2 & 3.4) are based
on the use of virus infected cells as antigen, so maximising the probability of all
virally-encoded antigens being present. Moreover this data set is based on the experimental
infection of four sheep by the same route with a standard, known, amount of maedi-visna
virus, 106 TCID^.
No relationship between tissue culture infectious doses and animal infectious doses has
been described for visna, but in an SIV system the dose of virus required to infect rhesus
monkeys was 100 times less than that needed to establish an infection in vitro
(Murphey-Corb et al, 1989). If a similar ratio between virus infectious dose in vivo and in
vitro holds for visna then the virus inocula used in these experiments, although less than
those used by other workers (De Boer, 1970., Griffin et al, 1978., Larsen et al, 1982b.,
Sihvonen, 1984), are likely to be far in excess of that required to establish infection in vivo.
Any significance of this on the pathogenesis of visna infection and/or the host immune
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response is not known. No data is available on the dose of virus involved in natural
transmission of infection.
Primates experimentally infected with either HIV or SIV produce anti-viral antibodies first
detectable around 1 month post-infection. At these early time points antibodies to both p24
and gp120/gp160 are present (Kannagi et al, 1986., Nara et al, 1987a). Similarly in HIV
infection both anti-gag and anti-env antibodies are among the first anti-viral antibodies
detected at or around seroconversion (Cooper et al, 1987). Thus the patterns of antibody
responses to lentivirus infection are similar between visna infection of sheep and
immunodeficiency virus infection of man and monkeys.
Analysis of the antibody isotypes produced in response to visna infection revealed that
anti-viral antibodies were present in both IgM and lgG1 isotypes, but that lgG2 anti-visna
antibodies were not detectable (Figures 3.3, 3.4, 3.5). Previous reports had also suggested
that no significant anti-visna antibody activity was present in either the IgM class (Petursson
et al, 1983) or the lgG2 subclass (Mehta & Thormar, 1974., Petursson et al, 1983), but
these studies were subject to several major criticisms; firstly, both these studies were based
on analysis of serum immunoglobulin from only one sheep. Secondly, anti-visna antibody
activity was assessed using techniques such as virus neutralisation and complement fixation,
yet a heterologous source of complement was used in these assays (Petursson et al, 1983).
Ovine lgG2 does not activate heterologous complement (see Table 3.1). Last, antibody
activity in the various immunoglobulin isotypes was assessed by fractionation of serum Ig on
the basis of physico-chemical properties. Since some cross-contamination of lgG1 with lgG2
and vice-versa is difficult to exclude using these techniques (Butler, 1986., Dr. P. Bird,
personal communication), these studies were unable to state definitively whether or not lgG2
anti-visna antibodies were present in infected sheep. In the experiments presented here
antibody activity was assessed directly in antigen binding assays, and analysis of antibody
isotypes was carried out directly using mouse monoclonal antibodies specific for various
isotypes of sheep immunoglobulin. Moreover assay of a number of sheep, at known times
after infection has clearly demonstrated the occurrence of IgM anti-visna antibodies.
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Isotypic restriction is not a feature of the immune response to HIV. Anti-HIV antibody
activity is detectable in all four human IgG subclasses (Sundquist et al, 1986., Klasse &
Blomberg, 1987., Khalife et al, 1988), although the lgG1 and lgG3 responses predominate,
as they do in the majority of human antibody responses to viral infection (Skvaril, 1986). It is
not valid to compare Ig isotypes across species, since speciation is thought to have occurred
before the genetic events which gave rise to the development of the individual IgG
subclasses (Callard & Turner, 1990).
The basis of the restriction of the IgG anti-visna antibody response to the IgG-, subclass
is not known. A selective deficiency of serum lgG2 has been observed in some HIV infected
individuals (Aucouturier et al, 1986., Parkin et al, 1989), but a specific defect of lgG2
antibody production in visna infected sheep is unlikely. Visna infected sheep make both lgG1
and lgG2 antibodies when challenged with antigens such as ovalbumin and KLH (Dr. P. Bird,
personal communication) and in a similar ratio to uninfected sheep.
There is evidence in the mouse that different lymphokines influence the production of
different IgG subclasses in vitro (Snapper & Paul, 1987., Coffman et al, 1988) and that
distinct types of murine helper T cell clones preferentially produce different lymphokines,
(reviewed in Mosmann & Coffman, 1989) although the significance of these observations in
vivo is unclear (reviewed in Finkelman et al, 1990).
Although a similar division of T helper cells may not hold true for other species, T cells
with differing lymphokine production have been reported in man (Dohlstein et al, 1988.,
Umetsu et al, 1988) and the presence of particular subsets of T cells may correlate with
resistance or susceptibility to certain infections (Salgame et al, 1991). In man, however, it is
not clearly defined to what extent IgG subclass regulation is lymphokine dependent. Virtually
no information on lymphokine regulation of IgG synthesis is available in the sheep, but it is a
plausible hypothesis that the isotypic restriction seen in the humoral immune response to
visna may reflect a bias in the nature of'T-cell help' supplied by visna-specific T ceils and/or
that visna infection in vivo results in production of a particular set of cytokines. Consistent
with this hypothesis, it has recently been reported that IFN-a preferentially enhances IgG^
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secretion in the mouse (Finkelman et al, 1991). Virus infections tend to induce the
production of IFN-a/p (reviewed in Joklik, 1990) and the predominant anti-viral isotype, in
mice, is IgG^ (Coutelier et at, 1987). Circulating visna specific CD4+ 'T-helper cells' are
present in infected sheep (Tables 3.3 & 3.4., Figure 3.12) and when (if ?) reagents allowing
accurate quantitation of ovine cytokines become available then these cells could be
examined for any bias in cytokine production.
Experiments to investigate the function of anti-visna antibody against visna virus infected
cells yielded surprising results. Plasma from visna infected sheep contains antibodies
capable of binding specifically to visna infected cells and mediating complement-dependent
lysis of these cells (Figure 3.9). However these same plasma samples do not appear to
mediate ADCC activity (Figure 3.7).
The major effector cells mediating ADCC in ruminant systems have been reported to be
neutrophils and monocyte/macrophages (Rouse et al, 1976., Grewal et at, 1977., Grewal &
Rouse, 1979). The PBMC's used as effector cells in these assays contained around 20%-
25% monocyte/macrophages (Table 3.2), moreover they were capable of lysing antibody-
coated erythrocytes (Figure 3.10). In human systems, monocyte/macrophages have been
reported to be the major cell type capable of mediating lysis of antibody-coated erythrocytes
(Poplack et al, 1984). The ability of sheep sera to direct ADCC in another virus system was
not investigated here, although on reflection this would have been a better positive control
system. Other workers, however, have demonstrated that bovine herpesvirus infected cells
can be lysed in ADCC assays using PBMC and unfractionated sera (Rouse et at, 1976.,
Grewal et al, 1977., Grewal & Rouse, 1979).
That anti-visna antibodies mediate ACC, but not ADCC is in contrast to the situation
observed in human infected with HIV. Anti-HIV antibodies have been reported to mediate
ADCC (Rook et al, 1987., Ojo-Amaize et al, 1987), but not ACC (Nara et al, 1987b).
Interestingly, chimpanzees infected with HIV or goats immunised with gp120 produce
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antibodies capable of mediating both ADCC and ACC against HIV-infected cells (Nara etal,
1987a., 1987b).
Given the biological properties of ruminant immunoglobulins (Table 3.1) it is tempting to
speculate that the failure to detect visna-specific ADCC is related to the isotypic restriction of
the IgG anti-visna antibody response. lgG2 is cytophilic for both neutrophils and fresh
monocytes, whereas lgG1 is only capable of adhering to peripheral blood monocytes which
have been cultured in vitro. In vitro culture of monocytes is often equated with activation
and/or differentiation of monocyte/macrophages and it would be interesting to assess the
efficacy of cultured monocytes in anti-visna ADCC assays.
A proviso to the hypothesis that it is the absence of lgG2 antibody in the humoral immune
response to visna that results in the lack of detectable ADCC activity is that there is a report
in the literature that lgG1 antibody can mediate ADCC against murine mastocyoma cells
(Grant et al, 1975). However this study was based on the fractionation of immunoglobulins
into IgG! and lgG2 by ion-exchange chromatography, a procedure which will not result in
complete separation of IgG! from lgG2 without further purification (Butler, 1986). Grant et al
did not present data on the purity of their fractionated immunoglobulins. It is interesting to
note that the data reported by Grant et al indicates that the 'IgO^ fraction caused lower
levels of specific lysis and that the kinetics of the lytic reaction were slower. This may indicate
that a proportion, at least, of the ADCC activity measured was due to lgG2 contamination of
the IgG! fraction. However it is difficult to compare the relative activities of the IgG fractions
assayed in this paper in directing ADCC, as no data is presented on the protein
concentrations of the different IgG fractions used in these assays. Alternatively, Grant et al
used high titre hyperimmune antiserum in their experiments and the apparent discrepancy
between that data and the results presented here could be simply explained if IgG!
antibodies are much less efficient at mediating ADCC than lgG2 antibodies, but that their
IgG! fractions contained more specific antibody than their lgG2 fractions. The anti-visna
antibody titres of the serum used in these experiments was relatively low.
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It is unclear whether this lack of detectable anti-visna ADCC activity in vitro is of any
significance in vivo. Antibody-mediated fixation of complement has been shown to enhance
ADCC of target cells infected with a bovine herpes virus (Rouse et al, 1977a., 1977b). It is
thus possible that lgG1 bound to visna infected target cells could fix complement and then
indirectly activate ADCC by cells expressing complement receptors.
The role of different T cell subsets during immune responses to viral infection has been
studied in a number of model systems (Cobbold et al, 1984., Leist et al, 1987., Taylor &
Askonas, 1986) and while CD8+ cytotoxic T lymphocytes are capable of clearing viral
infections optimal antiviral responses require the presence of both CD4+ and CD8+ immune
T cells. This has been directly shown in a murine retrovirus system where in adoptive transfer
experiments both T cell subsets were required for protection from virus-induced disease
(Horn et al, 1991). The data described here indicates that sheep persistently infected with
the lentivirus maedi-visna mount a T cell immune response to the virus which includes CD4+
T cells. In this connection it is interesting to note that although the majority of the visna
reactive T cells in this assay were CD4+, in two individuals CD8+ lymphocytes appeared to
make some contribution to this in vitro lymphoproliferation (Table 3.4). Lymphocyte
proliferation to exogenous protein antigen in vitro is generally thought to result from MHC
Class II restricted presentation of antigen to CD4+ T cells (reviewed in Moller, 1988., Brodsky
& Guagliardi, 1991).
It is interesting to note that in HIV infection, lymphocyte proliferation in response to HIV
antigen is weak or absent in infected individuals (Wahren et al, 1987). Failure to detect a
secondary T cell response to HIV antigen could result from either the failure of infected
accessory cells to recruit HIV specific T cells into the immune response or as a direct
consequence of viral infection of CD4+ T cells. Since the sheep lentivirus is restricted in its
tropism to cells of the monocyte/macrophage lineage, the data presented here suggest that
the failure of the T cell response to HIV antigens is more likely to be due to lymphocyte
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infection and dysfunction rather than a failure of antigen presenting cells to recruit HIV
specific T cells.
That said, the significance of this CD4+ T cell response in visna is unclear since visna
infected sheep do not clear the viral infection. Quantative statements on the extent and
significance significance of the T-helper response in visna infected sheep, requiring limiting
dilution analysis of the T cells responding to visna and assay of the cytokines secreted by
these cells may help to clarify this issue.
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Chapter 4
The acute immune response to maedi-visna virus studied at the level of
a single lymph node
4.1 Introduction
Lentiviral infections of man and animals result in disease characterised by a long
asymptomatic period and a slow progression of clinical signs (Narayan & Clements, 1990).
The pathogenesis of lentiviral disease in vivo can be thought of as occurring in several
stages: acute infection (primary exposure to virus),
establishment of infection,
slow progression of disease (virus generally in restricted replication state), with
development of pathological changes indirectly mediated by immune and
inflammatory response of the host,
death, due to either primary or secondary disease.
Little is known about the progression of any of these stages in vivo. The
pathophysiologic events occurring immediately post infection and in the interval between
infection and development of clinical disease remain obscure; yet it is at these stages of the
infective process that any immune mechanisms induced by prior vaccination must act to
prevent, or clear, viral infection.
Moreover, it is possible that immune mechanisms activated in the acute response to
lentiviral infection are important in driving the virus to adopt the 'restricted replication' state
which is thought to be a major mechanism underlying both the persistence and spread of
lentiviruses and the slow evolution of lentiviral disease (Haase, 1986). However, since early
immune responses are likely to occur in lymphoid organs and may not even be apparent in
peripheral blood (Westermann & Pabst, 1990), relatively little is known about the nature of the
acute immunologic and virologic events which occur in the acute immune response to
lentiviral infection.
Reimann et al (1991) studied the acute changes seen in lymph nodes of macaques in
response to intravenous challenge with SIV. The major finding reported by these workers was
a marked increase in numbers of CD8+ T cells within the node early after infection with SIV.
No consistent change in CD8+ PBMC was noted during this time. The CD8+ cells within the
node appeared activated, in that they exhibited increased levels of MHC class II expression
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and decreased expression of leukocyte adhesion molecule-1, however these same cells did
not express CD25 (IL-2R) and were not proliferating. This phenotype resembles the 'chronic
state of activation' of CD8+ T cells seen in AIDS patients (Pantaleo et al, 1990). The basis of
this 'semi-activated' phenotype of the CD8+ lymph node cells from these macaques was not
clear, but there was no correlation between the presence of CD8+, MHC class II positive T
cells and the detection of SIV-specific cytotoxic responses. These findings were interpreted
as suggesting that this numerically important CD8+ population may serve a regulatory
function and may represent a suppressor population analogous to that detected in HIV
infected individuals (Joly et al, 1989).
A model system which allows the study of acute (and chronic) immune responses by
lymphoid tissue following viral challenge is lymphatic cannulation (Lascelles & Morris, 1961.,
Hall & Morris, 1962). The peripheral lymph nodes of sheep are easily accessible and, under
general anaesthesia, it is possible to cannulate the efferent lymphatic vessel exiting a lymph
node. Thereafter, lymph can be collected, in a quantitative manner, for periods of hours to
months. The output of lymphocytes from a single resting lymph node of approximately 1g
weight averages around 3-5 x 107 lymphocytes per hour (Hall & Morris, 1962., Hay & Hobbs,
1977). Of the small lymphocytes exiting the node, about 90% come from the blood, some
2%-4% are produced within the node and 5%-10% are derived from peripheral lymphatic
input to the node (Hall & Morris, 1965a., Schoefl, 1972). Peripheral lymph is lymph.that has
not passed through a lymph node and differs from efferent lymph in that it contains some
10%-20% macrophage/dendritic cells and fewer B cells (MacKay et al, 1988., Bujdoso et al,
1989a). Afferent lymph T cells have been shown to be predominantly of a 'memory'
phenotype, as defined by their level of expression of 'memory' T cell markers such as LFA-3
and CD2 (Mackay et al, 1990). In contrast, efferent lymph contains few, if any,
macrophage/dendritic cells, 20%-30% B cells and approximately 70% T cells. Efferent lymph,
from a resting node, is enriched for CD4+ T cells (Mackay et al, 1988., Bujdoso et al, 1989b)
and these T cells are predominantly of a 'naive' phenotype (Mackay et al, 1990).
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Injection of antigen(s) into the drainage area of the cannulated node results in alterations
in the efferent lymph output from the challenged node. Primary challenge of a lymph node
with soluble protein antigens such as Ovalbumen (OvA) and PPD causes only small changes
in lymph flow and cell outputs (Hopkins et al, submitted for publication) thus the bulk of the
published data on responses to antigen, in this system, deal with secondary immune
responses.
Antigenic challenge of the lymph node in primed animals results in marked alterations in
the efferent lymphatic output of that node. From 6-24hrs after antigen challenge there is a
striking reduction in the output of cells from the node, but no reduction in the flow of lymph
fluid; a phenomenon known as cell shutdown (Cahill et al, 1976., Hall & Morris, 1965b). The
cell shutdown response is believed to be a result of prostaglandin E2 synthesis within the
node, secondary to complement activation (Hopkins et al, 1981a., McConnell & Hopkins,
1981).
Following shutdown there is a biphasic increase in cell output from the node. About 48hrs
after antigen challenge there is an initial peak in cell output which is thought to be due to the
release of cells which had accumulated within the node during cell shutdown. This
recruitment of cells to the antigenically stimulated node is not antigen-specific, but instead
results from changes in lymphocyte traffic through the stimulated node. These changes are
due to increases in both vascular permeability and lymphocyte input (Cahill et al, 1976., Hay
& Hobbs, 1977). The second peak in cell ouput occurs 4-6 days after antigen challenge and is
associated with firstly, an increased migration of cells from blood to the node, and secondly
with antigen-driven lymphoproliferation within the node.
These kinetic changes in cell output are accompanied by changes in the lymphocyte
subset composition of efferent lymph T cells. After antigenic stimulation of the node the
composition of efferent lymph is altered initially by an increase in the proportion of CD4+ T
cells, followed by an increase in the proportion of CD8+ T cells, this wave of CD8+ T cells
tends to occur when the cell output of the node is at its maximum (Bujdoso et al, 1989b).
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Efferent lymphocytes are responsible for the establishment of immunological memory and
the dissemination of the immune response to other lymphoid organs. If cells leaving an
antigen stimulated node are removed by chronic lymphatic cannulation there is no priming for
a secondary immune response (Hall & Morris, 1967., Smith et al, 1974); intravenous infusion
of cells collected during the response, but free of antigen, can reverse this effect.
Thus using the model system described above injection of maedi-visna virus into the
drainage area of a cannulated peripheral node allows continuous monitoring of the
immunological and virological events occurring in the acute and sub-acute phases of the
immune response of lymphoid tissue to lentiviral infection. The protocol used for these
experiments is shown in Figure 4.1.
This chapter describes the antibody response to maedi-visna virus, as analysed in this
system, and the visna-specific T cell response, as measured using in vitro lymphocyte
proliferation assays. These data are my own work. These experiments, however, were
carried out as part of a larger group of workers utilising this sytem to study a number of
aspects of lentiviral pathogenesis and where appropriate, and with due acknowledgement,
their results will also be discussed.
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Figure 4.1 Experimental protocol
The efferent lymphatic vessel for the prefemoral lymph node of 1 -3yr old randomly bred
Finnish-Landrace sheep was cannulated as described by Hall (1967). The cannulation was
allowed to stabilise following surgery and, about one week after cannulation, approximately
5 x 105 TCID^ of maedi-visna virus (strain EV1 (Sargan et at, 1991)), grown in autologous
skin cells was injected intradermal^ and subcutaneously into the drainage area of the node.
Control sheep were challenged with autologous skin cell culture supernatant alone.
Within the efferent lymph exiting the node changes in cell number and phenotype (Dr. P.
Bird & D.J. Allen), the development of visna-specific antibody (HTR), lymphocyte proliferation
(HTR), cell-mediated cytotoxicity (Dr. B.A. Blacklaws) and the presence of infectious virus





4.2.1 Maedi-visna virus specific antibody in efferent lymph
In total, five sheep with prefemoral efferent cannulations were studied in these
experiments: three of these, sheep 657R, 649R and 683R were infected with 'autologous
visna' (see Figure 4.1), sheep 1060P and 663R were mock-infected with autologous cell
supernatant.
Maedi-visna virus specific antibody was first detected 3-4 days post infection (Figures 4.2
& 4.3). Immunoblot analysis (Figure 4.2, left-hand panel) demonstrated weak antibody
reactivity to bands of apparent Mr of 24kDa and 28kDa (p25) around days 4-12 post¬
infection. Antibody to the viral envelope glycoprotein (gp135) was undetectable at this time,
but later, from day 12 onwards anti-env antibody could be detected (Figure 4.2, left-hand
panel). Antibody to p25 was also detected later in the infection, apparently peaking at around
days 26-30 post-infection. These bands were not seen when blots were probed with lymph
plasma from a control sheep, 1060P (Figure 4.2, right-hand panel). Antibody reactivity to
bands of 50-70kDa was also seen on immunoblots. This was not visna-specific since it was
detected using lymph plasma from sheep 649R collected prior to visna challenge and with
lymph samples from control sheep 1060P. The nature of the non-visna specific reactivity is
unclear. It may represent an antibody response to cellular proteins or components of the
tissue culture medium, however the challenge virus is grown in autologous cells and weak
reactivity is seen prior to challenge in both sheep. This reactivity to bands of 50-70 kDa
titrates at least as far as the anti-visna reactivity and is not inhibited by high salt
concentrations (0.5M) or the presence of detergent (0.05% Tween 20).
Quantitative data on the anti-visna antibody response (Figure 4.3) was obtained by
ELISA against recombinant p25 protein (see Chapter 5). There was some variation in the
time at which anti-visna antibody was first detected after visna infection. Sheep 683R
produced two discrete peaks of anti-p25 antibody; days 4-6 and days 12-18, which were of
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Figure 4.2 Immunoblot analysis of the antibody response to maedi-visna virus in efferent
lymph
Lymph was collected as described in section 2.14.3.2 and centrifuged to separate cells
from lymph plasma. The cell-free plasma was stored at -20°C until used.
Visna antigen, prepared as described in section 2.8.1 was separated on 5-20% linear
gradient SDS-PAGE, run under reducing conditions, and electroblotted onto a nitrocellulose
membrane. Strips, cut from these blots, were incubated overnight with pre- and post-infection
samples of lymph, diluted 1:10 in PBS/5% non-fat dried milk. Blots were developed using
affinity-purified anti-sheep immunoglobulin conjugated to alkaline-phosphatase (Sigma).
Positions of molecular weight standards are indicated. The arrows indicate the anti-p25 and
anti-env antibody reactivities. The bands on the blots probed with 1060P lymph are slightly
higher as these strips were cut from a separate blot to that labelled 649R. Both blots, when
probed with anti-visna sheep sera showed similar patterns of reactivity.
The left hand panel shows a set of blots obtained using lymph plasma samples from
sheep 649R (visna challenged), from left to right the strips were probed with plasma samples
collected every second day from 2 days pre-infection ie. day -2, day 0 etc. till day 32. For
comparison with visna specific bands seen on blots probed with sheep serum see Figures
3.2 & 3.4. The right hand panel shows a set of blots probed with plasma from sheep 1060P
(mock-challenged). In this panel the strips are probed with samples taken every second day
from day 0 to day 18.
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Figure 4.2
649R (EV1) 1060P (Mock)
Figure 4.3 Anti-p25 antibody in efferent lymph plasma
Samples of lymph plasma collected as described previously were assayed for anti-
p25 antibody by ELISA against recombinant p25 protein (see Chapter 5).
Purified recombinant p25 (5pg/ml in 0.1 M NaHC03, pH 9.6) was coated onto Falcon
PVC plates by overnight incubation at 4°C. After washing in BBS/0.05% Tween 20, the wells
were blocked by incubation with BBS/1% BSA (200pl/well) for 1 hr at 37°C. Samples of
lymph, diluted in BBS/BSA/ 0.05% Tween 20, were titrated in doubling dilutions starting from
a 1/5 dilution. After 1 hr incubation at 37°C, the plates were washed in BBS/Tween and then
incubated for a further 1 hr with a 1/4000 dilution of rabbit anti-sheep Ig conjugated to HRP
(Dako) in BBS/Tween/BSA before washing and developing the plates with OPD as substrate.
Antibody titre is expressed as endpoint titre, taken as the reciprocal of the highest
dilution of plasma which gave an OD492 twice that of background values (no lymph).
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roughly equal titre. This cannulation stopped on day 23. For sheep 649R and 657R antibody
was first detectable at around days 4-6 and the first peaks of anti-p25 antibody were at days
6-9 and 12-14 respectively, after this antibody titres declined slightly and then rose gradually
to a peak at day 22. These kinetics are in good agreement with those seen on immunoblot
analysis (Figure 4.2 & 4.4). When these cannulations were stopped antibody titres had not
yet begun to decline. No anti-p25 antibody was detected in lymph from control sheep (Figure
4.3).
Analysis of the isotypes of the anti-visna antibody responses (Figure 4.4) suggests that
the initial peak of antibody is of the IgM isotype whereas later in the infection lgG1 anti-visna
antibodies predominate. Again (see Chapter 3), no lgG2 anti-visna antibodies were detected.
The data shown was obtained by probing blots of visna antigen with lymph samples from
sheep 657R. Blots probed with lymph from 649R and 683R also showed that the initial
anti-visna antibody response is IgM while antibody produced later in the response is of the
lgG-| isotype (data not shown). These changes were parallelled by changes in the isotype of
the slg expressed on efferent lymph B cells. The anti-env response in these blots is
obscured by the non-visna specific smearing at the top of the blots. A number of approaches
to eliminate this problem were tried, but none of these were successful.
Some of the observed variation in the anti-p25 antibody response between these sheep
probably reflects the expected variation in immune responses between individuals in an
outbred population. However, it is also possible that some of the variation in anti-p25
antibody titre seen using these assays may be due to failure to detect anti-p25 antibody
because it is complexed with p25 antigen. In HIV infection, p24/anti-p24 immune complex
formation in vivo has been shown to result in a decline in anti-p24 antibody titres (Von
Sydow et at, 1988). This possibility was tested using a p25 antigen capture ELISA (see
Chapter 5) developed with either anti-p25 antibody (Figure 4.5A) or antibody to sheep
immunoglobulin (Figure 4.5B). These data demonstrate that a proportion, at least, of the anti-
p25 antibody produced after visna infection may not be detectable in the ELISA used in
Figure 4.3. This assay, however, does not distinguish between immune complexes formed
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Figure 4.4 Analysis of the antibody isotypes detected in the primary anti-visna antibody
response of the prefemoral lymph node
Immunoblots of visna antigen were prepared as described in Figure 4.2. Blots were
incubated with lymph plasma (1/10) overnight at room temperature. Four immunoblots were
used in this experiment; a single blot for all the lymph samples developed with each isotype
specific reagent (Each blot contained similar amounts of all the visna antigens, as judged by
probing each blot with pooled sera from visna infected sheep). After washing the strips were
then probed with either McM1 (anti-yl, 1/2000), McM3 (anti-y2, 1/500), McM9 (anti-p, 1/1000)
or normal mouse serum (NMS) (1/500) and developed using affinity-purified anti-mouse-
immunoglobulin conjugated to alkaline phosphatase. Positions of molecular weight standards
are indicated.
In each panel the strips were probed with plasma samples collected, from sheep 657R,
every second day of the experiment from 2 days pre-infection ie., from left to right, day -2,
day 0 etc. till the end of the experiment.
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Figure 4.4
Figure 4.5 Detection of p25 antigenaemia and p25/anti-p25 immune complexes in sheep
649R
Affinity-purified rabbit anti-p25 antibody (10pg/ml in BBS) was coated onto flexible Falcon
PVC plates by overnight incubation at 4°C. After washing in BBS/0.05% Tween 20, the wells
were blocked by incubation with BBS/1% BSA/1% rabbit serum (BBR) (200pl/well) for 1 hr at
37°C. After washing samples of undiluted lymph plasma (200pl), collected on the days
indicated and stored at -20°C until use, were added to the wells . After 1 hr incubation at
37°C, the plates were washed in BBS/Tween and then incubated for a further 1 hr with either
(A) biotinylated rabbit anti-p25 (20pg/ml in BBR), washed again and then incubated with
extravidin-HRP (1/4000 in PBS/1% BSA) or (B) a 1/4000 dilution of rabbit anti-sheep Ig
conjugated to HRP (Dako) in BBS/Tween/BSA . After a final wash plates were developed
with OPD and absorbance at 492nm read using a Titertek ELISA reader.
In A, p25 antigen concentrations were derived by reference to a standard curve obtained
by titrating known concentrations of recombinant p25 in the assay as described in Figure
5.11. In B, the data is presented as the mean OD492 of duplicate wells. The p25 antigen
detection assay is sensitive down to around 150-300pg/ml (see Chapter 5), thus the levels of
p25 antigen indicated for days 6, 20 and 22 should be interpreted only cautiously.
138
ure 4.5
Visna Challenge Days post infection
in vivo and soluble p25 antigen in the lymph competing, with p25 antigen bound to the
ELISA plate, to bind efferent lymph anti-p25 antibody during the assay.
For sheep 657R and 683R, the levels of the initial peak of free p25 antigen in efferent
lymph plasma (Figure 4.6) could be correlated with the exit of visna virus from the node, as
judged by co-cultivation experiments (Appendix A, Figure A.1). It should, however, be pointed
out that p25 antigen levels do not accurately reflect levels of infectious virus (see Chapter 5,
section 5.5). Experiments using inert antigens, such as PPD and A. 'phage indicate that 80%-
90% of an injected antigen exits the node within 6hrs post injection (Professor Ian McConnell,
personal communication). It is thus unlikely that this p25 antigen in efferent lymph, first
detected 8-10 days post infection, is merely antigen passively carried through the node, but
rather reflects active viral replication. This is consistent with the detection, by PCR, of proviral
DNA sequences within efferent lymph cells (Dr. D. R. Sargan, personal communication).
Interestingly, the second peak of p25 antigen, which may be complexed with anti-p25
antibody (Figure 4.5A), was not parallelled by a second peak of infectious virus. This may be
a reflection of a difference in sensitivity between the two assays, although it could also be
interpreted as suggesting that viral replication (and hence p25 antigen production) is
continuing, but that infectious virus is either neutralised by antibody or not released from the
infected cell(s).
The development of virus neutralising antibody after visna challenge was therefore
investigated (Figure 4.7). These experiments demonstrate that visna virus neutralising
activity could first be detected 12-14 days post infection and that this activity gradually
increased in titre with time. This correlates well with the development of antibody to visna
env, the major target antigen for virus neutralising antibodies (Scott et at, 1978), (Figure
4.2), and with the development of lgG1 anti-visna antibody (Figure 4.4). The titres of
neutralising antibody detected here (1/16) appear low when compared to other reports
(Gudnadottir & Palsson, 1966., Petursson et al, 1976), however it should be remembered
firstly, that the assays used are not directly comparable since the assay described here used
500 TCID^ of visna, rather than the 100 TCID^ of virus used by these workers Secondly
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Figure 4.6 Detection of p25 antigen in efferent lymph of visna infected sheep
Lymph plasma (undiluted) was assayed for the presence of p25 antigen as described in
Figure 4.5A. p25 antigen concentrations were derived by reference to a standard curve
obtained by titrating purified recombinant p25 in the assay.
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Figure 4.6
Figure 4.7 The development of maedi-visna virus neutralising activity after infection
Serial dilutions (from 1/2, in DME/2% FCS) of heat inactivated lymph plasma samples,
collected on the days indicated, were mixed with 500 TCID^ of EV1 virus and incubated for
24 hrs at 4°C. Infectious virus remaining was then assayed on skin cells (see section 2.11.3)
and virus titres calculated by a quantal method (Reed & Muench, 1938).
Antibody titres are expressed as the reciprocal of the highest dilution of lymph which
gave a 50% reduction in virus titre compared to controls (virus incubated with non-immune
plasma, or virus incubated with medium alone).
Sheep 683R, 649R and 657R were challenged with maedi-visna virus. Sheep 1060P was
'mock-infected' with autologous cell supernatant.
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Figure 4.7
this neutralising antibody is being detected 10-14 days post infection rather than 30-40 days
into the response.
In these experiments lymph plasma collected from control sheep (challenged with
autologous cell supernatant) did not neutralise visna virus (Figure 4.7). However, it has been
reported that a non-immunoglobulin inhibitor of visna virus replication can be found in normal
sheep serum (Thormar et al, 1979). Thus experiments were carried out to directly test
whether the virus neutralisation observed in Figure 4.7 was antibody mediated. Samples of
lymph, previously shown to have high titre neutralising activity were treated with either
antiserum to sheep immunoglobulin or control, non-immune antiserum and then re-tested
invirus neutralisation assays. The results of such an experiment are shown in Table 4.1. this
demonstrates that at least the high titre neutralisation of visna virus observed in Figure 4.7 is
antibody mediated.
4.2.2 Visna specific T cell responses
Maedi-visna virus infection results in a significant (P<0.05), almost four-fold increase in
the percentage of lymphoblasts in efferent lymph compared to controls (Appendix A, Figure
A.2). The peak of this response varied from day 7-16 between sheep and the maximum
output of blast cells from the node exceeded 2 x 107 lymphoblasts/hour (Blacklaws et al,
manuscript in preparation).
The most striking feature of this lymphoblast response was a dramatic increase in the
percentage of CD8+ blasts, peaking between days 6-10 (Appendix A, Figure A.2). At the
peak of this response 20%-50% of the cells exiting the node were blast cells and 60%-80% of
these lymphoblasts were CD8+; on day 0, 2%-5% of the efferent lymphocytes were blast
cells and only 10%-20% of these cells were CD8+ (Blacklaws et al, manuscript in
preparation). Visna specific cell-mediated cytotoxic activity was detected within the lymph





Treatment 649R (day 31) 683 R (day 22)
A medium 32 16
B control antiserum 32 16
C anti-sheep Ig 2 0
Neutralisation assays were performed as for Figure 4.6, except that lymph plasma was
diluted in medium (A), medium plus 200pl of high titre donkey anti-sheep IgG antiserum (C)
or medium plus 200pl of control non-immune serum (B). The volume of medium added to
each mixture was adjusted so that the final volume of each was equivalent. These mixtures
were incubated overnight at 4°C and the remaining virus assayed as before. Samples of
lymph plasma were not titrated beyond 1/32.
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4.2.3 Lymphocyte proliferation
The ability of efferent lymphocytes to proliferate in response to visna antigen was tested,
in in vitro lymphocyte proliferation assays, on the indicated days pre & post infection.
Efferent lymph is mainly composed of T & B cells (around 70% and 30% of total cell numbers
respectively) and contains few, if any, macrophage/dendritic cells. It has previously been
reported that lymphocytes, including efferent lymphocytes, are poor stimulators of T cell
proliferation in primary immune responses (Bujdoso et al, 1989c., Inaba & Steinmann, 1984).
Thus a possible explanation for any failure to detect antigen-specific lymphoproliferation
could be the absence of 'professional' antigen-presenting ceils. To control for that possibility
these assays were set up in duplicate; ie. in the presence, and absence, of autologous
PBMC, collected prior to infection and cryopreserved, as a source of
monocyte/macrophages.
In 2/2 visna infected sheep tested (649R & 683R) in vitro lymphocyte proliferation (S.I. >
2) to visna antigen (either sucrose-purified EV1 (Figure 4.8A) or p25 (data not shown)) was
detected from day 15 post infection onwards. Significant proliferation to antigen was
observed only when autologous PBMC were added to the cultures. Control antigens such as
ovalbumin did not stimulate lymphoproliferation.
During the period of the CD8+ lymphoblast response markedly decreased stimulation
indices were obtained when efferent lymphocytes were cultured with the mitogen
Conconavalin A, as can be seen in Figure 4.8B. The data in Table 4.2 indicates that this
phenomenon is primarily due to a decrease in lymphocyte proliferation, although there is a
slight contribution of an increased background. It is thus possible that antigen-specific T-cell
responses may have occurred earlier than day 15, but not have been detected in this in vitro
assay system since the phenomenon described above effectively results in a decreased
sensitivity of the assay during the peak of the blast response.
The available data does not allow elucidation of the basis of this effect, but it is clear that
its appearance coincides with the CD8+ lymphoblast peak. One possible explanation could
be that after five days culture in vitro the rapidly dividing blast cells have terminally
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Figure 4.8 Lymphocyte proliferation by efferent lymphocytes in response to visna antigen
On the days indicated, freshly collected efferent lymphocytes were washed once and
then cultured, at 5 x 105/ml, for 5 days with either an optimal dose of sucrose purified visna
(4pg/ml) and 3 x 105 autologous PBMC (A), or Con A at 5pg/ml (B). Cultures were then
pulsed with 3H-Tdrfor 5 hours and harvested. Data is expressed as stimulation indices:
S.I. = (mean cpm. antigen stimulated cultures/mean cpm. unstimulated culture). Controls
included cells cultured without antigen, cells cultured with an equal concentration of an
irrelevant protein antigen and cells cultured with material prepared from mock-infected skin
cell cultures. Autologous PBMC, collected prior to visna challenge and cryopreserved,
proliferated in response to the mitogen Con A (5pg/ml), but did not proliferate in response to







-T 1 » 1 " 1 1 1 « | ' 1 ' 1 ' |-
-2^2 6 10 14 18 22 26 30
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Table 4.2
Response (cpm[3H1-Tdr ± so) to
649R 683R
Days post infection Medium Con A (S.I.) Medium Con A (S.I.)
0 88 ±15 3091 ± 200 (35) 130 ± 12 734 ± 161 (5.6)
2 1534 ±369 114112 ±4293 (74) 3363 ± 209 30197 ±331 (9)
6 754 ± 251 122236 ±9273 (162) 624 ±212 101088 ±4020 (162)
8 1577 ±634 88818 ±5423 (56) 770 ±192 129593 ±2059 (168)
10 N/Aa N/A 1730 ±60 109759 ±3000 (63)
12 274 ± 12 15315 ±500 (55) 270 ± 42 18259 ±7864 (67)
14 1263 ± 126 75297 ± 4621 (59) 1293 ±250 112649 ± 1212 (87)
16 821 ± 44 105766 ±5460 (128) 350 ± 23 67494 ±627 (193)
18 1376 ±821 223483 ±7844 (162) 773 ± 50 112649 ± 1212 (131)
22 1400 ±400 203000 ±2102 (145) NDb ND
25 1908 ±743 257352± 1481 (134) ND ND
27 758 ±123 127344 ± 1428 (168) ND ND
31 1700 ±259 244470 ±4000 (143) ND ND
a. These cultures were lost due to bacterial contamination.
b. This cannulation stopped on day 23 post-infection.
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differentiated and ceased to divide, thus this phenomenon may be an artefact of a five day
culture period. Alternatively, and perhaps more interestingly, this phenomenon could be
explained by suppression of lymphocyte proliferation by the activated CD8+ cells which
predominate in the lymph at these times. This latter possibility could be tested by titrating
purified CD8+ cells, collected at this time, into autologous antigen and mitogen stimulated
cultures and assaying for inhibition of lymphocyte proliferation.
4.3 Summary of Chapter 4 results
1. Acute maedi-visna infection results in the production of anti-viral antibody within 3-4
days post-infection. Initially this antibody is of the IgM isotype, but later lgG1 anti-visna
antibody was detected.
2. Virus neutralising antibody was first detected in efferent lymph plasma around 12 days
after infection and increased in titre with time.
3. In vitro lymphocyte proliferation to visna antigen could be detected about 15 days
post-infection.
4.4 Discussion
The acute immunologic events following lentiviral infection are likely to be crucial in
determining the course of disease. These early events in the pathogenesis of lentiviral
infection are likely to occur in lymphoid organs, however, apart from the work of Reimann et
al (1991), relatively little is known about acute immune responses to lentiviruses in these
sites.
The model system described here: experimental infection of sheep with maedi-visna
virus, via acute challenge of a cannulated lymph node, has the advantage that this system
allows continuous monitoring of the acute events occurring in regional lymphoid tissue after
lentiviral infection.
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A striking feature of the early immune response to visna is the increased cellularity of the
efferent lymphatic output from the challenged node (see Appendix A, Figure A.2). Seven to
sixteen days after infection with maedi-visna virus there is an approximate four-fold increase
in the percentage of lymphoblasts exiting the node. Continuing antigenic exposure is one
obvious reason why these changes, in a primary response to visna virus, are much more
dramatic than those seen in a primary response to soluble protein antigen, where only small
changes in lymphocyte and blast cell output are seen (Hopkins et al, submitted for
publication).
The majority of the lymphoblasts within this increase in cell output are CD8+ (Appendix
A. Figure A.2. Blacklaws et al, in preparation). This finding parallels the acute changes seen
in the lymph nodes of macaques challenged with SIV (Reimann et al, 1991) and those of
mice infected with LCMV, where again CD8+ T cells predominate in the response (Lynch et
al, 1989). The work of Reimann et al provides an intriguing parallel with one aspect of the
immune response to visna seen in this system; visna infection results in a striking CD8+
lymphoblast response, but, in the majority of sheep tested this CD8 lymphoblastosis was not
associated with detectable levels of visna-specific cytotoxic activity. By analogy to HIV
infection (Joly et al, 1989) and the SIV system described by Reimann et al, this could be
interpreted as suggesting the presence of both virus-specific effector cells and 'suppressor
cells' within this CD8 population. The balance between these two populations determining
whether or not a CTL response can be detected in vitro. Certainly the data presented in
Figure 4.8B and Table 4.2 could be interpreted as suggesting the existence of a population of
'suppressor cells', although there are other hypotheses to explain those observations.
In contrast to the failure to detect CTL activity, in vitro lymphocyte proliferation to visna
antigen was detected in 2/2 infected sheep tested (Figure 4.8A). This proliferation was
detected relatively late in the response, day 15 post infection onwards, but there is some
evidence; the switch in isotype of the anti-visna antibody response, from IgM to IgG-, (Figure
4.4), for 'T-helper', presumably CD4+, activity within the node earlier in the response. The
late detection of antigen-specific in vitro lymphocyte proliferation may be related to the
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delayed kinetics of the lymphoblast response: lymphoblasts were detected between days 5-
18. Previously it has been shown that specific antigen reactive T cells can be detected exiting
a challenged node only when the blast response is declining (Hay et al, 1974., Cahill et al,
1979). This has been interpreted to mean that antigen causes the selective retention of
antigen-specific lymphocytes within the node and that this is followed by the proliferation and
differentiation of large numbers of antigen-sensitised cells which then leave the node as small
lymphocytes (Trnka & Cahill, 1980). Another explanation for the failure to detect antigen-
specific in vitro lymphoproliferation before day 15, which does not exclude the above, is that
the relatively weak antigen-specific responses are masked by a decrease in the sensitivity of
the assay during the period when blast cells are in the cultures (Figure 4.8B).
A third factor which could affect the T cell responses seen after infection with visna virus
is that in vivo the major target cells for visna are those of the monocyte-macrophage lineage;
the 'professional' antigen-presenting cell. In peripheral blood and afferent lymph the number
of visna infected cells is low, approximately 1 in 10® cells infected as judged by in situ
hybridisation analysis (Peluso et al, 1985., Gendeiman et al, 1986., Dr. D.J. Roy, personal
communication), and it is difficult to reconcile such a low frequency of infected cells with any
direct, major effect of visna infection of macrophages on immune function or recognition. The
possibility exists, however, that visna infection of macrophages may result in disordered
secretion of monokines such as IL-1 and TNF-a and that this could influence the pattern of T
cell responses observed. However no formal demonstration of such an effect has been
reported.
In contrast to the late detection of antigen-specific T cells in efferent lymph, visna specific
antibody was first detected 3-4 days post-infection (Figures 4.2 & 4.3) and antibody titres
were then maintained or increased with time. Although there was some variation in the
kinetics at which the antibody response developed, a reasonably similar pattern of antibody
response could be discerned between sheep. There was an initial peak of anti-p25 antibody,
which was mainly of the IgM isotype, followed by a second peak of IgG anti-p25 antibody.
The anti-visna antibody titres detected are comparable to those observed in efferent lymph
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following infection with Orf virus (Yirrell et al, 1991), the differences in the kinetics of the two
reponses are probably due to the fact that Yirrell et al were studying secondary responses to
Orf virus.
Some of the variation in anti-visna antibody response between sheep may reflect the fact
that outbred sheep were used in these experiments, but it is interesting to note that sheep
683R, which produced more antibody and earlier than the other two sheep, had a low titre
anti-p25 antibody response prior to visna infection. A similar phenomenon has been reported
in an SIV system (Gotch et al, 1991), and it has been suggested that this may represent
cross-reactivity between anti-SIV antibodies and antibodies to endogenous retroviruses. If a
similar situation obtained for sheep 683R, then such antibodies may have influenced the
development of the anti-visna p25 antibody response. It is important to note that visna virus
could not be isolated from this sheep prior to infection with visna virus (Appendix A, Figure
A.1), that this sheep was seronegative for antibodies to other visna proteins, as judged by
western blot analysis (data not shown) and did not develop neutralising antibodies to visna
virus until a time after infection similar to sheep 649R and 657R (Figure 4.7).
The detection of virus-specific antibody in efferent lymph coincided with both increased
levels of total immunoglobulin in lymph and with increased levels of Ig synthesis by efferent
lymph B cells cultured in vitro (Appendix A, Figure A.3a & b). However visna specific
antibody in efferent lymph is of relatively low titre (Figure 4.3) and it was not possible to
determine whether this antigen specific immunoglobulin is secreted by cells within the node
or by free-floating, lymph borne B cells.
In response to challenge with salmonella lipopolysaccharide (LPS), specific antibody was
produced by both lymph-borne B cells and cells within the node (English et al, 1976), but
interpretation of this data is complicated by the fact that LPS is a potent B cell mitogen. In
these visna challenge experiments 106 efferent lymph cells (20%-30% B cells), collected at
various times through the cannulation, and cultured in vitro for seven days did not secrete
detectable levels of anti-p25 antibody (data not shown). However, given that the virus specific
antibody in efferent lymph is of relatively low titre, this may reflect a low frequency of visna
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specific B cells exiting the node, a lack of sensitivity of the assay or both. In contrast to this
failure to detect in vitro production of anti-visna antibody by efferent lymphocytes, Yirrell et al
(1991) detected peak titres of anti-Orf antibody ranging from 1/40 to 1/320 in in vitro cultures
of efferent lymphocytes collected during a secondary response to the virus. Other workers,
studying secondary immune responses to protein antigens, have given estimates of the
frequency of antigen-specific B cells exiting a challenged node ranging from 0.5% (Flynn,
1988) to 6% (Hay et al, 1972). Staining, with biotinylated p25 (followed by avidin-FITC), of
efferent lymph cells exiting a node challenged with visna virus revealed very few p25 specific
B cells (Dr. P. Bird, personal communication). Although it is possible that the presence of
antigen-specific B cells may have been masked by binding of free p25 to surface
immunoglobulin, these data imply that it is perhaps more likely that most of the anti-visna
antibody is secreted by B cells within the node. This suggestion is supported by the
observation that significant levels of visna-antigen specific lymphoproliferation were seen only
when the cultures were supplemented by autologous PBMC. Visna specific B cells exiting the
node would have been expected to act as antigen-presenting cells (reviewed in
Lanzavecchia, 1990). No such effect was observed. The PBMC did not proliferate when
cultured with visna antigen, thus it is likely that addition of these cells enhanced the
proliferative response by supplying monocyte/macrophages to act as APC's.
Antibodies to p25, while a useful marker of the immune response to visna infection, are
not thought to be of major importance in protection from disease. In contrast, dissemination
of virus by extracellular routes has been reported to cease after the appearance of virus
neutralising antibodies even though infectious virus, as detected by co-cultivation, is almost
exclusively cell associated (Petursson et al, 1976). The basis of this correlation is unclear:
immunosuppression does not relieve the restriction in virus gene expression (Nathanson et
al, 1976., Narayan et al, 1977), but these data do not exclude the possibility that this
restriction is initially imposed by host immune responses and then maintained by other
mechanisms. This hypothesis is consistent with the data presented here: a reduction in viral
replication in vivo, as measured by either infectious centre assay (Appendix A, Figure A.4) or
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p25 antigen assay (Figures 4.5 A & 4.6), coincides with the appearance of virus neutralising
antibody in efferent lymph (Figure 4.7). Direct evidence of a causal relationship is lacking, but
these data provide strong circumstantial evidence for an important role in restriction of the
dissemination of virus in vivo by neutralising antibody to maedi-visna virus produced shortly
after infection.
However this suggestion is in contrast to the observations reported by Geballe et al
(1985). Using quantitative in situ hybridisation these workers demonstrated that restriction in
viral nucleic acid synthesis became evident 7-8 days after infection of sheep by intra-
pulmonic inoculation of visna virus. In these experiments virus neutralising antibody was not
detected until 3-4 weeks after infection, but these workers were assaying blood plasma for
neutralising antibody, rather than the efferent lymphatic output of the regional lymphoid tissue
draining the site of virus infection. It is therefore possible that virus neutralising antibody was
produced early after infection and influenced viral replication, but that initially this antibody
was diluted, when the lymph entered the circulation, below detectable levels in blood plasma.
In one of these cannulation experiments (657R), serum antibody responses were analysed in
parallel with the efferent lymph antibody response. Interestingly, no visna-specific antibody
could be detected in the serum of this sheep until approximately one month after the end of
the cannulation (in agreement with Figure 3.1), whereas visna specific antibody could be
detected in efferent lymph from 3-4 days after infection (data not shown). This data is in
agreement with the above hypothesis, but it is possible that the removal of antigen-specific
efferent lymphocytes via the cannulated lymphatic may also have contributed to this delayed
systemic response (McConnell et al, 1974., Hopkins et al, 1981).
As described above there appears to be an inverse relationship between detection of cell
associated virus and the appearance of virus neutralising antibody, but the significance of
virus-specific T cell responses in this system is unclear. Cellular immune responses are
believed to be critical determinants of protection and clearance in most viral infections (Mims
& White, 1984., Reddehase et al, 1989) and yet there is no obvious temporal correlation
between either the CD8 lymphoblast response (Appendix A, Figures A.2) or virus specific in
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specific in vitro lymphoproliferative responses (Figure 4.8A) and a decline in virus replication.
Further, virus-specific CTL activity was not detected in the majority of sheep tested, although
that said, inhibition of HIV replication in acutely infected CD4+ T cells has been shown to
involve a non-cytotoxic mechanism mediated by CD8+ T cells (Brinchmann et at, 1990.,
Walker et at, 1991). These studies have demonstrated a role for soluble factor(s) in
suppression of virus growth, although celkcell contact appears to be required for optimal
antiviral activity (Walker et al, 1991). Thus although in vitro neutralisation of visna virus
appears to be mediated entirely by antibody (Table 4.1); in vivo the products of activated T
cells eg. IFN-y, and tumour necrosis factor (Yamamoto et al, 1986., Paliard et al, 1988) may
contribute to the observed reduction in virus replication. Further investigation of this point
would require assay of both efferent lymph, and the supernatant of cultures of efferent
lymphocytes proliferating in vitro in response to visna antigen, for cytokines suspected to be
important in regulating lentiviral gene expression in vivo.
Whatever the basis of the observed restriction in virus dissemination in vivo, viral
replication is not completely eliminated. The data in Figures 4.5A and 4.6 indicate that while
the first peak of p25 antigen production initially declines, a second wave of antigenaemia can
be detected later in the course of the cannulation. Thus although viral replication, as
measured by infectious centre assay, cannot be detected, these data imply that viral
replication, albeit at a low level, is continuing in the face of the host immune response.
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Chapter 5
Cloning and expression of p25, the major core protein
of maedi-visna virus
5.1 Introduction
Maedi-visna virus infection of sheep results in a spectrum of disease pathology:
encephalomyelitis, interstitial pneumonitis, lymphadenopathy and wasting, reminiscent of that
seen in HIV infection of man (Georgsson et al, 1990). However, in contrast to HIV, the major
cell types productively infected with visna in vivo are of the monocyte-macrophage lineage
(Gendelman et al, 1985., 1986). Maedi-visna virus infection of sheep may thus prove to be a
useful model for certain aspects of HIV pathogenesis, since both the effects of lentiviral
infection on the immune system and the immune response to lentiviral infection can be
studied in a situation where viral infection of lymphocytes is not a recognised feature of
disease.
The utility of this system is, however, limited by the paucity of visna virus specific
reagents. In order to generate large quantities of an individual viral protein for use in
immunological assays (see Chapters 3 & 4) and the generation of specific antisera the gene
encoding p25 was cloned via PCR (Saiki et al, 1988) and expressed using the yeast Ty-VLP
system (Adams et al, 1987a).
In this system p25 is expressed as a Ty-p25 fusion protein which self-assembles to form
virus-like particles. Exploitation of the physical properties of these properties allows relatively
easy purification of the Ty-p25 VLP's from yeast. This is the first report on the cloning and
expression of a structural protein of maedi-visna virus.
Recombinant p25 protein was then used to generate p25 specific antisera, both
polyclonal and monoclonal antibodies, which have been used to develop a sensitive detection
assay for the major core protein of maedi-visna virus.
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5.2 Results
5.2.1 Cloning and expression of the p25 structural gene
The p25 gene was cloned by polymerase chain reaction (PCR) performed on
extrachromosomal DNA isolated from visna infected cells. Using PCR allowed precise cloning
of p25 coding sequence only, without the necessity for extensive in vitro manipulation of
DNA. Further, the PCR primers were designed to create restriction sites (Bam HI) flanking
the p25 gene and to insert a stop codon immediately following the p25 coding sequence
(Figure 5.1 A), thus facilitating subsequent steps in cloning. Sequence coding for a Factor Xa
protease cleavage site (Nagai & Thorgerson, 1984) was also inserted into the 5' PCR primer,
thus facilitating subsequent purification of p25 from the hybrid Ty-p25 particle. In order to
allow efficient cleavage of p25 from the fusion protein using Factor Xa enzyme, nucleotides
coding for the first amino acid of p25, a proline residue (CCT), were omitted from the 5'
primer (Gilmour et at, 1989).
PCR generated a product of the predicted size (approximately 650bp) for the p25 gene.
This PCR product, when cloned into pTZ 19R and sequenced, proved to be a full length p25
gene with 98% homology to the EV1 nucleotide sequence (Sargan et at, 1991) (Figure 5.1 B).
The p25 gene was then excised from pTZ 19R by Bam HI digestion and ligated into the
unique Bam HI site of the yeast/ E. coli shuttle vector pOGS 40 (Fig. 5.2) (Gilmour et al,
1989). A gene inserted into the Bam HI site of this plasmid is expressed as a TyA fusion
protein, under the control of a hybrid PGK-GAL (PAL) promoter. This is the strong yeast
phosphoglycerate kinase (PGK) gene promoter (Dobson et al, 1982) which has been
modified to become galactose inducible (Kingsman et al, 1990).
A number of recombinant plasmids containing a single copy of the p25 gene in the
correct orientation for expression were identified by Southern blot analysis of Pvu II digested
plasmids (Fig. 5.3). Double strand sequencing through the 5' vector-insert junction of one of
these plasmids (track 7), using a primer derived from the TYA gene sequence (Mellor et al,
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Figure 5.1
A. Sequences of the sense and antisense primers used in a PCR to clone the visna p25
gene, from a Hirt DNA template, for expression in yeast.
B. The PCR product was cloned into pTZ 19R. Single stranded DNA was prepared (section
2.5.1) from recombinant plasmids containing the p25 gene, identified by restriction enzyme
digest of DNA extracted from overnight cultures grown from white colonies, and sequencing
reactions carried out as described (section 2.5.2). Sequence analysis and amino-acid
translation was done on a Vax system using version 6.2 of the University of Wisconsin











































Figure 5.2 Plasmid map of expression vector pOGS 40
The piasmid pOGS 40 is a derivative of the TYA plasmid pMA 5620 (Adams et al,
1987a), in which the constitutive PGK promoter (Dobson et al, 1982) has been modified by
deletion of the UAS-PGK gene and the insertion of an upstream activating sequence from the
GAL1-10 gene (UAS-GAL) (West et al, 1984). This hybrid PGK-GAL (PAL) promoter is
repressed by culture in glucose and induced by galactose (Kingsman et al, 1990). Signals
for termination of transcription (PGK terminator) are located 3' of the unique Bam HI site
(Kingsman et al, 1990). For replication in yeast the plasmid contains sequences from the
endogenous multi-copy yeast plasmid, the 2pm circle and the LEU2-d gene as a selectable
marker (Kingsman et al, 1990). For replication and selection in E. coli the plasmid contains
sequences derived from pAT 153 (Twigg & Sherratt, 1980).
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Figure 5.3 Southern blots of plasmid DNA to establish orientation of p25 gene in
p25/pOGS 40 recombinants
A. Linearised plasmid pEV1P25.0 (10kbp)
Positions of restriction enzyme sites are shown: B - Bam HI and P - Pvu II.
B. Southern blot
Plasmid DNA was extracted from transformed E. coli by lysis in alkaline-SDS and
digested with Pvu II. Electrophoresis and Southern blotting procedures were carried out as
described in Chapter 2. The blot was probed with the p25 gene PCR product which had been
cloned into pTZ and sequenced (120ng DNA, 2.3 x 108cpm/pg). The p25 gene was excised
from pTZ by Eco Ftl/Hind III digestion, gel purified and radiolabeled according to Feinberg &
Vogelstein (1983., 1984). The blot was exposed to Kodak X-Omat S film for 20 minutes.
Marker DNA fragments were Eco Ftl/Hind III digestion products of X DNA, marker sizes
are indicated on left.
Predicted sizes of Pvu II fragments:
Correct orientation: 2 fragments - 8833bp, 1217bp
Wrong orientation: 2 fragments - 8583bp, 1467bp
The arrow indicates the 1217bp band in those plasmids where the p25 gene is in the
correct orientation for expression. Tracks 5 and 12 contain plasmids with no p25 insert. The
















1985), confirmed that the gene was in the correct reading frame for expression. This plasmid
was designated pEV1 P25.0.
The protease deficient Saccharomyces cerevisiae strain BJ 2168 was simultaneously
transformed to leucine and uracil independence with plasmids pEV1P25.0 and pUG 41S.
Plasmid pUG 41S overexpresses GAL4 protein under the control of a galactose inducible
promoter (Lue et a/, 1987). Co-transformation of yeast with this vector and a PAL-promoter
containing VLP plasmid (Kingsman et at, 1990) results in increased expression levels since a
major constraint on the level of protein expression in galactose inducible systems is the low
level of GAL4 gene expression (Johnston & Hopper, 1982), especially if the cell contains
multiple copies of the expression plasmid (Baker et at, 1987). Regulated overproduction of
GAL4 increases protein expression levels and retains the inducibility of the system (Schultz et
al, 1987).
Preliminary analysis of protein extracts of a number of yeast transformants containing
pEV1 P25.0 and pUG 41S indicated that they all expressed similar levels of Ty-p25 fusion
protein. One of these transformants was chosen for more detailed analysis and this strain
was designated TEV1 P25.U.
TEV1 P25.U, either induced or uninduced, has a doubling time and growth curve similar to
that of untransformed BJ 2168, indicating that high level expression of Ty-p25 protein is not
toxic for yeast cells. As a result of this observation, the standard protocol for induction of
protein expression in this system (24hrs in galactose medium, Burns et al, 1991), was
modified so that p25 expression was induced by culture in galactose for 36-48hrs. This
resulted in a 4-5 fold increase in yield of p25 fusion protein, per volume of culture fluid, over
cultures induced for 24hrs.
On Coomassie stained SDS-PAGE a prominent band of Mr. 75kd. could be seen in
extracts of TEV1 P25.U, but not untransformed yeast (Figure 5.4A). This is the predicted size
of a Ty-p25 fusion protein (wild type VLP, on SDS-PAGE have an apparent Mr of 50kd.). p25
expression was confirmed by immunoblot analysis using a p25 specific monoclonal antibody,
mAb 396 (Houwers & Schaake, 1987), which recognised a single strong band of
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Figure 5.4 Expression and purification of Ty-p25 protein
Crude extracts (see section 2.6.4) of untransformed yeast, induced TEV1 P25.U and
gradient purified Ty-p25 (from left to right tracks 1 to 3 respectively) were electrophoresed on
10% SDS-PAGE and the gels either stained with Coomassie blue (A) or electroblotted and








approximately 75kd. in extracts of TEV1 P25.U, but not untransformed BJ 2168 (Figure 5.4B)
or yeast transformed with pOGS 40 alone (data not shown). The same band was recognised
when these samples were probed with sera from visna infected sheep.
Hybrid Ty-p25 virus-like particles (VLP's) could be purified, by centrifugation through
sucrose gradients, to greater than 95% purity (Figure 5.4A, track 3), as judged by
densitometric examination of Coomassie stained gels. Batch cultures of induced TEV1 P25.U
yielded 50-60mg of fusion protein per litre of culture fluid (estimated using a BioRad dye-
binding assay) and immunoblotting confirmed that the sucrose-gradient purified particles
carried p25 antigen (Figure 5.4B, track 3).
Recombinant p25 could be further purified by cleavage from the Ty-p25 particle using
Factor Xa protease (Nagai & Thorgerson, 1984). Under optimum conditions (10mM CaCI2
100mM Tris pH 7.4, 0.05% CHAPS) established by preliminary time course and titration
experiments, complete cleavage of p25 from the Ty-p25 VLP's could be achieved and the
soluble p25 purified from the VLP's by ultracentrifugation (Figure 5.5), yielding 15-20mg of
p25 per litre of culture fluid. Non-specific degradation of VLP's was not observed.
5.2.2 Antigenic authenticity of recombinant p25 protein
The cleaved, purified recombinant p25 migrated as native p25 protein on SDS-PAGE and
was reactive with an anti-p25 monoclonal antibody (Figure 5.5). To further examine the
antigenicity of the recombinant p25 rabbits were immunised with purified p25 protein. When
tested in immunoblot analysis against a lysate of virus infected cells these antisera showed
reactivity not only against p25, but also recognised the gag precursor protein, p55, and
processing intermediates between p55 and p25 (Figure 5.6). A similar pattern of reactivity
was seen when these antisera were used in immunoprecipitation analysis of visna infected
skin cells (data not shown). In immunofluorescence experiments these antisera specifically
stained EV1 infected monolayer cultures and not uninfected controls. This staining was
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Figure 5.5 Purification of p25 protein
Ty-p25 VLP's were treated with Factor Xa protease and then centrifuged to separate
solubilised p25 from the VLP's. Samples of the digest (track 1), centrifuge pellet (track 2) and
p25 containing supernatant (track 3) were electrophoresed on 5%-20% linear gradient
SDS-PAGE and the gels either stained with Coomassie blue (A), or developed with an anti-
p25 monoclonal antibody (B), (Houwers & Schaake, 1987). The weakly staining band seen

















Figure 5.6 Rabbits immunised with recombinant p25 protein produce antibodies reactive with
native viral protein
A lysate of EV1 virus infected cells (see section 2.8.1) was separated on 5%-20% linear
gradient SDS-PAGE and electroblotted onto a nitrocellulose membrane. These blots were
then probed with either immune (Rabbit 187) or non-immune rabbit antisera. The left-hand
panel shows a titration, in doubling dilutions from 1/100, of rabbit anti-p25 antiserum. A









mainly confined to the cytoplasm of the cell although a ring of patchy staining at the plasma
membrane was also seen (see Figure 3.9).
5.2.3 Monoclonal antibody production
Balb/c mice were immunised with 10pg of purified recombinant p25 emulsified in
Freund's complete adjuvant. Secondary immunisations were given by intraperitoneal injection
of 10pg p25 in PBS. Three days before fusion mice were given an intravenous injection of
5pg of p25 antigen. The procedure of cell fusion was performed as described in Chapter 2.
A number of hybridomas were positive in ELISA assay against purified p25 antigen. The
majority of these were of IgM isotype, but one hybridoma was found to secrete lgG1 anti-p25
antibody. This hybridoma, designated 1D10, was cloned and the monoclonal antibody further
characterised (Figure 5.7). This antibody is reactive with p25 from EV1 infected cells in both
immunoblotting (5.7A) and immunofluorescence assays (5.7B & C).
Interestingly, while testing sera from mice immunised with the recombinant proteins prior
to hybridoma production it was noted that mice immunised with Ty-p25 VLP's had made
lower titre antibody responses than those immunised with similar amounts of purified, soluble
p25 (Figure 5.8). It can be seen that there is an approximate four-fold difference in anti-p25
antibody titre between the two groups. It has been suggested that antigen presented in a
polyvalent, particulate form is particularly immunogenic (Adams et al, 1987a), yet here that is
clearly not the case. Antigenic competition between p25 and the p1 protein may be one
explanation for this finding. Another possible explanation is that mice, if previously exposed
to yeast, may have already made an immune response to p1 protein on the 'wild-type' VLP's
present at low levels in yeast cells and the secondary anti-p1 response predominates in the
response to Ty-p25 . Lastly, this result may be related to physical distortion of p25 in the
hybrid Ty-p25 particle, leading to loss or masking of discontinuous epitopes.
In this expression system the virus-like particle is formed by self assembly of multiple
copies of a truncated form of the yeast TYA gene product, designated p1, which is analogous
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Figure 5.7 Characterisation of monoclonal antibody 1D10
A. Immunoblot analysis
Visna antigen, prepared as described in section 2.8.1, was separated on 5-20% linear
gradient SDS-PAGE run under reducing conditions and electroblotted onto a nitrocellulose
membrane. Strips, cut from these blots, were incubated with either neat culture supernatant
of 1D10 (track 1), or a control, isotype-matched irrelevant antibody (track 2). After washing,
bound antibody was detected with rabbit anti-mouse Ig conjugated to alkaline phosphatase.
Positions of molecular weight standards (kDa) are indicated.
B. & C. Indirect immunofluorescence analysis
Monolayer cultures of either EV1 infected (B) or mock-infected (C) skin cells were grown
on glass coverslips, fixed in 80% acetone/0.15M NaCI and then incubated in neat 1D10
culture supernatant. After washing, cells were incubated with biotinylated anti-mouse Ig.
Bound antibody was visualised using avidin-FITC. Visna infected cultures stained with a
control, isotype matched mouse antibody showed similar fluorescence to C. Magnification for
both panels is x1,714.
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Figure 5.8 Relative immunogenicity of soluble p25 and hybrid Ty-p25 VLP's
Serial dilutions of sera from mice immunised with either soluble p25 or particulate Ty-p25
were tested in ELISA assay against purified maedi-visna virus. Mice were immunised with
approximately 30pg of Ty-p25 or 10pig p25, ie.equivalent amounts of p25 antigen. This assay
was performed as described in the legend to Figure 3.1, except that a rabbit anti-mouse Ig
HRP conjugate (diluted 1/4000) was used to detect bound antibody.
Values are geometric means, ± 1 standard deviation, of groups of three mice.
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Serum dilution
to retroviral gag proteins (Adams et al, 19876). p25, in visna, forms the core of the viral
particle (Narayan & Clements, 1990) and it is possible that interactions between p25 and p1,
each attempting to assemble into a preferred conformation, results in the observed distorted
morphology of hybrid Ty-p25 VLP's (Figures 5.9 & 5.10).
Negatively stained Ty-p25 VLP's, when examined by transmission electron microscopy,
show considerable heterogeneity in size and shape (Figure 5.9). In contrast to Ty-VLP's
composed only of p1 protein, which have a characteristic regular morphology (Adams et al,
1987b and Figure 5.1 OA), many of the Ty-p25 particles had a distorted morphology. They
appeared irregular in shape with a distinct outer shell, and in general were larger than non-
recombinant VLP's. Many of them appeared to have internal core structures (Figure 5.10B).
These distortions in p25 and p1 may have resulted in loss and/or masking of
antibody epitopes on p25.
5.2.4 An assay for detection of p25 antigen
A specific and sensitive assay commonly used for the assessment of lentivirus replication
in HIV and SIV systems is the measurement of p25 antigen levels. In order to develop such
an assay for maedi-visna virus, the polyclonal and monoclonal anti-p25 antisera described
previously were tested, in various combinations, in antigen-capture assays.
The most sensitive assay was found to be one based on the use of affinity-purified
polyclonal anti-p25 for both antigen capture and antigen detection. Titration experiments
using soluble, recombinant p25 antigen, diluted in sheep serum, show that this assay is
sensitive down to 150-300pg of p25/ml. There is a linear relationship between the
concentration of p25 protein and the OD492 observed in this assay (Figure 5.11 A). A
sandwich ELISA using ID10 antibody for antigen captire was sensitive down to around
10ng/ml only (data not shown).
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Figure 5.9 Electron microscopy of negatively stained VLP's
Purified hybrid Ty-p25 VLP's, diluted to 1mg/ml in PBS, were placed onto Formvar
coated grids and negatively stained with uranyl acetate. The bar indicates 100nm.
Note the extensive heterogeneity in size and shape of the Ty-p25 particles.
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Figure 5.10 Electron microscopy of negatively stained VLP's
Purified preparations of either p1 particles (A) or hybrid Ty-p25 VLP's (B) were diluted to
1 mg/ml and then placed onto Formvar coated grids and negatively stained as described
previously (section 2.10.2).
The bars indicate 100nm. Arrows indicate particles with obvious core structures.
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Figure 5.11 Maedi-visna virus p25 antigen detection assay
A. Sensitivity and specificity of the p25 antigen detection assay
Rabbit anti-p25 antibody (10pg/ml in BBS), which had been affinity-purified on a
p25-sepharose column, was coated onto ELISA plates by overnight incubation at 4°C. Plates
were then blocked using PBS/1% BSA/1% rabbit serum (PBR) and incubated for 1 hour with
samples of sheep serum containing either p25 antigen or a control antigen, ovalbumin. After
washing six times with PBS/0.05% Tween 20, the plates were incubated for 1 hour with
biotinylated rabbit anti-p25 (20pg/ml in PBR), washed again and then incubated with avidin-
HRP (1/4000 in PBS/1% BSA). After a final wash plates were developed with OPD and
absorbance at 492nm read using a Titertek ELISA reader.
B. Titration of virus-containing culture supernatants in p25 antigen detection assay
Titration of high titre (106 TCID^/ml) and low titre (103 TCID^/ml) stocks, in DMEM 2%
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Titration of virus-containing supernatants of high and low infectivity titres (5.11B) showed
that over the dilution ranges tested the slopes of these titration curves are broadly parallel to
each other. These experiments suggest that no factors present in either tissue culture
conditioned medium or sheep serum interfere with this assay.
Interpolation of the OD492 values shown in Figure 5.11B onto a standard curve such as
that shown in Figure 5.11A allows calculation of the absolute concentration of p25 antigen in
these virus containing supernatants; the p25 antigen concentration of the high titre virus
stock (106 TOID^/ml) was 71 ng/ml, while the low titre virus stock contained 6.8ng of p25/ml.
Thus although there was a thousand-fold difference in infectivity titre between these virus
stocks, there was only a 10-fold difference in p25 antigen concentration.
5.3 Summary of Chapter 5 results
1. The gene encoding the major core protein of maedi-visna, p25, has been cloned and
expressed using the yeast Ty-VLP system.
2. Recombinant p25 protein has been used to generate both polyclonal and monoclonal
anti-p25 antisera.
3. A specific and sensitive p25 antigen detection assay has been developed.
5.4 Discussion
The low level of sequence variability between the p25 gene isolated here and that
previously reported for the EV1 p25 gene is about the expected level of 'within-isolate'
sequence variation seen in lentiviral populations (Balfe et al, 1990), and confirms that gag
p25 is among the most highly conserved of maedi-visna virus proteins (Sargan et al, 1991).
A notable feature of the cloning strategy described here is the design of PCR primers to
facilitate subsequent steps in cloning and protein purification. This approach allows a great
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deal of flexibility to be introduced into cloning and expression strategies and obviates the
need tor extensive DNA manipulations during cloning. Moreover the cloning and expression
strategy employed here should be well suited for the production of overlapping fragments of
viral and other proteins for use in epitope mapping studies.
A number of modifications to the expression and purification methodologies previously
described for this system (Burns et a/, 1991) were employed in this study. These
modifications helped to achieve the high levels of Ty-p25 expression (50-60mg/l) observed in
cultures of TEV1 P25.U. The major modification resulting in increased levels of fusion protein
expression was probably the increased time of culture in galactose containing medium, but
the choice of Ty-VLP vector utilised in this system also affected the yields of fusion protein
obtained. The combination of the galactose inducible pOGS 40 vector and the pUG 41S
'helper' plasmid generated the highest yield of p25 fusion protein. This was approximately
three times the yield achieved when Ty-p25 was expressed using the constitutive Ty-VLP
vector pMA 5620 (Adams et al, 1987a), and approximately six times greater than that
obtained when p25 was expressed from the pOGS 40 vector in the absence of pUG 41S
(data not shown).
The purification of these hybrid Ty-p25 VLP's was relatively simple and straightforward,
consisting, after breaking open the yeast cells and clarifying this lysate, of a single step of
differential centrifugation through a sucrose gradient. Ty-p25 VLP's were recovered from the
sucrose gradients at 90-95% purity and further purification steps were judged unnecessary.
p25 protein could be released from the VLP's by Factor Xa protease digestion with a final
yield of soluble p25 protein of 15-20mg/l of culture fluid. An advantage to using Factor Xa
enzyme is that it cleaves immediately carboxy-terminal to its recognition sequence thus the
released protein does not contain additional amino acids, however the amino-terminal proline
residue of p25 had to be omitted from the recombinant protein as this would otherwise have
inhibited Factor Xa cleavage (Gilmour et al, 1989., S.E. Adams, personal communication).
The reactivity of this purified protein with monoclonal antibody 396 (Houwers & Schaake,
1987) indicates that the protein contains at least one antigenic determinant recognised by an
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antibody raised against native viral protein. The ability of the recombinant p25 protein to elicit
mouse and rabbit antibodies which recognise native viral protein is further evidence of the
antigenic authenticity of this protein.
There are no previous reports of expression of a visna virus structural protein, but a
related protein, HIV p24, has been expressed in a variety of systems including E. coli
(Dowbenko et al, 1985., Shoeman et al, 1987), insect cells (Madisen et al, 1987) and
mammalian cells infected with vaccinia virus recombinants (Flexner et at, 1988). The yield of
p25 obtained in the yeast Ty-VLP system described here compares favourably with these
reports and the purification of Ty-p25 protein in this system is considerably simpler than for
these other systems. In some cases the expressed protein has been purified by
immunoaffinity chromatography or preparative SDS-PAGE (Dowbenko et al, 1985), but in
most cases the protein has been used in biochemical and immunological assays as crude
lysates (Madisen et al, 1987., Flexner et al, 1988) or as partially purified material following
solubiiisation of E. coli derived inclusion bodies (Shoeman et al, 1987). The use of crude
material in immunoassays may result in non-specific cross reactions, particularly if the
recombinant protein is produced in bacterial cells. In addition, it is possible that harsh
purification techniques and subsequent renaturation may affect some important antigenic
determinants. Use of the Ty-VLP system for expression has the major advantage that
purification of the recombinant protein is relatively straightforward.
The p25 protein generated in this system has been used in immunological assays of T &
B cell function in visna infected sheep (see Chapters 3 & 4). Given a supply of pure, soluble
p25 the epitopes being recognised in these assays could be further characterised by
assessing the reactivity of T cells and anti-p25 antibodies with fragments of p25 generated by
chemical or proteolytic cleavage of the recombinant protein. That said, given the current state
of knowledge regarding the ovine MHC, experiments mapping T cell epitopes within p25
would be difficult to interpret.
Given the highly conserved nature of p25 between visna isolates (Sargan et al, 1991) an
ELISA assay based on recombinant gag protein should prove useful as a sensitive and
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specific diagnostic tool for the detection of lentiviral infection of sheep and goats. Such an
assay would, however, require considerable work-up and validation with respect to the
incidence of false-negative and false-positive results. This would require the testing of large
numbers of samples from known visna seropositive and seronegative sheep. Recombinant
p25 protein may also be of use in immunocytochemical detection of visna p25 specific B cells
within lymphoid tissue (Laman et al, 1991) and in estimating the functional affinity of
antibodies to p25 in visna infected sheep.
The recombinant p25 protein has been useful in generating p25 specific antisera (Figures
5.6 & 5.7). The polyclonal antiserum obtained recognises both p25 and the gag precursor
p55 and other intermediate processed forms. This reagent will be useful for studying the
processing of p55 during viral replication. In contrast, monoclonal antibody 1D10 appears to
recognise mature p25 protein strongly, but precursor forms of the gag polyprotein only
weakly by immunoblot analysis (faint band on Figure 5.7A), implying that this antibody may
recognise an epitope which is more accessible after processing of p55. However, both the
rabbit anti-p25 antiserum and 1D10 will be of use in immunocytochemical localisation of p25
antigen within tissue sections. In this connexion it is interesting to note the pattern of p25
staining seen in fibroblasts, in tissue culture, infected with visna virus (Figure 3.9A). Virus
specific signals appear as linear arrays within the cells, a similar striated pattern is observed
when infected fibroblasts are probed for viral RNA by in situ hybridisation (Dr. D.J. Roy,
personal communication). These striated structures are reminiscent of cytoskeletai
components such as microtubules and actin filaments, and it is interesting to note that in vitro
infection of fibroblasts with visna virus has been reported to result in a redistribution of actin-
containing filament bundles within fibroblasts (Pautrat et al, 1980). It is tempting to speculate
on a role for intermediate filaments in intracellular viral protein trafficking and/or virion
assembly, however, two colour immunofluorescence analysis using antibodies to visna
antigens and intermediate filaments plus electron microscopic analysis would be necessary
to test the worth of this hypothesis.
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The rabbit anti-p25 antibody has also proved useful in setting up a sensitive and specific
assay for maedi-visna p25 antigen (Figure 5.11). That an assay based on monoclonal
antibody 1D10 is less sensitive than one based on affinity-purified rabbit antiserum is
probably a reflection of differences in the avidity of interaction between the antisera. The
higher avidity, multivalent interaction between p25 and the polyclonal antiserum resisting the
mechanical stresses of repeated washing of ELISA plates better than the single interaction
between 1D10 and p25 protein.
The p25 antigen detection assay described here is capable of detecting visna p25
antigen at levels down to 150-300pg/ml and has proved to be of use in quantitating viral
replication both in vitro (Figure 5.11) and in vivo (see Chapter 4, Figures 4.5A & 4.6). The
availability of the recombinant p25 protein and monospecific antisera described in this
chapter will enhance studies of maedi-visna virus replication in vitro and in vivo and will also





The central feature of the pathogenesis of lentiviral disease is viral persistence in vivo
despite the induction of both virus-specific antibody and T cell responses (Petursson et al,
1976., reviewed in Fauci, 1988., McCune, 1991). It is thus important to precisely define the
immune mechanisms activated in response to lentiviruses and to attempt to understand the
strategies employed by lentiviruses to evade and subvert the immune system. The aims of
this thesis were therefore two-fold: to analyse the acute phases of the immune response to
lentiviral infection, and secondly, to re-examine and investigate more closely the immune
response to maedi-visna in persistently infected sheep.
6.2 Maedi-visna as a model system for lentiviral pathogenesis
Studies of maedi-visna virus infection of sheep, because of the opportunity to directly
access both lymphoid tissue and the lymphatic output of lymph nodes of sheep via lymphatic
cannulation, provide a unique in vivo model system for investigation of acute immune
responses to (lenti-)viral infection. Moreover, since the ruminant lentivirus maedi-visna is
restricted in its tropism to cells of the monocyte-macrophage lineage (Gendelman et al,
1985. 1986) there exists the potential for study of the significance of accessory cell infection
in the pathogenesis of lentiviral disease in the absence of the concomitant infection of other
cell types which complicates study of the pathogenesis of disease caused by the
immunodeficiency-viruses, such as HIV, FIV and SIV (Rosenberg & Fauci, 1990., Narayan &
Clements, 1990). This, however, assumes that infection, of for example a macrophage, by
visna will have the same effect(s) on the infected cell as infection of a macrophage by HIV. It
is not yet clear whether this is a justifiable assumption. Further, in vivo it is possible that the
dysfunction and dysregulation of CD4+ lymphocytes which is the hallmark of HIV infection
may feedback, through the release of factors such as IFN-y, IL-2, IL-4, M-CSF and GM-CSF,
and have profound effects on accessory cell phenotype and function. Thus although studies
on the pathogenesis of maedi-visna disease may provide insights into the role of accessory
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cell infection in the biology of lentiviral disease generally; these should be interpreted only
cautiously when discussing the specifics of any particular lentiviral disease.
6.3 A model of the acute immune response to lentiviral infection
Naturally occurring stimulation of the mammalian immune system usually results from the
entry of antigens, such as viruses, bacteria and allergens, through intact or damaged skin
and mucosa. Having gained access to the tissue spaces, a proportion, at least, of the antigen
enters the lymphatic capillaries draining the site of entry, and is transferred, via afferent
lymphatic vessels to the regional lymph node where an immune response is initiated and
subsequently disseminated by the lymphatic and circulatory systems. An important
component of this immune response is believed to be the movement of Langerhans cells (or
other antigen-presenting cells) from the site of infection into the node which they enter as
interdigitating cells (Silberberg-Sinakin & Thorbecke, 1980., Hoefsmit et al, 1982., Kraal et al,
1986). The function of these cells is believed to be to carry antigen, from the site of entry of
the antigen/pathogen, to the paracortical areas of the node for presentation to T cells
(Macatonia et al, 1987., Kripke et al, 1990) and to play a role in the movement of antigen
and immune complexes from the marginal sinus to the follicles (B cell zones) of the lymph
node (reviewed in Szakal et al, 1989). Antigen-activated CD4+ T cells then move to the
interface between the paracortex and the primary follicle (Rouse et al, 1982) and a rapid
oligoclonal B cell response occurs. This results in the formation of a germinal centre
containing CD4+ T cells, a few antigen-bearing germinal centre and follicular dendritic cells
and large numbers of dividing B cells which give rise to antibody producing plasma cells and
memory B cells (Szakal et al, 1989).
The above summarises the pattern of events which, based on studies of immune
responses to inert protein antigens, is thought to occur normally in response to antigenic
challenge. In most instances, the T and B cell immune responses initiated in the lymph node
by this process are sufficient to clear infection by a pathogen.
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Analysis of the acute immune responses of lymphoid tissue to infection by a lentivirus,
studied via lymphatic cannulation, has revealed that lentiviral infection activates many of the
immune mechanisms seen in a 'normal' immune response to antigen, but that in this case
these fail to prevent the establishment of a persistent viral infection.
The early events in lentiviral infection, once the vims has gained access to the body
across a mucosal and/or epithelial surface, are likely to include localised infection of
permissive cells with subsequent migration, via afferent lymphatic vessels, of infected cells,
antigen-presenting cells carrying viral antigen and free virus into draining lymph nodes. In
visna this will usually mean the transfer of infected monocytes/macrophages to regional
lymphoid tissue after aspiration/ingestion of either virus-infected cells in colostrum or
aerosolised virus exhaled by an infected sheep (Narayan & Cork, 1985).
After the entry of lentivirus infected cells into the paracortex antigen presentation to T
cells, in the context of MHC class I, would be expected to occur and result in the activation
and proliferation of CD8+ T cells. Indeed a marked increase in the number of CD8+ blast
cells, both within the lymph node and exiting it, is a striking feature of the early immune
response to lentivirus infection (Reimann et al, 1991., Appendix A, Figure A.2). However, the
extent of this CD8+ lymphocytosis does not appear to correlate with the development of
cytotoxic T cell activity (Reimann et at, 1991., Dr. B. A. Blacklaws, personal communication).
This is in contrast to the situation observed in mice acutely challenged with LCMV or HSV,
where 5-6 days after infection high levels of MHC class I restricted CTL activity can be
generated from lymph nodes draining the site of infection (Pfizenmaier et al, 1977., Lynch et
al, 1989). There are two possible explanations for this observation; firstly the CD8+ cells may
be specific for viral antigen, but not able to mediate cytolysis in vitro. It is, for example,
possible that these CD8+ T cells are producing cytokines such as IFN-g and TNF that may
affect viral replication without causing lysis of infected cells in vitro. Secondly, it is possible
that only a proportion of these T cells are specific for viral antigens. Given the available data,
it is not possible to distinguish between these alternative, although not mutually exclusive,
explanations.
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The basis for any suggested non-specific activation of CD8+ T cells is not clear, but the
appearance of non-antigen-specific blast cells prior to the detection of antigen-specific
efferent lymphocytes has been described previously (Poskitt et al, 1977., Issekutz, 1985).
This phenomenon has been suggested to result from cytokine release within the lymphoid
micro-environment leading to proliferation of both antigen-specific and non-specific
lymphocytes. It is possible that such non-antigen specific blast cells, if IL-2R+, may act to
modulate the cellular response by acting as passive sinks for cytokines such as IL-2. This,
however, does not explain why the majority of the activated T cells in lymphoid tissue after
lentiviral infection are CD8+ rather than a mixture of CD4+ and CD8+ phenotypes.
Interestingly however, other viral infections eg. Epstein-Barr virus and cytomegalovirus
infections in man can also result in a CD8+ lymphocytosis (Carney et al, 1981., Tomkinson
et al, 1987), which may suppress various immunologic functions (Reinherz et al, 1980).
Association between virus antigen and antigen-presenting cells in the paracortex of the
lymph node would also be predicted to result in the activation of CD4+, MHC class II
restricted 'T-helper' cells specific for viral antigen. In vivo antigen-activated CD4+
lymphocytes are believed to be the main source of cytokines such as IL-2, IL-4, IL-5, IFN-y,
and, despite increasing evidence that CTL activity can develop independently of CD4+ T cell
function (Bennink & Doherty, 1979., Leist et al, 1987., Ahmed et al, 1988) such 'T-helper
cells' are thought to play an important role in the generation and maintenance of both specific
antibody-producing B cells and optimal cytotoxic T cell (CTL) responses (reviewed in Vitetta
et al, 1991). For example, it has recently been shown, using an adoptive transfer system,
that protection from a murine retrovirus disease (Rauscher leukaemia-sarcoma virus
complex) requires both immune CD4+ and CD8+ T cells (Horn et al, 1991).
Analysis of the occurrence of virus antigen-specific CD4+ T cells in HIV and SIV infection
is complicated by the fact that these viruses infect, and subvert the function of, CD4+
lymphocytes and this may explain the difficulties reported in detecting HIV antigen-specific
CD4+ T cells by in vitro analysis (Wahren et al, 1987). However, in vitro lymphocyte
proliferation to maedi-visna antigen, presumably mediated by CD4+ T cells (see section
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3.4.1) was clearly demonstrated during the acute immune response to visna in 2/2 sheep
tested (section 4.3).
Acute maedi-visna infection also induced a relatively normal humoral immune response,
including the production of virus-specific neutralising antibodies (section 4.2). The
appearance of these antibodies coincides with the disappearance of infectious virus in
efferent lymph, as judged by co-cultivation experiments (Figure 4.7 and Appendix A, Figure
A.1), but the basis of this correlation is unclear. All the infectious virus exiting the node was
cell-associated (Bird et al, in preparation). Therefore if neutralising antibody is directly causing
the decrease in infectious virus production this implies that in vivo cell .ceil transmission of
virus may not be an important mechanism in the spread of viral infection. Alternatively this
correlation may be related to the fact that neutralising antibody is mainly directed against the
viral env protein (Scott et al, 1979) and it may be that anti-env antibody is acting against
virus infected cells, perhaps via complement activation and cell lysis (see section 3.2.3).
In summary, acute infection with the ruminant lentivirus maedi-visna activates both
cellular and humoral arms of the immune system, but the local immune response, while able
to modulate the initial burst of viral replication and dissemination to an extremely low level
(section 4.2 & Appendix A, Figure A.1), is not sufficient, as judged by the continued low level
production of p25 antigen (section 4.2), to completely eliminate lentiviral infection. This is
probably due to the establishment of a persistent lentiviral infection associated with the
'restricted replication' phenotype characteristic of lentiviral pathogenesis in vivo (Flaase,
1986).
6.4 Host-virus interactions in persistently infected animals
"The best current explanation for the persistence of lentiviruses is the immunologically
silent nature of the infection." (Haase, 1986)
The seminal studies of Haase and coworkers have demonstrated the existence of a
striking dichotomy between the behaviour of lentiviruses in vitro and in vivo. In tissue culture
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visna virus reproduces rapidly to high titre in a lytic cycle of infection: infected cells contain
thousands of copies of genomic and messenger RNA's, these are translated into millions of
copies of virion proteins and more than 50-100 progeny virions are produced by each infected
cell (Brahic et al, 1977., Haase et al, 1982). In contrast replication of the virus in animals is
characterised by a markedly restricted replication cycle. Only a few cells are infected and
these contain relatively low numbers of copies of viral RNA, only 50-150 per cell.
Interestingly, less than 0.02% of infected cells contain detectable quantities of viral antigens
(Haase et al, 1977., Brahic et al, 1981., Peluso et al, 1985). On the basis of these
observations Haase and his coworkers have proposed that "most infected cells harbour the
virus in a latent state in which viral antigens are not produced in sufficient quantities for
detection and destruction by immune surveillance mechanisms."
Taken at face value this hypothesis would seem to indicate little, if any, role for the
immune system in controlling viral replication in persistently infected animals. However there
are a number of provisos to this hypothesis. Firstly, the conclusion that in vivo only a small
percentage of virus infected cells are expressing viral antigens was based on
immunofluorescence analyses using antisera specific for viral structural proteins such as gag
(Haase et al, 1977., Brahic et al, 1981). However the levels of expression of the regulatory
proteins, encoded by the short ORF's within the lentivirus genome, was not investigated.
Visna, at least in vitro, does not appear to integrate (Harris et al, 1984) and in vivo
virtually every cell containing viral DNA also contains viral RNA (Brahic et al, 1981),
suggesting that true latency does not occur in visna infection in vivo. The nature of the RNA
transcripts expressed in vivo is not known, however in vitro, cell lines chronically infected
with HIV, but not producing viral particles have been shown to contain mainly doubly spliced
transcripts (Michael et al, 1991), consistent with the hypothesis that expression of viral
regulatory proteins may be a feature of the restricted replication state observed in vivo. The
validity of this hypothesis is not known, but, using techniques such as immunocytochemistry
and in situ-PCR (Haase et al, 1991), it is is fully testable.
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If expression of regulatory proteins such as tat and rev is a feature of restricted lentiviral
replication in vivo then it would be interesting to investigate the occurrence of T cells specific
for these proteins in visna infected sheep. In HIV infection, one of the proteins encoded by
short ORF's, net, has been shown to be a target for CTL activity (Chenciner et at, 1989), but
I am not aware of any published work on the occurrence of CTL to other regulatory proteins.
The second proviso to the hypothesis that lentiviral infection is largely immunologically
silent is that leukocytes have a finite life span in vivo and therefore the maintenance of viral
burden in the infected host can be predicted to require continual recruitment of newly infected
cells. A logical corollary of this prediction is that in some infected cells viral replication with
expression of viral structural proteins and production of progeny virions must be occurring.
Such ceils, and any free virus produced by them, would be expected to be fully susceptible to
immune attack by CTL, natural killer cells and anti-viral antibody. It is possible that such cells
may represent the isolated visna infected ceils, surrounded by clusters of inflammatory cells,
described by Stowring et al (1985).
The occurrence of occasional cells in which a complete viral replication cycle takes place
could also serve to provide a chronic trickle of antigenic stimulation. Such a phenomenon
could contribute to the infiltration and proliferation of mononuclear cells in the active-chronic
inflammatory process typical of the histopathological lesions associated with visna infection
(Narayan & Cork, 1985). Since, in visna, the majority of virus infected cells are monocyte-
macrophages it is also conceivable that disordered monokine secretion may play a role in the
genesis of these inflammatory lesions.
Lentiviruses may employ a number of strategies to evade such immune surveillance. The
immune dysfunction subsequent to infection of CD4+ T cells by lentiviruses such as HIV and
SIV is one obvious mechanism for escaping immune responses. However lentiviral infection
may also be associated with other more subtle immune defects eg. the unusual pattern of
isotypic restriction of anti-visna antibodies to the lgG1 subclass (section 3.2.2), which may
prevent activation of anti-viral ADCC mechanisms (see section 3.2.3).
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Another potential mechanism by which lentiviruses may escape immunological control is
antigenic variation. The occurrence of lentiviral variants, including visna virus, which evade
the antiviral antibody response has been described (reviewed in Narayan et al, 1987.,
Clements et al, 1988), but the significance of these variants is unclear. In visna, antigenic
variants do not replace the infecting serotype and in most long-term infections the inoculum
virus strain persists and spreads (Lutley et al, 1983., Thormar et al, 1983). Mutation in CTL
epitopes has been described in HIV infection (Phillips et al, 1991). This was associated with
loss of recognition by the patient's CTL of that epitope; however this resulted not in the
generation of viral escape mutants, but rather recognition of a different epitope in the viral
antigen. Therefore the significance of this mechanism in pathogenesis of lentiviral disease
remains unclear.
6.5 Future prospects
Several major points emerge from the preceding discussion with regard to the role of the
immune system in lentiviral infection. Firstly, there is a clear correlation between the
appearance of antibodies to the viral envelope proteins/virus neutralising antibodies and a
marked reduction in the dissemination of infectious virus (section 4.2., Petursson et al,
1976). Secondly, local immune responses are able to down-modulate viral replication and
dissemination, but once virus has entered a cell and adopted a 'restricted replication' state
these immune mechanisms are not able to clear the pathogen (sections 4.2 & 4.3).
Lastly, although T cell and antibody responses specific for visna virus structural proteins
such as the gag antigens can be demonstrated in persistently infected animals (sections 3.2
& 3.4), these are unlikely to be of major significance in clearing the pathogen. In persistently
infected animals the predominant viral replication state is not associated with expression of
these antigens in infected cells (Haase et al, 1977., Brahic et al, 1981).
Bearing the above in mind, it is clear that the major candidate viral protein for inclusion in
any vaccine is the envelope protein of the virus. Env is the major target antigen eliciting virus
201
neutralising antibodies (Scott etal, 1979., Rosenberg & Fauci, 1989), moreover it has been
reported that in SIV infected macaques that env is also a major target for CTL responses
(Yamamoto et at, 1990). This may be related to relatively inefficient transport of env protein
to the cell surface from the ER and Golgi (Willey et al, 1988) resulting in the production, after
protein degradation, of a pool of env peptides in the cytosol which may re-enter the ER and
associate with nascent MHC class I molecules (Townsend etal, 1989).
Given the above, it is a not unreasonable hypothesis that a pre-existing high titre anti-env
antibody response, together with high levels of env specific T cells, may be able to prevent
the establishment of a persistent infection.
That said, genetic diversity in the lentiviral genome is largely associated with the env
genes and most anti-env antibody responses are type specific. This is a major potential
obstacle to the development of a successful vaccine based on env. Interestingly, however,
sequential immunisations with recombinant gp120's from different HIV strains has been
reported to result in the development of a broadly reactive env-specific antibody response
(Klinman et al, 1991). This observation may represent an approach to dealing with the
problem of antigenic diversity in env.
Once a persistent infection has been established, the potential for immune intervention to
alter the course of disease appears limited. If viral regulatory proteins are the major viral
antigens expressed by infected cells in vivo then it would be logical to try and promote the
development of a CTL response to these antigens. It is however, perhaps more likley that
pharmacological intervention, throught the use of compounds such as AZT (Hirsch, 1988.,
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Appendix
Figure A.1 Detection of infectious visna virus, by cocultivation, in efferent lymph
Washed efferent lymph cells and lymph plasma were titrated, in triplicate, onto a
preformed monolayer culture of sheep skin cells in 24 well plates. Co-cultures were
maintained for 14 days, after which time the skin cell monolayers were fixed in acetone/salt
and stained for visna gag antigen by immunofluorescence (see section 2.9.3). Virus titres
were calculated according to Reed & Muench (1938).
Cells and plasma were assayed separately and only cell associated virus was detected.





Figure A.2 Kinetics of efferent lymph cells exiting prefemoral lymph nodes challenged with
either maedi-visna virus (A,C,E,G) or 'mock-infected' with control antigen (B,D,F,H).
Total cell output (A,B), lymphoblast output (C,D), % lymphoblasts CD8+ (E,F) and %
small lymphocytes CD8+ (G,H) are shown against time for visna infected sheep 657R &
683R and for mock infected sheep 1060P & 663R. Arrows indicate time of challenqe.
Lymphoblasts were defined by their forward scatter/side scatter FACS profile^. FACS
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Figure A.3 Immunoglobulin levels in efferent lymph (A) and synthesised spontaneously by
efferent lymph B cells in vitro (B).
A. Total immunoglobulin was measured by radial immunodiffusion with purified preparations
of ovine Ig as standards.
B. 10® washed efferent lymphocytes were cultured in vitro for seven days. Culture
supernatant was then assayed for immunoglobulin in a capture ELISA using VPM8, a
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